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ABSTRACT
Cigarette smoking remains the leading cause of preventable disease and death worldwide, with
nearly half a million deaths per year in the United States alone. Of the 70% of adult smokers in
the United States that desire to quit, only ~7% are successful. The long-standing use and
dependence of these products, despite known health consequences, is primarily attributed to the
nicotine-induced neurobiological and neurophysiological adaptations that take place during
chronic use. Adolescent nicotine exposure alters the developing brain while also priming the
brain for other drug addictions later in life. Though nicotine-induced reinforcement, nicotinic
acetylcholine receptor (nAChR) upregulation, and enhanced dopamine neuron excitability have
been discovered and studied over the past several decades, another key player in nicotine
dependence is flavoring chemicals. Characterizing flavors other than menthol have been banned
in combustible cigarettes, yet more than 15,000 flavor options remain available for electronic
cigarette users. Electronic cigarettes, or electronic nicotine delivery systems (ENDS), were
originally intended to provide a cleaner nicotine delivery system for chronic smokers, yet due to
the enticing market of flavored products and the growing popularity of zero-nicotine flavored eliquids among ENDS users, these devices exhibit an even greater concern than combustible
cigarettes. With the new wave of nicotine users, especially those between the ages of 12 and 18,
further studies need to be done to identify the mechanisms that flavor chemicals have on the
dependence process and to contribute to future FDA regulations. This dissertation encompasses
the investigations into popular green apple flavor chemicals and identifies their roles on reward
and reinforcement in a vapor self-administration model with mice as well as their role in nAChR
trafficking within cultured neuroblastoma-2a cells. Additionally, this work summarizes the
effects of non-contingent vapor exposure, similar to human vaping patterns, on ex vivo nAChR

xxii

expression, neuronal firing, and subsequent dopamine release in the ventral striatum of mice.
These findings will provide insight into the neurological effects of persistent ENDS use in an
attempt to combat the growing use of these products among the adolescent population.
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CHAPTER 1
THE IMPACT OF ELECTRONIC NICOTINE DELIVERY SYSTEM (ENDS) FLAVORS
ON NICOTINIC ACETYLCHOLINE RECEPTORS AND NICOTINE ADDICTIONRELATED BEHAVIORS
A manuscript published in Molecules.
Skylar Y. Cooper1 and Brandon J. Henderson1
1

Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University,

Huntington, WV, USA

1

Abstract
Over the past two decades, combustible cigarette smoking has slowly declined by nearly
11% in America; however, the use of electronic cigarettes has increased tremendously, including
among adolescents. While nicotine is the main addictive component of tobacco products and a
primary concern in electronic cigarettes, this is not the only constituent of concern. There is a
growing market of flavored products and a growing use of zero-nicotine e-liquids among
electronic cigarette users. Accordingly, there are few studies that examine the impact of flavors
on health and behavior. Menthol has been studied most extensively due to its lone exception in
combustible cigarettes. Thus, there is a broad understanding of the neurobiological effects that
menthol plus nicotine has on the brain including enhancing nicotine reward, altering nicotinic
acetylcholine receptor number and function, and altering midbrain neuron excitability. Although
flavors other than menthol were banned from combustible cigarettes, over 15,000 flavorants are
available for use in electronic cigarettes. This review seeks to summarize the current knowledge
on nicotine addiction and the various brain regions and nicotinic acetylcholine receptor subtypes
involved, as well as describe the most recent findings regarding menthol and green apple
flavorants, and their roles in nicotine addiction and vaping-related behaviors.
Introduction
Cigarette smoking remains the leading cause of preventable disease and death worldwide,
with nearly half a million deaths per year in the United States alone (SGR, 2014). Additionally,
more than 16 million Americans are suffering from a smoking-related disease including diabetes,
stroke, cardiovascular disease, chronic obstructive pulmonary disease, or cancer (SGR, 2014).
Nearly 70% of adult smokers in the United States have a desire to quit, however, only ~7% are
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successful (Babb et al., 2017), with an average of 10 cessation attempts needed for success
(Health, 2001).
In 2009, the Family Smoking Prevention and Tobacco Control Act was put in place to
combat adolescent tobacco use and limit cigarette sales by banning all flavor additives other than
menthol from being added to combustible cigarettes, yet this refrained from addressing other
tobacco products including cigars, chewing tobacco, hookah, and more. As of 2018, mentholated
cigarettes made up 36% of all cigarette sales in the United States (FTC, 2019), however, it has
been established that regardless of labeling, even non-mentholated cigarettes contain traces of
menthol (Ai et al., 2016) as a potential attempt by cigarette manufacturers to promote smoking
initiation.
Over the past two decades in the United States, combustible cigarette use has declined by
nearly 11%, however, one form of nicotine administration has been replaced by another –
electronic nicotine delivery systems (ENDS) (Glasser et al., 2017). ENDS, or electronic
cigarettes (e-cigarettes), are handheld devices that vaporize an e-liquid solution, commonly
containing varying ratios of propylene glycol and vegetable glycerin, flavoring chemicals,
nicotine, and in some cases additional sweeteners (SGR, 2016a; SGR, 2016b; Omaiye et al.,
2019b). ENDS were initially intended to be a smoking cessation aid; however, ENDS companies
have begun to target a new market of nicotine users among the adolescent population. According
to the National Youth Tobacco Survey, usage rates continue to rise with over four million high
school students and one million middle school students currently using ENDS products (Cullen
et al., 2019; Health, 2020). Nicotine dependence is thought to be intensified among adolescents
when flavorants are present, as they mask the aversive sensations associated with nicotine and
may promote pleasure on their own. This occurs primarily through masking the initial harshness
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of nicotine/tobacco that is aversive to new and beginning smokers and therefore increases
smoking initiation (Willis et al., 2011; Mead et al., 2018). Although non-menthol flavors are
banned in combustible cigarettes, >15,000 flavor options are available for ENDS products with a
67% increase in flavor production from 2013 to 2014 (Zhu et al., 2014; Hsu et al., 2018). In
2019, more than 50% and 60% of high school users used menthol and fruit flavored ENDS,
respectively, and more than half of ENDS users prefer flavored products (Cullen et al., 2019;
Health, 2020). This has become a cause for concern with the number of adolescent ENDS users
continuing to rise and the growing popularity of zero-nicotine flavored e-liquids. Yet, little is
known regarding the effects of flavors on nicotine dependence and vaping-related behaviors.
Despite this gap in knowledge, there are numerous reports of menthol’s effect on nicotine
addiction, including menthol’s ability to enhance nicotine reward and reinforcement (Wang et
al., 2014; Biswas et al., 2016; Henderson et al., 2017; Cooper et al., 2021). These effects are due
to menthol-induced nicotinic acetylcholine receptor (nAChR) upregulation (Brody et al., 2013;
Henderson et al., 2016; Henderson et al., 2017), enhanced dopamine neuron excitability and
dopamine release (Henderson et al., 2018; Zhang et al., 2018), and TrpM8-dependent
mechanisms (Fan et al., 2016). Based on a recent study reporting green apple and other fruity
flavors to be the most popular of ENDS flavorants (Espino-Diaz et al., 2016; Omaiye et al.,
2019b), additional reports have identified popular green apple flavorants, farnesol and farnesene,
to not only enhance nicotine reward in a mouse model, but also display rewarding properties in
the absence of nicotine (Avelar et al., 2019; Cooper et al., 2020, 2021). These behavioral effects
were found to be caused by changes in nAChR upregulation or stoichiometry, and ventral
tegmental area dopamine neuron firing. Based on these findings, it is critical we further
understand how ENDS flavoring chemicals may alter the addictive properties of nicotine in an
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attempt to combat the growing ENDS-use epidemic.
This review summarizes the current knowledge-base of nicotine addiction and the major
neurobiological and neurophysiological adaptations that contribute to dependence. Additionally,
we summarize the effects of menthol on abuse liability and vaping-related behaviors and include
the major impacts that another popular ENDS flavor, green apple, has on addiction-related
behavior. This includes flavor-induced effects on nicotine’s actions in the brain and the major
neurocircuitry involved in the induction of addiction.
Background of Nicotine Addiction
Neuronal nAChRs: Structure and Function
nAChRs are ligand-gated ion channels in the Cys-loop superfamily, alongside N1-type
acetylcholine, GABAA (ionotropic form), glycine, and 5-HT3 receptors (Le Novere and
Changeux, 1995; Sine and Engel, 2006). nAChRs are responsible for mediating fast synaptic
transmission of nerve impulses (Albuquerque et al., 2009; Penton and Lester, 2009; Zoli et al.,
2015; Dang et al., 2016). Human neuronal nAChRs are assembled from various combinations of
subunits, including α2-α7 and β2-β4. Assembled subtypes consist of homomeric pentamers (α7)
or heteromeric pentamers (α2-α6 with β2-β4) (Figure 1A). Each subunit comprises a large Nterminal extracellular domain important for ligand binding, a short C-terminal extracellular
domain, four hydrophobic transmembrane domains (M1-M4), with M2 lining the channel’s
central pore, and a large cytoplasmic loop between M3 and M4 that varies among different
subunit complexes (Wells, 2008) (Figure 1B-C). The cytoplasmic loop is important for receptor
trafficking in both the anterograde and retrograde directions between the endoplasmic reticulum
to the plasma membrane (Wiesner and Fuhrer, 2006; Wells, 2008; Srinivasan et al., 2011;
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Henderson et al., 2014). These sites are also critical for protein interactions and serve as a site for
phosphorylation.

Figure 1. Human nAChR Structure and Assembly
(A) Homomeric and heteromeric nAChR complexes assemble as solely α-subunits or α/βsubunits, respectively. Homomeric nAChRs possess five agonist binding sites at each α-α
interface while heteromeric nAChRs possess two agonist binding sites at the α-β interface but
can still be weakly activated by ‘non-canonical’ sites at the α-α interface (if present). X indicates
other subunits may be present. (B) Single nAChR subunit topology consists of an extracellular
domain, four transmembrane domains, and an intracellular loop that varies in length depending
on subtype. (C) Pentameric nAChR complex from a top-side view identifying the formation of
the transmembrane domains of individual nAChR subunits with respect to the nAChR central
pore.
Neuronal nAChR agonists include the endogenous neurotransmitter, acetylcholine (ACh),
as well as various exogenous molecules. Homomeric receptors have five identical orthosteric
ACh-binding sites, whereas heteromeric receptors contain two or more orthosteric sites at the
interfaces between an α and β subunit (Figure 1A). The binding of two ACh molecules to the
orthosteric sites on the receptors induces a conformational change allowing the channel to open.
6

nAChRs are permeable to monovalent Na+ and K+ ions, as well as divalent Ca2+ ions. Calcium
that permeates the nAChR acts on intracellular cascades that can play a vital role in neuronal
signaling and plasticity (Gotti et al., 2009). Depending on the subtype assembly or stoichiometry
of nAChRs, Ca2+ permeability varies. For instance, among α4β2 nAChRs, the high-sensitivity
(α4(2)β2(3)) and low-sensitivity (α4(3)β2(2)) nAChR stoichiometries exhibit different Ca2+
permeabilities (Tapia et al., 2007); but homomeric α7 nAChRs exhibit the highest Ca2+
permeability of all nAChR subtypes (Conroy et al., 2000; Zhao et al., 2003). The net flow of
positive ions inward depolarizes the cell membrane causing an excitatory postsynaptic potential
(Albuquerque et al., 2009). nAChRs have a very widespread distribution throughout the brain
and are found on presynaptic and postsynaptic neuronal membranes, as well as non-neuronal
cells, such as glial cells (McGehee et al., 1995; Zoli et al., 2018). Neuronal nAChRs can control
excitatory and inhibitory neurotransmission which further excites and/or inhibits target cells
(Jensen et al., 2005; Albuquerque et al., 2009). Depending on the brain region and cell type,
nAChR subunits form differing complexes that are associated with a variety of
pathophysiological conditions. The most widely expressed neuronal subtypes in the brain are
heteromeric α4β2* (* = may contain other subunits) and homomeric α7 nAChRs (Alkondon and
Albuquerque, 2001; Picciotto et al., 2008; Picciotto and Kenny, 2013; Dani, 2015). Due to the
variability in nAChR formation, each complex differs functionally with respect to channel
opening, closing, and desensitization (Dani, 2015).
Nicotine’s Actions in the Brain
Nicotine crosses the blood brain barrier and binds with high affinity to nAChRs widely
distributed throughout the nervous system (Gotti et al., 2009; Picciotto and Kenny, 2013; Molas
and Dierssen, 2014; Zoli et al., 2015; Shivange et al., 2019). This interaction promotes a variety
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of neurophysiological changes including chaperone-mediated nAChR upregulation (Kuryatov et
al., 2005; Sallette et al., 2005; Nashmi et al., 2007; Albuquerque et al., 2009; Lester et al., 2009;
Srinivasan et al., 2011; Henderson et al., 2014), activation of the mesocorticolimbic reward and
reinforcement pathways (Tapper et al., 2004; Pons et al., 2008), enhanced synaptic plasticity
(Mansvelder and McGehee, 2000; Dani et al., 2001; McKay et al., 2007; Mansvelder et al.,
2009), and enhanced neuronal firing (Mansvelder and McGehee, 2000; Mansvelder et al., 2002;
Nashmi et al., 2007; Xiao et al., 2009; Yan et al., 2018), ultimately leading to the development of
nicotine addiction (Corrigall and Coen, 1989; Penton and Lester, 2009) (Table 1). This will be
expounded in detail in the following paragraphs.
Nicotine binding promotes a conformational transition of nAChRs from a resting, closed
state to an open state, allowing signal transduction to occur (Unwin et al., 2002; Miyazawa et al.,
2003). Initially, high affinity, high-sensitivity α4β2* and α4α6β2* nAChRs found on ventral
tegmental area (VTA) dopamine (DA) neurons are quickly activated by low nicotine
concentrations upon arrival into the midbrain region (Pidoplichko et al., 1997; Picciotto et al.,
1998; Liu et al., 2012; Engle et al., 2013). Further, nicotine acts on α7 nAChRs on glutamate
neurons of local and distal regions resulting in a net excitatory effect on VTA DA neurons and
synaptic strengthening between the two neuronal populations (Mansvelder and McGehee, 2000,
2002; Dani, 2015). In addition to this excitatory transmission through DA and glutamate
neurons, activation of the α4β2* nAChRs found on GABA neurons of the midbrain elicits an
inhibitory tone to VTA DA neurons, reducing the transmission of DA and decreasing reward
through the mesolimbic pathway (dopaminergic tracts from the VTA to the nucleus accumbens
(NAc)) (Johnson and North, 1992). However, the activation of α4β2* and α7 nAChRs on
midbrain DA and glutamate neurons, respectively, promotes a net excitatory effect on DA
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Steps of Nicotine Addiction
Nicotine binding promotes a conformational
transition of nAChRs from a resting, closed
state to an open state, allowing signal
transduction to occur (Unwin et al., 2002;
Miyazawa et al., 2003).
When an individual becomes a long-term
nicotine user, nAChR upregulation occurs.
Upregulated α4β2* nAChRs found on
GABA neurons of the midbrain elicit an
inhibitory tone to VTA DA neurons,
reducing the transmission of DA and
contribute to nicotine-seeking behaviors
(Johnson and North, 1992).
After long-term exposure to nicotine, α4β2*
nAChRs desensitize quickly, which
decreases the GABAergic transmission onto
DA neurons resulting in the disinhibition of
DA neurons.
The activation of α4*, α6*, and α7 nAChRs
on midbrain DA and glutamate neurons,
respectively, promotes a net excitatory effect
on DA neurotransmission from the VTA to
the NAc and PFC, leading to the rewarding
and reinforcing aspects of nicotine use
(Mansvelder and McGehee, 2002).
These effects are reinforced by the enhanced
glutamate neurotransmission from distal
regions and local mVTA glutamate neurons
to lateral VTA DA neurons (Yan et al., 2018;
Yan et al., 2019), leading to long-term
potentiation (LTP).

nAChR
Subunits

Brain
Regions

Nicotine
Duration of
Concentration Administration

α4β2*,
α6β2β3,
α4α6β2*,
α7

Midbrain

Small (<1 µM)

Acute

α4, α6,
β2, and β3

VTA

Midbrain
GABA

20-500 nM

Chronic

α4β2*

α4β2*

Midbrain
GABA

α4β2*,
α6β2β3,
α4α6β2*,
α7

VTA

20-500 nM

Chronic

α7

mVTA,
PFC

Table 1. Nicotine’s Actions in the Brain
Summarized details of the various steps (sensitization, upregulation, and desensitization) that
take place during the development of nicotine dependence. The major findings for each step are
indicated in the leftmost column. The specific nAChR subunits and brain region associated with
these changes are in the second and third column. The nicotine concentration and duration of
administration that induce these changes are located in the two rightmost columns. * = nAChR
may contain other subunits.
neurotransmission from the VTA to the NAc and prefrontal cortex (PFC), leading to the
rewarding and reinforcing aspects of nicotine use (Mansvelder and McGehee, 2002). More
recently, Yan et al. discovered functional β2* nAChRs on medial VTA (mVTA) glutamate
neurons that further contribute to this net effect (2018; 2019). In general, nicotine exerts strong
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effects on the local microcircuits of the VTA, that have differing acute and chronic effects. This
will be discussed further in a later section.
Persistent nicotine exposure further transitions the receptor to a desensitized state, where
it is less responsive to agonist stimulation (Jensen et al., 2005; Picciotto et al., 2008; Wells,
2008). nAChRs are activated and desensitized to a degree depending on the subtype, brain
region, and concentration of nicotine. According to Brody and colleagues, nAChRs will activate
and desensitize at brain nicotine concentrations of 20-100 nM following cigarette smoking
(2006). Following activation, most α4β2* nAChRs desensitize which decreases the GABAergic
transmission onto DA neurons resulting in the disinhibition of DA neurons (Figure 2C). These
effects are reinforced by the enhanced glutamate neurotransmission from distal regions and local
mVTA glutamate neurons to lateral VTA (latVTA) DA neurons (Yan et al., 2018; Yan et al.,
2019). This depolarization and enhanced action potential firing of glutamatergic neurons leads to
long-term potentiation (LTP) and synaptic strength onto the midbrain DA neurons, which is a
key role in the formation of nicotine dependence (Nashmi et al., 2007) (Figure 2). Additionally,
although the α4β2* nAChRs present on VTA DA neurons desensitize similar to VTA GABA
neurons, these DA neurons also express α6β2β3* and α4α6β2* receptors which don’t desensitize
as quickly as the high affinity α4β2* nAChRs (Tapper et al., 2004). Overall, their continues to be
a net excitatory effect on DA release in the presence of nicotine molecules.
When an individual becomes a long-term nicotine user, further neuroadaptations occur. A
major hallmark of nicotine dependence has been the occurrence of nAChR upregulation. This
phenomenon has been understood by many to be a post-translational occurrence, based on no
observable changes in mRNA levels (Marks et al., 1992; Henderson et al., 2014; Henderson and
Lester, 2015). Similar to desensitization, upregulation differs in response to nicotine
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Figure 2. Involvement of VTA Neuron Types in Nicotine Reward and Reinforcement
(A) In the absence of nicotine, glutamate and GABA inputs to VTA dopamine neurons modulate
activity of the mesolimbic reward pathway. (B) Acute nicotine on α7 and α4β2 nAChRs elicits
enhanced glutamatergic and GABAergic firing, respectively, onto VTA dopamine neurons,
resulting in a net enhancement of dopaminergic neuron firing and subsequent dopamine release.
(C) Following long-term nicotine use, α4β2 nAChRs desensitize rapidly with acute exposure to
nicotine and result in reduced GABAergic firing while glutamatergic firing is enhanced to
stimulate burst firing of dopaminergic neurons (see Table 1 for additional details).
concentration and time course (Hurst et al., 2013), and is brain-region, cell-type, and nAChR
subtype-specific, given that no upregulation has been noted in the thalamus, high-affinity
nAChRs are favored for plasma upregulation, and only α4, α6, β2, and β3 subunits upregulate.
Upregulation occurs through a process termed pharmacological chaperoning that involves
intracellular actions of nicotine that promote nAChR subunit assembly and enhanced trafficking
of nAChRs through the secretory pathway (Kuryatov et al., 2005; Srinivasan et al., 2011;
Henderson et al., 2014; Henderson and Lester, 2015). This process is a physiological response
following nAChR desensitization (Dani and Heinemann, 1996; Picciotto et al., 2008) that takes
approximately ten days of long-term use among human and rodents but can also occur in
cultured neuron and cell line preps as well (Mukhin et al., 2008; Henderson and Lester, 2015).
Through the use of fluorescently tagged nAChRs, changes in nAChR number have been
11

measured without the use of radioligand binding assays (Nashmi et al., 2007; Srinivasan et al.,
2011; Henderson et al., 2014; Henderson et al., 2016; Henderson et al., 2017). As previously
stated, high-affinity α4β2 nAChRs are stabilized during this process (Kuryatov et al., 2005;
Srinivasan et al., 2011; Srinivasan et al., 2012b). With higher nicotine concentrations, further
nAChRs are subjected to upregulation as well.
Given these effects are based on freebase nicotine that is present in combustible
cigarettes, it is critical to point out the distinct differences between the combustible cigarette and
the electronic cigarette that may affect the timespan of these steps towards addiction. With JUUL
(pod-based e-cigarette) being one of the most popular ENDS devices among the adolescent
population, studies have begun to surface identifying what makes JUUL so popular. The major
difference between these products is the use of nicotine salt in JUULs (Omaiye et al., 2019a).
Nicotine salt differs from nicotine freebase in that it contains benzoic acid in order to sufficiently
protonate most of the nicotine. The use of nicotine salt results in faster absorption, increased
palatability at high concentrations, and thus increased nicotine strength as opposed to nicotine
freebase. Based on the different pharmacokinetic properties of these two nicotine forms, JUUL’s
average nicotine concentration per e-liquid pod is ~60 mg/mL, or 1.5 times the nicotine
concentration in a pack of cigarettes. Although combustible cigarettes range in nicotine
concentration, the majority contain 2 mg of nicotine per cigarette. Additionally, various
other ENDS products (tank-based e-cigarette) also exhibit higher nicotine concentrations than
the average cigarette (3–18 mg/mL), however, they are still much lower than the prefilled JUUL
pods. Based on these differences, it is likely that ENDS enhance the steps of nicotine addiction
and are further detrimental to the adolescent brain.

12

nAChR Subtypes
α4β2* nAChRs:
To date, α4β2* nAChRs have been the most-studied subtype in relation to nicotine
addiction (Tapper et al., 2004; Picciotto et al., 2008; Penton and Lester, 2009; Xiao et al., 2009;
Srinivasan et al., 2011; Grieder et al., 2019), as demonstrated through genetically modified
mouse models (Picciotto et al., 2001; Tapper et al., 2004; Pons et al., 2008; Grieder et al., 2019).
Using knockout mice, Picciotto et al.Picciotto et al. (2001) investigated α4 and β2 subunits and
found attenuated nicotine self-administration and conditioned place preference in the absence of
these subunits. However, when α4 or β2 subunits were re-expressed in the VTA, a prominent
brain region associated with drug reward, it led to recovery of nicotine reinforcement and
reward, demonstrating the importance of α4β2* nAChRs in the formation of nicotine
dependence, specifically in the VTA. Alternatively, Tapper et al. Tapper et al. (2004) genetically
altered mice to express hypersensitive α4* nAChRs. This approach looked beyond the necessary
presence of α4β2* nAChRs in addiction, and instead investigated the specific role(s) that α4 may
play in addiction. The presence of hypersensitive α4* not only enhanced nicotine reward at low
concentrations, but it also mediated nicotine-induced locomotion through α4* nAChR
sensitization, and facilitated tolerance to nicotine, emphasizing its importance in the induction
and maintenance of nicotine dependence. Further, the administration of the β2* receptor-specific
antagonist, dihydro-β-erythroidine (DhβE) hydrobromide, into the VTA decreases nicotine
reward-related behavior as well as blocks the reinforcing effects of the drug (Corrigall et al.,
1994; Watkins et al., 1999).
α4β2* nAChRs exist in a high- and low-sensitivity stoichiometry, α4(2)β2(3) and α4(3)β2(2),
respectively (Nelson et al., 2003; Tapia et al., 2007). Due to its high sensitivity stoichiometry,
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α4β2* receptors have a high affinity for low concentrations of nicotine commonly present
following cigarette smoke inhalation (Picciotto et al., 1998; Kuryatov et al., 2008; Penton and
Lester, 2009). Nicotine-induced upregulation of α4β2* nAChRs has been shown to depend on
the specific subunit composition, with the high-sensitivity stoichiometry to be favored (Schwartz
and Kellar, 1983; Srinivasan et al., 2011; Srinivasan et al., 2012b; Henderson et al., 2014).
Further, it is important to note the more recent identification of genetic etiologies of CHRNA4,
CHRNB2, and CHRNB4. Liu et al. (2019) positively correlated these genes with smoking
phenotypes including ‘age of smoking initiation’, ‘cigarettes per day’, and ‘smoking cessation’.
α6β2β3* nAChRs:
Given the knowledge that α6* nAChRs are expressed in dopaminergic neurons
(Champtiaux et al., 2002), initial studies aimed to identify the specific brain regions expressing
these subtypes. The expression of α6β2β3* nAChRs is mostly limited to reward-related brain
regions, including the DA neurons of the mesolimbic tract, making them critical factors in the
induction of addiction (Champtiaux et al., 2003; Salminen et al., 2004; Wonnacott et al., 2005;
Mackey et al., 2012). However, investigations into the role of α6* nAChRs in addiction have
been very limited, with one of the first critical findings being reported by Pons et al. (2008).
Utilizing an intravenous nicotine self-administration paradigm and α6 knock-out mice, Pons et
al. discovered the essential role of α6* nAChRs in nicotine reinforcement by demonstrating the
lack of self-administration behaviors in α6 knock-out mice compared to their wildtype
counterparts (2008). Furthermore, re-expression of α6 through a lentiviral vector into the VTA
significantly increased self-administration behaviors to a similar extent as the wildtype control
mice. Nicotine-induced activation of the mesolimbic system is dependent upon the presence of
α4β2* and α6β2β3* nAChRs, as seen through conditioned place preference and self-
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administration assays (Picciotto et al., 2001; Walters et al., 2006; Pons et al., 2008). Similar to
α4β2* nAChRs, α6* nAChRs consist of two stoichiometric forms, α6β2 or α6 (2)β2(2)β3
(Henderson et al., 2014; Henderson et al., 2016). The inclusion of the β3 subunit results in a
much higher sensitivity to nicotine. Further, α6β2* nAChRs desensitize to a similar extent as
α4β2* nAChRs, however α6β2* nAChRs recover more quickly (Xiao et al., 2011) and are thus
more amenable to nicotine’s long-term effects.
α4α6β2* nAChRs:
Despite the wide presence of nAChRs throughout the central nervous system, recent
studies point to α4α6β2* nAChRs as a principle nAChR subtype that mediates nicotine reward.
As discussed earlier, deletions of α4 have shown the importance of this subunit; but additional
studies with mouse models tell us that α4α6β2* nAChRs mediate the rewarding effects of
nicotine. Deletion of α4, α6, or β2 nAChR subunits is sufficient to block the self-administration
of nicotine in mice (Pons et al., 2008). The selective re-expression of these deleted subunits in
the VTA was sufficient to re-instate self-administration of nicotine (Pons et al., 2008). Reexpression of these subunits in neighboring midbrain regions, the substantia nigra pars reticulata
(SNr) and substantia nigra pars compacta (SNc), did not ‘rescue’ nicotine reinforcement. The
nicotine-induced enhancement of DA neuron excitability that is required for reward is dependent
upon α4α6β2* nAChRs (Liu et al., 2012; Engle et al., 2013). Here, both Liu et al. (2012) and
Engle et al. (2013) revealed that the presence of both α4 and α6 were necessary for smokingrelevant concentrations of nicotine (300 nM) to activate nAChRs on VTA DA neurons. This
suggests that while studies have revealed the importance of α4 and α6 nAChR subunits
independently, the physiological response to smoking-relevant concentrations of nicotine (≤300
nM) depend on α4α6-containing nAChRs.
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α7 nAChRs:
Alongside α4β2*, α6β2*, and α4α6β2* nAChRs, the α7 nAChR subtype also plays a
prominent role in the formation of nicotine dependence. This homomeric nAChR subtype is
largely present on glutamatergic neurons in the prefrontal cortex (PFC), hippocampus, and
mVTA. Expression of α7 nAChRs in these brain regions plays multiple roles in nicotine
addiction: they aid in the formation of functional synapses (Molas and Dierssen, 2014), promote
the net excitatory effect on midbrain DA neurons of the reward pathway (Mansvelder and
McGehee, 2000), and enhance postsynaptic excitation through NMDA receptors in the
hippocampus and prefrontal cortex (Mansvelder and McGehee, 2000; Molas and Dierssen,
2014). More recently, a population of functional heteromeric nAChRs have been discovered on
mVTA glutamatergic neurons (Yan et al., 2018). This novel finding supports the previous work
demonstrating the intricate connections between VTA glutamate and DA neurons in reward and
reinforcement processing (Mansvelder and McGehee, 2000, 2002; Wang et al., 2015), but further
expands this knowledge by observing that nicotine mediates the excitatory transmission at this
connection, and thus amplifies the mesocorticolimbic reward transmission (Yan et al., 2018).
The α7 nAChR exhibits different receptor kinetics compared to α4β2* nAChRs,
exemplified by fast activation and desensitization (Jensen et al., 2005). Due to their
desensitization properties, α7 nAChRs recover very rapidly, explaining the net excitation
discussed earlier. The net excitation through rapid recovery following desensitization, and high
permeability to calcium, makes α7 nAChRs critical factors in the induction of long-term
potentiation (LTP) (Alkondon and Albuquerque, 1991, 2001). Nicotine-induced synaptic
plasticity, or LTP, of glutamatergic neurons in the VTA, PFC, and hippocampus are important in
the tolerance and associative learning of nicotine addiction. Regardless of the fast depolarization
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of VTA DA neurons through nicotine’s effect on α4β2*, α6β2*, and α4α6β2* nAChRs, these
receptors desensitize fairly quickly and recover slowly, rendering them inactive to the remaining
nicotine molecules circulating in the brain. Thus, it is the presence of α7 nAChRs and their rapid
recovery that contribute to the long-standing effects of long-term nicotine. Additionally,
administration of methyllycaconitine (MLA), an α7-selective antagonist, did not alter nicotine
CPP, but decreased self-administration, confirming α7 nAChRs’ role in reinforcement but not
reward (Walters et al., 2006). These findings were further verified by the lack of change in
nicotine self-administration behavior between α7-KO and α7-WT mice (Pons et al., 2008).
It is the reinforcing properties of nicotine that promote dependence, despite the many
health risks. VTA DA neurons receive local and distal (mainly PFC) excitatory glutamatergic
inputs that further prompts DA release into the NAc, amygdala, and PFC, which makes up the
mesocorticolimbic system (Swanson, 1982). However, when nicotine is persistently present in
this system, it causes modification of neural circuits that promotes drug-induced synaptic
plasticity (Lüscher and Malenka, 2011). This phenomenon outlasts the effects of the presence of
nicotine molecules and contributes to the formation of tolerance and memory consolidation to
nicotine. It’s the repetitive use and reinforcing properties of nicotine that causes the brain to form
an association between nicotine use and the physiological response to nicotine use. This
association is what drives nicotine dependence by mediating the behavioral effects of nicotine
addiction, including cue-induced craving and reinstatement (in rodents) or relapse (in humans)
(van Huijstee and Mansvelder, 2014).
α3* and α5* nAChRs:
Genetic polymorphisms in the α3/α5/β4 nAChR subunit gene cluster have been linked to
increased risk of nicotine addiction (Saccone et al., 2007; Berrettini et al., 2008). Variation in the
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amino acid sequence of CHRNA5 results in reduced α5* nAChR activity and increases the risk
for dependence (Berrettini et al., 2008; Bierut et al., 2008; Wang et al., 2009). Additionally,
Fowler et al. identified a null mutation in the CHRNA5 gene that results in significantly more
intravenous self-administration nicotine consumption, compared to their control mice (2011).
Interestingly, they found that α5* nAChRs are involved in mediating aversive stimuli, titrating
nicotine intake, and mediating somatic signs of withdrawal.
The α5* and α3β4* nAChRs are mostly expressed in the habenulo-IPN pathway, formed
by cholinergic and glutamatergic neurons that project from the medial habenula (MHb) to the
interpeduncular nucleus (IPN) through a bundle of axons termed the fasciculus retroflexus
(Penton and Lester, 2009; Fowler et al., 2011; Fowler and Kenny, 2014). Due to their low
affinity for nicotine, these subtypes require high concentrations of nicotine to sensitize them (~2
mg/kg or more) (Fowler et al., 2011; Fowler and Kenny, 2014; Dani, 2015). The opening of α5*
or α3β4* nAChRs activates the aversive pathways involved in the regulation of nicotine intake.
The activation of either the habenulo-IPN pathway or the lateral habenula (LHb) projections to
the rostromedial tegmental nucleus (RMTg) and VTA is a response to the aversive aspects of
nicotine, including high doses of nicotine or nicotine withdrawal (discussed later).
Neurocircuitry Involved in Nicotine Addiction
Ventral Tegmental Area (VTA)
The ventral tegmental area is among the most vital brain regions involved in addiction.
The VTA is a heterogenous collection of neurons that in part makes up the midbrain. Although
primarily studied for its DA neurons, the VTA also consists of γ-amino butyric acid (GABA) and
glutamatergic neurons (Nair-Roberts et al., 2008). VTA DA neurons have been widely studied in
various drug-related experiments for nearly all drugs of abuse act on VTA DA neurons to
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stimulate DA neurotransmission into the ventral striatum, or nucleus accumbens (NAc) –
commonly known as the mesolimbic pathway (Di Chiara and Imperato, 1988; Wise and Rompre,
1989; Pidoplichko et al., 1997; Koob and Le Moal, 2001). Further, nicotine-induced activation of
this pathway stimulates reward, as seen in conditioned place preference (CPP) assays (Tapper et
al., 2004; Wise, 2008; Avelar et al., 2019; Grieder et al., 2019). Whereas, lesioning of this
pathway completely abolishes nicotine reward-related behavior, nicotine self-administration, and
nicotine-induced locomotion (Corrigall et al., 1992; Corrigall et al., 1994; Louis and Clarke,
1998). Additionally, VTA DA neurons project to the prefrontal cortex (PFC) through the
mesocortical pathway, and synapse on cortical pyramidal neurons and GABAergic interneurons.
This dopaminergic pathway is largely associated with drug reinforcement and is commonly
activated during nicotine self-administration studies (Capriles et al., 2003; Counotte et al., 2012).
Together, these paths make up the mesocorticolimbic DA pathway and are often linked in studies
on drugs of abuse, although there are additional projections to various other brain regions,
including the hippocampus and amygdala. Each of these neuronal paths circle back to the VTA
and mediate the activity of the dopaminergic neurons (discussed further in their corresponding
sections).
The VTA also receives afferent projections from numerous parts of the brain that mediate
reward or aversion of certain stimuli. The cholinergic and glutamatergic projections of the
laterodorsal tegmental nucleus (LDTg) and pedunculopontine tegmental nucleus (PPTg) excite
the DA neurons of the VTA leading to burst firing, enhanced dopamine release, and rewardrelated behavior (Figure 3) (Omelchenko and Sesack, 2005; Lodge and Grace, 2006; Paladini
and Roeper, 2014). During long-term nicotine exposure, these glutamatergic projections can
initiate long-term potentiation (LTP) in the VTA, promoting a continuous excitatory effect
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(Wolf, 2002). On the contrary, the medial (MHb) and lateral habenula (LHb) neurons innervate
the interpeduncular nucleus (IPN) and rostromedial tegmental nucleus (RMTg) GABAergic
neurons, respectively, which employ an inhibitory tone onto VTA DA neurons of the mesolimbic
pathway (Figure 3) (Matsui and Williams, 2011; Lammel et al., 2012). This net inhibition is
stimulated during aversive stimuli, such as high nicotine concentrations, or during withdrawal
(Fowler et al., 2011; Fowler et al., 2013; Fowler and Kenny, 2014). Additionally, the LHb sends
direct projections to the VTA which are acted upon by aversive stimuli, including the absence of
an expected reward (Hikosaka, 2010). These different afferent projections regulate the firing
patterns of VTA DA neurons and influence behavioral outputs.
Although many drugs of abuse studies have focused on DA neurotransmission,
GABAergic and glutamatergic neurons of the VTA are prominent factors in the development of
nicotine dependence. Opioids, cannabinoids, and benzodiazepines primarily target the VTA
GABAergic interneurons, inhibiting their activity and causing disinhibition and burst firing of
the neighboring DA neurons (Sulzer, 2011). Both GABAergic and glutamatergic interneurons of
the VTA send projections to their neighboring DA neurons in order to maintain a homeostatic
balance of neuronal firing. Following a cigarette or ENDS puff, nicotine activates the nAChRs
found on each of these neuronal populations and increases neuronal firing (Maskos et al., 2005).
However, in a long-term user, these neuronal firing patterns become altered following nAChR
desensitization (see Figure 2). The α7 nAChRs expressed on glutamatergic neurons desensitize
(and recover) the fastest while β2* nAChRs (α4β2*, α6β2*, and α4α6β2*) desensitize (and
recover) much slower. As stated previously, a long-term nicotine user succumbs to various
neuroadaptations, including nAChR upregulation and altered neuronal firing. Throughout
abstinent periods, the GABAergic neuron firing patterns are enhanced, resulting in a net
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Figure 3. Neurocircuitry Involved in Nicotine Addiction
(A) Sagittal mouse brain schematic of the major brain regions and connections involved in
nicotine addiction. (B) Intricate schematic of the above neurocircuitry. DA: dopaminergic,
GABA: GABAergic, GL: glutamatergic, CH: cholinergic neurons. Blue arrows indicate
excitatory projections; red arrows indicate inhibitory projections; and green arrows indicate
modulatory projections.
inhibitory effect on the DA neurons. This not only reduces baseline DA neurotransmission but
causes a depressive state that often triggers craving and relapse. In order to relieve this, the user
will consume more nicotine, activate the nAChRs on the various neuronal populations, and
increase firing and DA release. With repeated exposure and stimulation, nicotine renders many
of the nAChRs inactive. Based on their desensitization properties, the GABA neurons
(containing α4β2*) have reduced output, resulting in disinhibition of the VTA DA neurons
(Mansvelder and McGehee, 2002). Additionally, the fast recovery of α7 nAChRs promotes a net
excitatory effect on these DA neurons. It has long been considered that nicotine exerts its effects
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on α7 and β2* nAChRs on VTA glutamate and GABA neurons, respectively, resulting in a
mediatory action on VTA DA neurons. However, recent studies have shown that these glutamate
neurons, found primarily in the mVTA, express α4, α6, and β2 nAChR subunits in a
somatodendritic manner (Yan et al., 2019). Further, Yan et al. has discovered that of the three
major neuronal populations in the mVTA (VGluT2+ (glutamatergic neurons), Gad2+
(GABAergic neurons), and VGluT2+/Gad2+ (glutamatergic/GABAergic co-releasing neurons)),
nicotine enhanced glutamate release in the latVTA via VGluT2+ neurons but decreased
glutamate (and GABA) release via Gad2+ and VGluT2+/Gad2+ neurons (2019). This further
demonstrates the complexity of the VTA, and the various microcircuits involved in reward
processing. It is due to these changes, that a person dependent on nicotine requires more nicotine
over time to achieve the rewarding feeling they once felt. Additionally, more studies are
identifying the role of glycine in this microcircuit. Although little work has been performed on
glycine’s impact on nicotine addiction, it has been shown that glycinergic neurotransmission
significantly alters ethanol intake most likely by impacting glutamate release via glycine
receptors on glutamatergic terminals of the VTA (Guan and Ye, 2016), however these receptors
are also present on GABAergic terminals and have resulted in reduced GABA release and
enhanced dopamine release (Ye et al., 2004; Li et al., 2012). Accordingly, glycine receptors may
play a role in nicotine’s actions; but this has yet to be determined.
Substantia Nigra (SN)
Another contributing cluster of neurons that makes up the midbrain is the substantia
nigra. The SN is composed of two sub-groups: pars compacta (SNc) and pars reticulata (SNr).
The SNc is composed of dopaminergic, glutamatergic, and GABAergic neurons while the SNr is
largely made up of GABA neurons. The third most extensively studied dopaminergic pathway in
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the brain aside from the mesocorticolimbic paths is the nigrostriatal pathway, a dopaminergic
tract from the SNc to the dorsal striatum (Tritsch and Sabatini, 2012). Activation of this pathway
is involved in the motor loop of the basal ganglia and has been shown to be acted on by drugs of
abuse (Drenan et al., 2010). The loss of dopaminergic neurons in this pathway is a pathological
classification of Parkinson’s disease, characterized by tremors and motor deficits.
Nucleus Accumbens (NAc)
A major output target of VTA DA neurons is the ventral striatum, or the nucleus
accumbens (NAc). This connection makes up the mesolimbic pathway. This pathway is highly
involved in reward-related effects of drugs of abuse (Di Chiara and Imperato, 1988; Pidoplichko
et al., 1997). The NAc contains two subregions: the core and the shell, and is made up of
specialized GABAergic neurons, termed medium spiny neurons (MSNs). MSNs consist of two
types: D1 (direct pathway) and D2 (indirect pathway) based on the DA receptors present, further
explained by Cooper et al. (2017). These neurons receive excitatory projections from the PFC,
hippocampus (HIPP), and the VTA (Lüscher and Malenka, 2011) to mediate the reinforcing and
drug-seeking behaviors of nicotine addiction (McFarland and Kalivas, 2001; Knackstedt and
Kalivas, 2009). Repeated activation of the afferent glutamatergic projections can lead to LTP in
the NAc, further driving drug-taking behaviors, as demonstrated through reduced AMPAR and
AMPAR/NMDAR ratios on MSNs following drug consumption (Lüscher and Malenka, 2011).
The D1 MSNs of the lateral NAc shell project in a cyclical manner back to the VTA and synapse
on VTA GABA neurons (Lüscher and Malenka, 2011; Yang et al., 2018). These projections
further regulate and disinhibit the VTA DA neuron activity, resulting in enhanced DA release
(Xia et al., 2011; Bocklisch et al., 2013).
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Prefrontal Cortex (PFC)
Dopaminergic projections from the VTA to the PFC make up the mesocortical pathway
involved in reinforcement and motivational salience (McFarland and Kalivas, 2001; Capriles et
al., 2003; Cooper et al., 2017). This pathway has enhanced neurotransmission during nicotine
self-administration, demonstrated by an increase in postsynaptic ionotropic glutamate receptors
in the PFC (Wang et al., 2007). PFC lesions significantly reduced nicotine self-administration in
adult rats, however, to date, this lesioning has only been performed in neonates (Rezvani et al.,
2008). Additionally, glutamatergic pyramidal neurons of the PFC project back to the VTA,
amygdala, hippocampus, and NAc. The connection between the PFC and NAc is stimulated
during drug seeking and reinstatement (Cornish and Kalivas, 2000; Kalivas and Volkow, 2005).
Due et al. has demonstrated PFC activation of smoker’s brains via functional magnetic resonance
imaging in the presence of a smoking-related cue (an image of a person smoking) (2002).
Activation of the PFC to VTA pathway results in enhanced firing of the VTA DA neurons and
increases DA release through the mesolimbic pathway (Taber et al., 1995), in part due to
upregulation of NMDA and AMPA receptor activation (Mansvelder and McGehee, 2000).
Based on the growing number of adolescent ENDS users, it is important to discuss the
effects of nicotine exposure on the developing brain. More specifically, the PFC is one of the last
brain regions to fully reach maturation in the developing brain which indicates the executive
control functions, including attention and working memory are not fully developed upon initial
nicotine exposure. Nicotine use or exposure during this critical development period is known to
negatively impact the developmental process, resulting in impaired cognition and psychiatric
disorders, including depression (Brown et al., 1996; Deas, 2006), and also often results in an
increased risk for drug abuse behaviors (Yuan et al., 2015).
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Hippocampus (HIPP)
The hippocampus (HIPP) is highly involved in learning and memory, which is of
importance to the tolerance-related aspect of nicotine addiction. The glutamatergic neurons of
the HIPP are simultaneously excited by VTA DA and PFC pyramidal neurons, which induces
LTP in the hippocampus. The strengthening of hippocampal synapses is a key feature to nicotine
addiction because of its underlying mechanism involved in cue-induced drug-seeking behavior
often leading to relapse (Pascoli et al., 2014). The changes in synaptic machinery are due to the
initial formation of immature glutamatergic synapses from the HIPP onto NAc MSNs, leading to
silent synapses, which promotes no electrical changes on the post-synaptic inhibitory neurons of
the NAc. These immature synapses are due to a large NMDA to AMPA ratio, however, during
nicotine withdrawal, stimulation of active synapses occurs in part due to the insertion of AMPA
receptors on the presynaptic glutamate neurons. This alteration leads to the propagation of
inhibitory signals through the reward pathway, ultimately driving drug craving behaviors (Huang
et al., 2015).
Habenula (Hb)
Although most drugs of abuse studies focus on reward pathways, aversive pathways play
an important role in addiction as well. The habenula consists of a medial (MHb) and lateral
(LHb) portion that has been known to be implicated during nicotine aversion. The most widely
studied aversive pathway is the habenulo-IPN tract, that runs from the MHb to the IPN. The
excitatory glutamatergic and cholinergic projections of the MHb activate the GABAergic
neurons of the IPN which then inhibits the DA neurons of the VTA (McLaughlin et al., 2017).
This, in turn, leads to decreased activation of the mesolimbic pathway and thus, reduced reward.
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Although many studies have shown the rewarding and reinforcing aspects of nicotine that
drive the drug-seeking and taking behaviors, nicotine is known to have an inverted U-shaped
dose response curve in rodents as well as humans (Corrigall and Coen, 1989). Due to this dosedependent effect, nicotine tends to be aversive at high concentrations. Humans have been shown
to titrate the amount of nicotine they consume when smoking or vaping because of the aversive
properties of too much nicotine. The process of titration occurs through α3/α5/β4* nAChRs
which are only activated in the presence of high nicotine concentrations (~2 mg/kg in a rodent)
(Fowler et al., 2011; Fowler and Kenny, 2014; Dani, 2015). These nAChR subunits are highly
populated in the habenulo-IPN pathway that mediates the aversive properties of nicotine. In the
absence of these subunits, individuals no longer titrate their nicotine consumption and lose the
mediatory effects of this pathway on the negative effects of high doses of nicotine. These
subunits are also important in the manifestation of withdrawal, including the somatic and
physical symptoms. Knockout mice lacking these subunits exhibited fewer somatic withdrawal
symptoms (Salas et al., 2004; Salas et al., 2009) in chronic nicotine administered mice.
Further, the less studied but still relevant aversive LHb pathway is a collection of
glutamatergic and cholinergic excitatory neurons that project to the tail of the VTA, the
rostromedial tegmental nucleus (RMTg). The GABAergic neurons of the RMTg then inhibit DA
cell firing of the VTA (Ji and Shepard, 2007). This pathway is acted on by aversive stimuli, such
as the aversive signals associated with nicotine withdrawal and the absence of an expected
reward, in an attempt to suppress the mesocorticolimbic DA system (Matsumoto and Hikosaka,
2007). Activation of the Hb pathways is important in the development of addiction, for their
influence on drug-seeking and taking behaviors.
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Flavoring Chemicals in Nicotine Addiction
In the late 1900s, cigarette smoking had little to no restrictions and was acceptable in
restaurants, hospitals, public transportation, and more, making them not only freely accessible
but a new trend among the United States, with ~50% of young women and ~60-70% of young
men being long-term smokers (SGR, 1964). This popularity was in part attributed to flavoring
additives. Mentholated cigarettes became a huge success, especially among the adolescent
population after the discovery that menthol provided a cooling sensation in the cigarette smoke.
Adolescent cigarette use continued to rise over the years due to the sweet aroma and taste that
“characterizing” flavors provided. It wasn’t until 2009 that the Family Smoking Prevention and
Tobacco Control Act (FSPTCA) gave the FDA the authority to ban “characterizing” flavor
additives such as strawberry and vanilla (not including tobacco or menthol) in combustible
cigarettes in an attempt to mitigate adolescent cigarette use (FSPTCA, 2009).
Since the FSPTCA, menthol has been the most widely studied flavor additive, for its
popularity and sole acceptance as a flavorant in combustible cigarettes. Aside from mentholated
cigarette popularity among adolescents, menthol has also long been popular among African
Americans, with more than 80% of non-Hispanic black adults using menthol cigarettes (Odani,
2018). It was recently determined that African Americans exhibit unique variants, including
MRGPRX4, that promotes a significant increase in the odds of menthol cigarette smoking
(Kozlitina et al., 2019). Now that ENDS products are commonly used among previous life-long
combustible cigarette smokers, menthol is still a very prominent flavor in e-liquids. Menthol is
known to intensify various smoking-related behaviors and facilitates first-time nicotine use by
masking the aversive properties of nicotine (Wickham, 2015), which may explain the popularity
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of flavored ENDS and signifies the concerns with adolescent ENDS use (Fan et al., 2016;
DeVito and Krishnan-Sarin, 2018).
Initially, menthol was considered to be an inert flavor additive, with the focus of tobaccorelated research being on nicotine dependence. It was not until the early 2000s that studies on
menthol began to surface. These initial studies suggested menthol smokers to be more nicotine
dependent based on (1) how quickly they smoke upon waking in the morning compared to nonmenthol smokers (Ahijevych and Parsley, 1999; Baker et al., 2007), and (2) the higher
nicotine/cotinine levels among menthol smokers versus non-menthol smokers (Ahijevych and
Parsley, 1999; Ahijevych and Garrett, 2004). Further, Ahijevych and Garrett (2004) identified
menthol to be a conditioned stimulus that enhances the rewarding and reinforcing properties of
nicotine through its positive sensory effects, resulting in drug-craving and drug-taking behaviors.
These behaviors were mimicked in female rats that earned more intravenous nicotine infusions in
the presence of an oral menthol cue during self-administration assays (Wang et al., 2014).
Conditioned stimuli paired with nicotine enhance the acquisition and maintenance of nicotine use
and are known to be a driving force in nicotine dependence (Caggiula et al., 2001). Menthol has
the unique minty taste profile and a cooling sensory effect that, when combined with nicotine can
contribute to craving and relapse when a person is going through an abstinent period (Harrison et
al., 2017). These sensory cues are common among other sweet oral flavorants as well, including
sucrose and saccharin. Interestingly, Wickham et al. (2018) utilized an intraoral delivery method
that resulted in sucrose- and saccharin-induced phasic DA release, and significantly increased
nicotine self-administration behavior. It is these conditioned sensory cues that often make
cessation so difficult.
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Based on these initial sensory effects, menthol was studied for its pharmacological
impact in the brain. Menthol was determined to act as a negative allosteric modulator (NAM) of
nAChRs following the observation of reduced nicotine-induced (but not ACh-induced) inward
currents through α4β2* nAChRs expressed in human embryonic kidney (HEK) cells (Hans et al.,
2012). This finding was supported by additional electrophysiological characterization utilizing
single-channel recordings that revealed menthol shifted α4β2 nAChRs towards the desensitized
conformation state. In separate investigations, menthol was identified as a noncompetitive
antagonist on both α7 and α3β4* nAChRs (Ashoor et al., 2013b; Ton et al., 2015). A
combination of computational docking, site-directed mutagenesis, and electrophysiology
revealed that menthol may exert its effect on nAChRs by binding to the 9’ position in the
transmembrane 2 (M2) helix of nAChRs (Henderson et al., 2018) (Figure 4A). Here, a series of
mutations at the 9’ leucine residues (L9’) of the high-sensitivity α4β2 nAChRs were made and
characterized with electrophysiology to investigate the connection between menthol’s
pharmacology and the L9’ site (Henderson et al., 2018). It was concluded that menthol’s
inhibitory actions rely on the presence of the L9’ site of the M2 helix and only one menthol
molecule is sufficient for α4β2 nAChR inhibition. Another recent study identified additional
menthol binding sites, including the M3-M4 extracellular interface on α4 subunits, various sites
at the M1–M4 interface on β2 subunits, and M2 residues positioned extracellularly (Shahoei and
Tajkhorshid, 2020). However, these binding sites have not been validated using functional
assays. Here, it is important to distinguish the fact that the concentrations of menthol used to
examine its inhibitory activity on nAChRs is several orders of magnitude higher (>30 µM) than
what is considered smoking/vaping-relevant (<2 µM). The studies that have used low
concentrations of menthol (0.5 µM) have determined that menthol combined with nicotine does
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Figure 4. Menthol Binding Patterns and Mechanisms of Action
(A) Top panel: Menthol molecule (in green) binding in the transmembrane 2 (M2) helix lining
the central pore of the nAChR. Bottom panel: A closer look at menthol binding within the 9’
leucine residues of the M2 helix of the nAChR. (B) Compared to saline, menthol induces
upregulation of low-sensitivity (LS) α4* nAChRs on VTA GABA neurons (in red) and α4* (LS)
and α6* nAChRs on VTA dopamine neurons (in green). This results in reduced neuronal firing
based on the desensitization properties of the nAChRs, with a net excitatory effect of VTA
dopamine release. * = nAChR may contain other subunits.
enhance nAChR upregulation on VTA dopamine neurons and also enhances the excitability of
these same neurons (discussed further below) (Henderson et al., 2017; Henderson et al., 2018). A
previously published review has extensively disseminated the recent investigations that have
elucidated the mechanism of menthol’s actions on nicotine reward and reinforcement (Wickham,
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2015). To avoid repeating what has been eloquently explained and summarized previously, we
direct interest into the specifics to the review by Wickham et al. (2015).
Much like nicotine’s prominent ability to promote nAChR upregulation, menthol has
previously been determined to induce nAChR upregulation in the brainstem, cerebellum, corpus
callosum, PFC (Brody et al., 2013), hippocampus, striatum (Alsharari et al., 2015), and VTA
(Henderson et al., 2016; Henderson et al., 2017). More specifically, Henderson and colleagues
observed increased levels of α4 and α6 nAChR subunit expression in VTA neurons following
10-day chronic menthol exposure (Henderson et al., 2016), as well as increased levels of α4 and
α4α6* nAChRs in VTA neurons following 10-day chronic menthol + nicotine exposure
(Henderson et al., 2017) through osmotic minipumps and daily intraperitoneal injections in mice.
However, unlike nicotine, chronic menthol treatment caused a shift from α4(2)β2(3) (highsensitivity) to α4(3)β2(2) (low-sensitivity) nAChRs in cultured cells (Henderson et al., 2016). This
stoichiometry shift was accompanied by reduced VTA DA neuron firing frequency and an
attenuation of reward-related behavior, dissimilar to nicotine. Interestingly, menthol + nicotine
not only resulted in α4α6* nAChR upregulation, but also enhanced VTA DA neuron excitability,
and enhanced nicotine reward-related behavior (Henderson et al., 2017).
These neurobiological and neurophysiological alterations via menthol contribute to the
behavioral effects demonstrated in rodent studies. As stated previously, menthol lacks the
rewarding properties that nicotine presents, but menthol has the ability to enhance nicotine
reward-related behavior with rodents in a conditioned place preference assay (Henderson et al.,
2017). Further, to determine menthol’s effect on smoking initiation, self-administration
paradigms have been used to determine menthol’s role in nicotine acquisition. In numerous
studies, menthol facilitated intravenous nicotine self-administration and increased the rate of
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nicotine intake compared to control groups (Wang et al., 2014; Biswas et al., 2016). This
behavior was followed by enhanced withdrawal-like behaviors, demonstrated through somatic
signs and anxiety-related assays (Alsharari et al., 2015), and enhanced menthol-induced
reinstatement (Wang et al., 2014). Menthol presents a minty and cooling sensation through a
transient receptor potential M8 (TRPM8)-mediated mechanism, which in turn, masks the
aversive and harsh taste of nicotine by shifting nicotine’s inverted U-shaped dose-response curve
to the left and contributing to the enhanced nicotine acquisition behavior. Aside from menthol’s
ability to enhance smoking initiation, chronic menthol enhances the reinforcing properties of
nicotine, leading to enhanced nicotine self-administration and dependence over time (Biswas et
al., 2016). This may partially be due to menthol’s effect on nicotine metabolism (Wickham,
2019). More specifically, menthol smokers exhibit reduced nicotine metabolism compared to
non-menthol smokers (Alsharari et al., 2015; Valentine et al., 2018), likely due to a competitive
effect of menthol on the availability of CYP2A6, the major cytochrome enzyme involved in
metabolizing nicotine (Wickham, 2019).
With the common knowledge that smokers of menthol cigarettes exhibit lower cessation
rates (Villanti et al., 2017) and the growing use of flavored ENDS products (see Table 2),
studies are beginning to arise on the role of other flavor additives. Recently these studies have
included the popular green apple ENDS flavorants, farnesol (Avelar et al., 2019) and farnesene
(Cooper et al., 2020), for they are structurally similar to menthol in the terpene class (see Figure
5). According to Espino-Diaz et al., apple biochemistry varies during the maturation process,
with aldehydes primarily making up the apple flavor profile during the beginning, and following
maturity, the flavor profiles transition to primarily alcohols and esters (2016). Farnesol, like
menthol, is a terpene alcohol, which makes them more water soluble than a typical hydrocarbon,
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Flavor Chemical

Chemical Class

Vanillin

Aldehyde

Ethyl Vanillin

Aldehyde

Ethyl Maltol

Alcohol

Maltol
Benzaldehyde
Benzyl Alcohol
Ethyl Butyrate
Menthol
Hexyl Acetate
Ethyl Acetate
Methylbutyl Acetate
Farnesol
Farnesene

Alcohol
Aldehyde
Alcohol
Ester
Alcohol
Ester
Ester
Ester
Sesquiterpene
Sesquiterpene

Flavor Profile
Vanilla, Chocolate, Cotton Candy, Mint, Coffee,
Tobacco
Vanilla, Chocolate, Cotton Candy, Coffee, Tobacco
Vanilla, Chocolate, Cotton Candy, Mint, Coffee,
Tobacco, Grape, Cherry
Vanilla, Chocolate, Mint, Coffee, Tobacco, Grape
Cherry, Bubble Gum
Cherry, Vanilla, Coffee, Tobacco
Vanilla, Cherry, Bubble Gum, Apple, Tobacco, Grape
Mint
Apple
Bubble Gum, Apple, Grape, Tobacco
Bubble Gum, Apple
Apple
Apple

Table 2. Popular Flavoring Chemicals in E-liquids
Comprehensive list of popular flavoring chemicals including their chemical class association and
various flavor profiles that varying concentrations of these flavoring chemicals can be found in.
given their hydroxyl functional group. Both farnesene and farnesol differ from menthol given
they are acyclical sesquiterpenes (natural 15-carbon organic compounds consisting of three
isoprene units). Sesquiterpenes, alongside monoterpenes, are the main aroma components that
make up apple flavorants. Additional to these two flavorants, green apple flavor includes
numerous other flavorant compounds including hexyl acetate, ethyl acetate, and methylbutyl
acetate (Tierney et al., 2016). However, ENDS-related studies on these flavorants have not yet
been performed.
Similar to menthol, both farnesol and farnesene exhibited a significant enhancement of
nicotine reward-related behavior in mice (Avelar et al., 2019; Cooper et al., 2020). In the case of
farnesol, there was an observed sex-dependent effect as only male mice (at the doses tested)
exhibited changes in reward-related behavior. Interestingly, unlike menthol, both green apple
flavorants exhibited significant reward-related behavior in the absence of nicotine compared to
saline-control. The finding that ENDS flavors may produce reward-related behavior on their own
is a significant contribution to the field of nicotine addiction and may explain the continued use
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Figure 5. Flavorant Chemical Profiles
Similarity in chemical structure formation of (A) menthol, (B) pulegone (peppermint), (C)
limonene (citrus), (D) farnesol, (E) farnesene, and (F) geraniol (fruity), despite the wide array of
flavor profiles.
by adolescents and their strong preference for fruity flavors. This also reveals some insight into
why there may be a rise in vaping of zero-nicotine flavored e-liquids.
Much like the previous menthol findings, Avelar et al., identified farnesol-induced
upregulation of α6* and α4α6* nAChRs on VTA DA neurons and a complementary increase in
firing frequency of these neurons (2019). Here, it was reported that farnesene, by itself, produced
a greater change in nAChR upregulation and enhancement in firing frequency when compared to
farnesol plus nicotine. They speculated that the differences in flavorant-induced reward is likely
due to the fact that menthol-alone only upregulates low-sensitivity α6* (not α4α6*) nAChRs and
decreases VTA DA neuron firing (Henderson et al., 2016), whereas farnesol not only increased
VTA DA neuron firing but also upregulated both α6* and α4α6* nAChRs (Avelar et al., 2019).
Desensitization of the α4β2* nAChRs on SNr GABA neurons reduces the inhibitory outputs, and
results in disinhibiting the VTA DA neurons (Keath et al., 2007). Based on these previous
findings, farnesol treatment was examined for effects on SNr GABA neurons because of
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potential downstream effects on VTA DA neurons (Avelar et al., 2019). Here, in male mice only,
Avelar et al. found a significant downregulation of α4 subunits on SNr GABA neurons, and this
contributed to a decrease in the firing frequency of these neurons.
Similar to the farnesol study, we performed conditioned place preference assays with
mice and observed significant farnesene-induced reward-related behavior (Cooper et al., 2020).
Unlike farnesol, farnesene exerted its effects through changes in nAChR stoichiometry, not
nAChR upregulation. Through the use of mouse brain slices and cultured neuroblastoma 2a cells,
it was determined that farnesene triggered a stoichiometric shift toward high-sensitivity α4β2
nAChRs on VTA DA neurons. This was accompanied by a leftward shift in the concentrationresponse of nicotine-induced inward currents on VTA DA neurons in a brain slice preparation.
Finally, VTA DA neurons in farnesene-treated mice exhibited an increase in excitatory
postsynaptic current frequency and amplitude. Considering that this finding was observed in a
coronal brain-slice preparation, this suggests farnesene alters local VTA GABAergic or
glutamatergic transmission and results in a net increase of excitatory input on to VTA DA
neurons. The above flavorant studies demonstrate the potential risk for the abuse potential of
ENDS flavorants and highlights the need to understand zero-nicotine flavored products.
Future Directions
Although flavorant studies are becoming more prevalent, there is still much to be learned.
Currently, menthol and green apple are the only flavors studied for their effects on nicotine
addiction-related behaviors. Given the distinct differences between menthol and green apple, and
more specifically between green apple flavorants: farnesol and farnesene, it is safe to assume that
the various flavor profiles on the market will have differing effects in future studies as well. This
is especially true given that prominent chemical flavorants used in ENDS e-liquids have similar
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chemical scaffolds as menthol, farnesene, and farnesol (see Figure 5). It is likely these effects
will also differ among specific classes of flavor chemicals being studied. For example, a majority
of the flavorants used in these devices are alcohols or aldehydes, and some flavorants are present
in numerous flavor subcategories outside of their major flavor category (i.e. Vanillin (vanilla)
flavorant in Chocolate, Mint, Cotton Candy flavored products; (Tierney et al., 2016)). It will be
interesting to determine how heavily used flavorants (like Vanillin) differ from farnesol or
farnesene, which are primarily found in apple flavored products; as well as general differences in
chemical classes.
Another important gap in this field of research, is the gap in knowledge regarding the
difference between adult, adolescent, and in utero exposure. This is a critical gap to fill
considering the constant rise in adolescent ENDS use. Despite not knowing the age-dependent
effects on flavored ENDS use, it is common knowledge that adolescent nicotine use has a variety
of detrimental impacts on the developing brain including greater tolerance for high doses of
nicotine (Chen et al., 2007), enhanced nicotine reward sensitivity (Kota et al., 2007), reduced
PFC activation and thus impaired cognitive function (Goriounova and Mansvelder, 2012a, b),
and enhanced risk for other drug abuse later in life through a process known as “priming” (Yuan
et al., 2015; Romoli et al., 2019). With the current flavor studies resulting in an enhancing effect
on nicotine pharmacology, it is likely flavors may also enhance the above neurological impacts
as well. Yet, more information must be gathered.
Currently, menthol and green apple have been studied for their effects on midbrain
dopamine and GABA neurons, however glutamatergic and cholinergic afferents are important
contributors to the activity of the mesocorticolimbic pathway. It would be interesting to
determine the role that flavors may play in glutamate firing, including synaptic plasticity. It is
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also critical to utilize fast-scan cyclic voltammetry to determine if flavorants induce DA release
in the NAc. Although we have observed flavorant-induced alterations in firing of presynaptic
midbrain neurons, it is important to determine the postsynaptic effects as well.
With crucial evidence pointing to the aversive pathways as a mediator for nicotine
addiction, it is also important to determine if flavors elicit effects in these specific regions.
Flavorants may act on these pathways by reducing the inhibitory transmission from the RMTg
and IPN to the VTA, resulting in net excitation and dopamine release. Furthermore, the habenula
consists of more diverse nAChR subtypes than the midbrain. Flavorants may have a more (or
less) pronounced effect on these subtypes. Regardless, there is plenty of research that still need
to be done in order to fully understand how these devices and their additives affect a chronic
user.
Lastly, although combustible cigarette plus electronic cigarette use (termed ‘dual-use’)
has been explored, these studies have focused more on lung-related and cardiovascular-related
impacts, as opposed to the impacts on the brain. It will be interesting to identify the effect that
dual use has on a chronic user’s brain and whether ENDS use exacerbates the already-addicted
brain, or merely maintains the combustible cigarette-induced neuroalterations.
Conclusions
Here, we have discussed the major flavorant-induced changes in neurobiology and
neurophysiology that include changes in nAChR function, nAChR subtype assembly, and
nAChR upregulation. Together, these changes cause an impact on reward- and reinforcementrelated behavior. Thus far, basic science investigations into smoking- and vaping-related
behavior have only focused on menthol and green apple flavorants. These studies suggest that
there are complex effects that ENDS flavorants exert on nicotine reward and reinforcement.
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Based on these findings, and the current knowledge regarding nicotine, it is important to
continue investigating ENDS flavorants to determine their impact on the neurobiology and
neurochemistry of addiction. In parallel, there is a need to understand the toxicology of these
ENDS flavorants as well.
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CHAPTER 2
GREEN APPLE E-CIGARETTE FLAVORANT FARNESENE TRIGGERS REWARDRELATED BEHAVIOR BY PROMOTING HIGH-SENSITIVITY NACHRS IN THE
VENTRAL TEGMENTAL AREA
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Abstract
While combustible cigarette smoking has declined, the use of electronic nicotine delivery
systems (ENDS) has increased. ENDS are popular among adolescents, and chemical flavorants
are an increasing concern because of the growing use of zero-nicotine flavored e-liquids. Despite
this, little is known regarding the effects of ENDS flavorants on vaping-related behavior.
Following previous studies demonstrating the green apple flavorant, farnesol, enhances nicotine
reward and exhibits rewarding properties without nicotine, this work focuses on the green apple
flavorant, farnesene, for its impact on vaping-related behaviors. Using adult C57BL/6J mice,
genetically modified to contain fluorescent nicotinic acetylcholine receptors (nAChRs), and
farnesene doses of 0.1, 1.0, and 10 mg/kg, we observed farnesene-alone produces reward-related
behavior in both male and female mice. We then performed whole-cell patch-clamp
electrophysiology and observed farnesene-induced inward currents in ventral tegmental area
(VTA) putative dopamine (pDA) neurons that were blocked by the nAChR antagonist, DhβE.
While the amplitudes of farnesene-induced currents are ~30% of nicotine’s efficacy, this
indicates the potential for some ENDS flavorants to stimulate nAChR function. Additionally,
farnesene enhances nicotine’s potency for activating nAChRs on VTA dopamine neurons. This
may be because of changes in nAChR stoichiometry as our data suggest a shift toward highsensitivity α4β2 nAChRs. Consequently, these data show that the green apple flavorant,
farnesene, causes reward-related behavior without nicotine through changes in nAChR
stoichiometry that results in an enhanced effect of nicotine on VTA dopamine neurons. These
results demonstrate the importance of future investigations into ENDS flavorants and their
effects on vaping-related behaviors.
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Significance Statement
Although combustible cigarette use has decreased by ∼11% in America over the past two
decades, the use of electronic nicotine delivery systems (ENDS) has increased by 135% and
218% among high school and middle school students, respectively, in the last two years alone
(Cullen et al., 2018; Cullen et al., 2019). Most ENDS users vape flavored nicotine products and
there is growing use of zero-nicotine flavored e-liquids. These facts raise questions regarding
chemical flavorants’ effects on nicotine addiction and abuse liability. We show that one chemical
flavorant and odorant of green apple, farnesene, causes reward-related behavior on its own.
These results increase our understanding on how flavorants promote neurologic changes and
affect nicotine addiction.
Introduction
Tobacco use remains the leading preventable cause of disease and death in America and
results in nearly half a million deaths per year. Although there has been a decline in the use of
combustible cigarettes, the use of electronic nicotine delivery systems (ENDS) has increased
tremendously with over three million users between the ages of 14 and 18 (Cullen et al., 2018).
The former U.S. Food and Drug Administration (FDA) Commissioner, Scott Gottlieb, stated that
he believes the ENDS companies are creating a new demographic market among the youth,
rather than simply helping adult smokers quit; which was the original objective for the
production of ENDS (FDA, 2018). Since their inception, ENDS have become more of a concern
among the adolescent population due to the dramatic increase in use among their age
demographic and because of the numerous flavor options available (Cullen et al., 2018; FDA,
2018; Mead et al., 2018; Schneller et al., 2018). Unlike combustible cigarettes which are limited
to menthol flavor, there is no restriction on flavored ENDS and currently over 15,000 unique
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flavors are on the market (Hsu et al., 2018). Additionally, >90% of adolescent and ~70% of adult
ENDS users prefer flavored products (Mead et al., 2018; Schneller et al., 2018).
Menthol is the most prominent flavor for tobacco products and was considered to be an
inert flavor additive, yet studies have shown that menthol enhances nicotine reward-related and
reinforcement-related behaviors in rodents (Wang et al., 2014; Biswas et al., 2016; Henderson et
al., 2017). The menthol-induced enhancement is due to a combination of effects on nicotinic
acetylcholine receptor (nAChR) upregulation (Brody et al., 2013; Henderson et al., 2016; 2017),
dopamine neuron excitability (Henderson et al., 2018), dopamine release (Zhang et al., 2018),
and TRPM8-dependent mechanisms (Fan et al., 2016). In addition to menthol, similar
investigations into other popular ENDS flavors are being conducted. A recent report determined
that green apple and other fruit flavors are nearly the most popular among all flavorant options
available (Espino-Diaz et al., 2016; Omaiye et al., 2019b). An investigation into one chemical
flavorant of green apple, farnesol, reported that farnesol produced reward-related behavior in
mice in the absence of nicotine (Avelar et al., 2019). Furthermore, this effect was sex-dependent
and was found to be caused by changes in nAChR upregulation and ventral tegmental area
(VTA) dopamine neuron firing in males only at the doses examined.
Based on these previous investigations, we have examined another chemical flavorant of
green apple, farnesene, to determine its effect on vaping-related behaviors. We used conditioned
place preference assays to observe farnesene’s effect on reward-related behavior, confocal
microscopy to observe nAChR changes on midbrain dopamine and GABA neurons associated
with the reward pathway, and whole-cell patch-clamp electrophysiology to study changes in
midbrain neuron function. These experiments were performed with mice genetically modified to
express fluorescently labeled nAChRs and were used in microscopy or electrophysiology
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following behavioral assays. Following these experiments, we have demonstrated that farnesene
enhances nicotine reward-related behavior and prompts reward-related behavior in the absence
of nicotine, and thus, may explain the prominence of green apple flavors among ENDS users.
Additionally, we discovered farnesene acts as a partial agonist for nAChRs and stimulates
inward currents on VTA dopamine neurons. Finally, we observed that while farnesene does not
exert a pronounced effect on VTA nAChR upregulation, long-term treatment with farnesene
alters nAChR stoichiometry to promote the assembly of high-sensitivity nAChRs. Overall, these
data identify the significance in studying ENDS flavors and demonstrate the potential underlying
mechanisms that may promote the initiation and maintenance of ENDS use among the youth.
Materials and Methods
Reagents and Dose Selection
(‒)-Nicotine hydrogen tartrate (product number – 1463304) and Farnesene (product
number – W383902-100G-K, lot number – MKCB6021) were obtained from Sigma-Aldrich.
According to Tierney et al. (2016), flavorants range from 1- to 20-fold the amount of nicotine in
the traditional cigarette as well as ENDS, with an average flavor concentration of ~12 mg/mL
(Omaiye et al., 2019b). It has been confirmed that 0.5 mg/kg nicotine is rewarding for mice in
conditioned place preference assays (Tapper et al., 2004; Henderson et al., 2016; 2017). Given
this dose of nicotine, we determined the behaviorally relevant dose of farnesene is 0.5 - 10 mg/kg
and used a dosing range of 0.1, 1.0, and 10 mg/kg for this study.
Mice
All experiments were conducted in accordance with the guidelines for care and use of
animals provided by the National Institutes of Health. Protocols were approved by the
Institutional Animal Care and Use Committee at Marshall University. Mice were group housed
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on a standard 12/12 hr light/dark cycle at 22oC and given food and water ad libitum. For all
assays, we used α4-mCherryα6-GFP mice originated from a C57BL/6J strain that are genetically
modified to contain α4* and α6* nAChR fluorescent tags. These mice have been shown to
exhibit similar levels of nAChRs to wild-type mice and behave similar to wild-type mice in CPP
assays (Mackey et al., 2012; Srinivasan et al., 2016; Henderson et al., 2017; Avelar et al., 2019).
Following CPP assays, mouse brains that were homozygous for α4-mCherry and transgenic for
α6-GFP were used in confocal microscopy assays (20 mice; Figure 8). For a portion of the
behavioral experiments, wildtype littermate mice and The Jackson Laboratory C57BL/6J mice
were used alongside α4-mCherryα6-GFP mice. For all experiments, we used adult (3 – 6 months
old) mice. Both male and female mice were used and numbers of each are detailed below in the
methods for specific experiments and given in detail in corresponding figures.
Our genetically modified α4-mCherryα6-GFP mice were the result of crossing α4mCherry homozygous knock-in mice (Srinivasan et al., 2016) with α6-GFP bacterial artificial
chromosome transgenic mice (Mackey et al., 2012). α4-mCherry knock-in mice are backcrossed
to C57BL/6J mice every 10 generations while α6-GFP mice are continuously backcrossed to
C57BL/6J mice (from Jackson Laboratory; https://www.jax.org/strain/000664).
Genotyping
On postnatal day 21, mice were weaned and housed with same-sex littermates.
Concomitantly, tail biopsies were taken for genotyping analysis by PCR (Transnetyx). Only mice
that were transgenic for α6-GFP and homozygous for α4-mCherry were used in confocal assays
(see below), with the exception of α6-GFP and α4-mCherry mice used for Normalized Förster
Resonance Energy Transfer (NFRET) controls.
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Locomotor Assays
Adult male and female non-transgenic α4-mCherryα6-GFP mice (3 - 5 months old) were
habituated to the experimental room for ~1 hr prior to the experiment (n = 6-7 mice/sex). Mice
were placed in an open field (40 x 40 x 36 cm) immediately after an intraperitoneal injection of
saline or farnesene (0.1 mg/kg). Distance traveled over a period of 20 min was recorded using
motion tracking software (SMART 3.0). Number of mice are listed in Figure 6B.
Conditioned Place Preference (CPP) Assays
CPP assays were conducted in a three-chamber spatial place-preference apparatus
(Harvard Apparatus, PanLab) over a 10-day period, using male and female mice (Figures 6-7).
Time spent in chambers was recorded by motion tracking software (SMART 3.0). The test
consisted of three stages: pre-test, injections, post-test. An unbiased protocol was used where
‘drugs’ (saline, nicotine (0.5 mg/kg), farnesene alone (0.1, 1.0, or 10 mg/kg), or 0.1 mg/kg
farnesene plus 0.5 mg/kg nicotine) were given immediately before confinement in the right
white/gray chamber on ‘drug’ days and saline was given immediately before confinement in the
left white/black chamber on saline days. Each conditioning period lasted 20 minutes. Before the
use of experimental mice during each stage, a scrap mouse of the same sex was used to deposit
odors for 20 minutes. In the pre-test stage, mice were placed in the central chamber and given 20
minutes of free access to all chambers. Drug-naïve mice that spent >65% of their time in one of
the two conditioning chambers were removed from the study and the remaining mice were
counter-balanced, similar to previously published methods (Neugebauer et al., 2011; Einstein et
al., 2013; Lee et al., 2020). Eight males and five females were excluded. During stage 2,
intraperitoneal injections were given in the white/gray chamber (saline control, farnesene,
nicotine, or farnesene plus nicotine, dissolved in saline) or white/black chamber (saline). The
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mice received their designated drug injections on days 2, 4, 6, and 8, and received saline
injections on days 3, 5, 7, and 9. In the post-test stage, mice were again placed in the central
chamber and given 20 minutes of free access to all chambers. Adult male and female mice, 3-6
months old, were used in CPP assays (60 males and 57 females total). Previous reports have
shown that α4-mCherryα6-GFP mice displayed no differences in nicotine reward-related
behavior as tested by CPP in comparison to C57BL/6J mice (Henderson et al., 2017; Avelar et
al., 2019). Sex differences are further discussed in Results. Data are expressed as a change in
baseline preference between the post-test and pre-test. Drug treatments were blind to
experimenters until all data analysis was completed.
Confocal Imaging of Mouse Brain Slices
α4-mCherryα6-GFP mice used in CPP assays were also used in microscopy assays.
Following the completion of CPP assays, mice were euthanized with CO2 and subjected to a
swift cardiac perfusion with 10 mL ice-cold saline to reduce autofluorescence in the mCherry
emission range. Brains were then swiftly removed, flash frozen with acetone and dry ice, and
then stored at -80oC. Brains were coronally sectioned (20 µm) using a cryostat, mounted with
Vectashield (Vector labs, H-1000), and coverslipped. We targeted bregma -3.1 mm (anteriorposterior limits of -2.9 to -3.3 mm) because this region gave the most consistent sections that
contained a large portion of the VTA, substantia nigra pars reticulata (SNr) and substantia nigra
pars compacta (SNc) in a single slice.
A Leica SP5 TCSII confocal microscope was used to excite α6-GFP and α4-mCherry at
488 and 561 nm, respectively. 20X images with a 10X digital zoom were collected for the
quantitative measurements of α4-mCherry and α6-GFP neuron raw integrated density (RID).
NFRET was calculated using the PixFRET ImageJ plug-in to identify α4α6* nAChRs.
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All experimenters were blind to drug treatment until all data analysis was completed.
Approximately 30-60 VTA dopamine neurons (GFP+ and mCherry+) and ≥30 VTA and SNr
GABA neurons (mCherry+) were imaged. Data from these images were averaged to provide RID
values for each mouse. A total of 20 mice were used in confocal assays, aged 3–5 months (n
provided in Figure 8).
Neuro-2a Cell Culture and Transient Transfections
Mouse neuroblastoma 2a (neuro-2a) cells were cultured in the following medium: MEM
with 5% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin. Cells were
plated by adding 90,000 or 50,000 cells (microscopy and electrophysiology, respectively) to
poly-ᴅ-lysine-coated 35mm glass-bottom imaging dishes (MatTek Corporation) and cultured in a
humidified incubator (37oC, 95% air, 5% CO2). Cells were transfected with 500 ng of each
nAChR subunit cDNA plasmid (α4-mCherry, α4-GFP, and β2wt or α4-mCherry, α6-GFP, and
β2wt depending on intended subtype target and FRET pairing). Following plating procedures,
plasmid DNA was mixed with 250 µL of Opti-MEM and Lipofectamine-3000 was separately
added to the Opti-MEM. After 5 min at 24oC, the two solutions were combined and incubated at
24°C for 25 min. Plated neuro-2a cells then received the mixed solution and were incubated for
24 hr. The next day, Opti-MEM was removed, and the cells received growth medium. 500 nM
filter-sterilized farnesene (or sham treatment) was added after replacing the Opti-MEM with
standard culture medium. Twenty-four hours after drug/sham addition, neuro-2a cells were
imaged on a confocal microscope (discussed above) or examined using electrophysiological
methods (discussed below).
Whole-Cell Patch-Clamp Electrophysiology
Using brain slices from 3-5-month-old male and female α6-GFP mice, we identified
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putative dopamine (pDA) neurons of the VTA for recordings. Dopamine neurons of the lateral
VTA selectively express α6* nAChRs making our α6-GFP mice suitable for identifying pDA
neurons in electrophysiological assays. After recent work detailing the presence of α6* nAChRs
on medial VTA glutamate neurons (Yan et al., 2018), we restricted our recordings to the lateral
VTA to increase our chance of accurately identifying pDA neurons. Following behavioral
assays, mice were anesthetized with CO2 and then cardiac perfusion was performed using icecold NMDG-based artificial cerebral spinal fluid (NMDG-ACSF) saturated with 95% O2/5%
CO2 (carbogen) containing the following: 93 mM NMDG, 2.5 mM KCl, 1.2 mM NaH2PO4, 10
mM MgSO4, 0.4 mM CaCl2, 30 mM NaHCO3, 5 mM Na-ascorbate, 3 mM Na-pyruvate, 2 mM
thiourea, and 25 mM glucose. Brains were removed and kept in agarose for slicing with a
Compresstome® VF-300-OZ (Precisionary Instruments). Coronal brain sections (250 µm) were
cut into cold carbogenated NMDG-ACSF to obtain slices containing the VTA (target bregma 3.1 mm; anterior-posterior limits of -2.7 to -3.5 mm) and were then allowed to recover at 32oC in
carbogenated NMDG-ACSF for 12-15 min. Following this, slices were transferred to standard
ACSF containing the following: 125 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 1.2 mM
MgCl2, 2.4 mM CaCl2, 26 mM NaHCO3, and 11 mM glucose for 1 hr at 32oC. One hour later,
slices were transferred to the recording chamber and continuously perfused with carbogenated
ACSF (1.5 - 2.0 mL/min) at 32oC.
Neurons were visualized with an upright microscope (Axio Examiner A1, Zeiss)
equipped with an Axiocam 702 mono using DIC near infrared illumination. Blue illumination
was used to visualize α6-GFP presence in pDA neurons. Whole-cell patch-clamp techniques
were used to record electrophysiological signals with an Integrated Patch-Clamp Amplifier
(Sutter). Patch electrodes had resistances of 4 – 10 MΩ when filled with intrapipette solution (in
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mM): 135 K gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP.
Recordings were sampled at ≥10 KHz. The junction potential between patch pipette and bath
solutions was nulled just before gigaseal formation. Series resistance was monitored without
compensation throughout experiments using SutterPatch software. The recording sessions for
neurons were terminated if the series resistance changed by >20%. Nicotine and farnesene
(dissolved in ACSF at pH 7.4) applications were applied using pressure microinjection
(Picospritzer III, Parker) at 5 psi. Drug concentrations and duration of applications are given in
Results. While microinjections of nicotine mitigate many of the complications of usage in brain
slices (diffusion in and out of tissue and cells), we used a maximum of 3 nicotine puffs per brain
slice.
For the recordings of spontaneous excitatory post-synaptic currents (sEPSCs), bath
perfusion of ACSF was switched to an ACSF solution containing 100 µM picrotoxin (SigmaAldrich, catalog number 124-87-8) to block GABAA receptors. After 5 min, pDA neurons in the
VTA were voltage clamped at -65 mV to record sEPSCs.
For cultured cells, 50,000 neuro-2a cells were plated onto sterilized 12 mm circular glass
coverslips, placed in 35-mm culture dishes and cultured in a humidified incubator (37oC, 95%
air, 5% CO2). Cells were transfected as described above. For patching of neuro-2a cells, we used
extracellular solution containing the following: 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 10 mM HEPES, and 10 mM glucose (320 mOsm, pH set to 7.3 with Tris-base). For
voltage-clamp experiments, neuro-2a cells were voltage clamped at a holding potential of -55
mV. To avoid nAChR desensitization by repetitive nicotine application, we applied drug puffs at
~3-min intervals and continually perfused the recording chamber with extracellular solution.
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Statistical Analysis
All results are presented as mean ± SEM and all statistical analyses were performed using
Graphpad Prism. CPP data (Figures 6A and 2) were analyzed with either a one-way (drug
factor) or two-way ANOVA (sex x drug x interaction) with a post-hoc Tukey for means
comparison. Unpaired data (Figures 6B, 8, 9, 10, 11, 12, and 13E1-2) were analyzed by t-test.
Data in Figure 13B was analyzed with a one-way ANOVA (drug factor) with a post-hoc Tukey
for means comparison. Power analyses (G*Power software; www.gpower.hhu.de) were used to
determine efficient sample sizes.
Results
Farnesene-Alone Prompts Reward-Related Behavior
Here, we examine a chemical flavorant of green apple, farnesene, for its ability to alter
reward-related behavior. Using male and female α4-mCherryα6-GFP mice (C57BL/6J
background) and farnesene doses of 0.1, 1.0, and 10 mg/kg, we conducted CPP assays to
measure reward-related behavior. The previous report that examined another green apple
flavorant, farnesol, observed a sex-dependent effect on mice in CPP assays (Avelar et al., 2019).
Accordingly, we hypothesized that farnesene may produce a sex-dependent effect given the fact
that its chemical structure is very similar to farnesol. We observed a sex-dependent and drugdependent effect in our CPP assays with the above farnesene doses, as well as a significant
interaction between sex and drug factors (two-way ANOVA (sex x drug dose x interaction); sex
factor: F(1, 88) = 10.55, p = 0.002; drug factor: F(5, 88) = 12.21, p < 0.0001; and interaction factor:
F(5, 88) = 3.045, p = 0.014). Following the significant sex-dependent effect, we examined the
effect of farnesene on reward-related behavior separately for male and female mice.
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We noted a significant effect of farnesene in male and female mice (males: one-way
ANOVA, F(3, 30) = 5.98, p = 0.003, Figure 6A1; females: one-way ANOVA, F(3, 25) = 9.81, p =
0.0002, Figure 6A2). In males, farnesene at a dose of 0.1 mg/kg prompted a significant
rewarding effect compared to saline-treated (p = 0.0065), 1.0 mg/kg farnesene-treated (p =
0.020), and 10 mg/kg farnesene-treated mice (p = 0.005). Higher doses of farnesene in male mice
did not exhibit a significant change from baseline compared to saline, which may mimic
nicotine’s inverted-U dose response in CPP assays. On the other hand, female mice exhibited a
significant change from baseline with all farnesene doses when compared to saline (1.0 mg/kg, p
= 0.013; 10 mg/kg, p = 0.040; Figure 6A2), with the greatest change from baseline at 0.1 mg/kg
(p < 0.0001, Figure 6A2). We note, farnesene doses tested may need to be higher in order for the
females to observe an inverted-U response similar to the males. Similarly, we may need to test
lower doses in both males and females to determine the threshold dose for reward-related
behavior. Overall, these data support the idea that farnesene at 0.1 mg/kg is rewarding on its own
in both male and female mice. Following these observations, follow-up assays were performed
with 0.1 mg/kg dosing in male and female mice.
Additionally, we conducted locomotor assays to determine the effects of acute farnesene
treatment on locomotor behavior in male and female mice. It is well understood that nicotine
increases locomotor activity in mice (Wall et al., 2017), and was recently determined that green
apple flavorant, farnesol, also increased this behavior (Avelar et al., 2019). Here, male and
female mice were administered intraperitoneal injections of saline or 0.1 mg/kg farnesene, and
locomotor activity was assessed in an open field test (Figure 6B1-2). Unlike the previous reports,
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Figure 6. Farnesene-Alone Produces Reward-Related Behavior in Male and Female Mice
(A) Male and female mice were administered saline or farnesene at doses of 0.1, 1.0, or 10
mg/kg in a CPP assay. (B) Male and female mice were administered saline or 0.1 mg/kg
farnesene in an open field locomotor assay. All data are mean ± SEM; *, p < 0.05; **, p < 0.01;
****, p < 0.0001; one-way ANOVA with post hoc Tukey (A) or unpaired t test (B). Exact p
values are given in Results. Number of mice for each treatment group in CPP assays is indicated
in parenthesis. Dots within bars represent the CPP scores or locomotor activity from individual
mice within the designated treatment groups.
farnesene did not significantly alter the ambulatory behavior of either male or female mice
compared to saline treatment (males, p = 0.111, Figure 6B1; females, p = 0.801, Figure 6B2).
Farnesene Enhances Nicotine Reward
Because of the fact that many ENDS users prefer flavored nicotine-containing products,
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and the findings that farnesene-alone is rewarding (Figure 6A), it is important we study the
combining effect of farnesene and nicotine on reward-related behavior. To do so, we performed
additional CPP assays using saline, nicotine, and nicotine combined with the peak farnesene dose
(0.1 mg/kg). Many previous reports have used 0.5 mg/kg nicotine (intraperitoneal) to produce a
rewarding effect in C57 mice (Tapper et al., 2004). Accordingly, we selected this dose for these
CPP assays. Only male mice exhibited significant nicotine reward-related behavior (one-way
ANOVA, p = 0.017 and p = 0.292 for males and females, respectively; Figure 7A-B), however
in both sexes we noted a significant nicotine + farnesene effect compared to saline (one-way
ANOVA; males, p = 0.002, Figure 7A; females, p = 0.0001, Figure 7B). Additionally, both
sexes exhibited enhanced rewarding effects in the nicotine + farnesene group compared to
nicotine alone, but only females exhibited a significant enhancement (p = 0.004).

Figure 7. Farnesene (0.1 mg/kg) Enhances Nicotine Reward-Related Behavior in Both
Sexes
(A, B) Male and female mice were administered saline, nicotine (0.5 mg/kg), or nicotine (0.5
mg/kg) plus farnesene (0.1 mg/kg) in a CPP assay. All data are mean ± SEM; ; *, p < 0.05; **, p
< 0.01; ***, p < 0.005; one-way ANOVA with post hoc Tukey. Exact p values are given in
Results. Number of mice for each treatment group is indicated in parenthesis, and dots within
bars represent the CPP scores from individual mice within the designated treatment group.
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Despite Effects on Reward-Related Behavior, Farnesene Does Not Upregulate
nAChRs on VTA Dopamine Neurons
Following behavioral assays, we performed confocal microscopy to observe potential
changes in nAChR levels based on the long-standing knowledge that chronic nicotine exposure
upregulates nAChRs (Nashmi et al., 2003; Nashmi et al., 2007; Henderson et al., 2014;
Srinivasan et al., 2016) and that green apple flavorant, farnesol, worked in a similar manner
(Avelar et al., 2019). Following the well-characterized effects of nAChR upregulation in
midbrain neurons, we focused on dopamine and GABA neurons in the VTA and GABAergic
neurons in the SNr (Figure 8A). Using α4-mCherryα6-GFP mice, we examined α4β2* (*
denotes other subunits may be present), α6β2*, and α4α6β2* nAChR density of pDA and GABA
neurons in the VTA and SNr in response to saline or farnesene treatment. Here, we used the
same mice that were employed in conditioned place preference assays to maintain dosing
relevant to reward-related behavior. To aid in the identification of pDA neurons in the VTA, we
used α6-GFP fluorescence as a marker, as α6-GFP nAChR subunits are highly expressed in
dopamine neurons in the lateral VTA (Mackey et al., 2012) (described further in methods for
electrophysiology). Given that GFP and mCherry are FRET pairings, we used pixel-based FRET
methods to identify nAChRs that contain both α4 and α6 nAChR subunits (Figure 8B). Changes
in nAChR number was determined by quantifying a change in raw integrated density (RID) of
α4-mCherry or α6-GFP fluorescence. Unlike the previous study by Avelar et al. demonstrating
farnesol’s ability to upregulate nAChRs (2019), farnesene treatment produced no significant
changes in nAChR number within putative dopamine or GABA neurons in the VTA or SNr
(Figure 8C-D).
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Despite the Absence of Upregulation, Farnesene Alters Stoichiometry of nAChRs
In addition to examining the upregulation of nAChRs in mouse brain slices, we also
investigated farnesene-induced changes in nAChR stoichiometry. Nicotine has long been known
to selectively upregulate high-sensitivity nAChRs, including α4* and α6* nAChRs (Kuryatov et
al., 2005; Srinivasan et al., 2011), while menthol and cytisine have been shown to upregulate

Figure 8. Farnesene Treatment Has No Effect on nAChR Number in the Midbrain
(A1) Schematic of target mouse brain region (bregma -3.1 mm). (A2) Sample 10X image of a
mouse coronal brain section at approximately bregma -3.1 mm. Scale bar, 250 mm. (B) Sample
images of saline and farnesene treated VTA dopamine neurons. Scale bar, 15 mm. (C-D) RID of
α4*, α6*, and α4α6* nAChRs of VTA dopamine neurons (C1 and D1) α4* nAChRs of VTA
GABA neurons (C2 and D2) and α4* nAChRs of SNr GABA neurons (C3 and D3) in salinetreated and farnesene-treated (0.1 mg/kg) male (C) and female (D) mice. All data are mean ±
SEM. Unpaired t test. Dots indicate the RID values from individual mice.
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low-sensitivity nAChRs (Srinivasan et al., 2012a; Henderson et al., 2016). α4β2 nAChRs exist
in two stoichiometries – high-sensitivity (α4(2)β2(3)) and low-sensitivity (α4(3)β2(2)) (Nelson et al.,
2003). α6* nAChR stoichiometries are characterized as α6β2, α6β2β3, or α4α6β2β3 (Lindstrom
et al., 1987; Xiao et al., 2011; Henderson et al., 2014).
To determine farnesene’s effects on nAChR stoichiometry, we used a pixel-based,
NFRET method (Srinivasan et al., 2012a). Aside from quantifying the RID of α4*, α6*, and
α4α6* nAChRs, we additionally examined the effect of farnesene treatment on NFRET intensity
and pixel count as both are informative measurements regarding the change in number of nAChR
pentamers that contain both an α4 and α6 nAChR subunit (Figure 9). In both males and females
we saw no significant changes in the mean NFRET intensity between saline and farnesene
treatment groups (Figure 9A1 and 9B1). Yet, in females-only we observed a significant decrease
in the mean pixel count following farnesene treatment (p = 0.048; Figure 9B2-3). This indicates
that farnesene reduces the number of α4α6* nAChRs on VTA dopamine neurons in female mice.
Given that females demonstrated the greatest range in farnesene-induced reward-related
behavior, this finding may explain why we only see an effect on pixel count in female mice.
Given that our mouse model only allows analysis of changes in α4α6* nAChR
stoichiometry, we used in vitro methods to examine both α4α6β2 and α4β2 nAChR
stoichiometry following farnesene exposure. Accordingly, we studied nAChR stoichiometry
changes using neuro-2a cells that were transiently transfected with α4-mCherry, α6-GFP, and
β2wt or α4-mCherry, α4-GFP, and β2wt nAChR subunits to examine changes in α4α6β2 and
α4β2 nAChR stoichiometry (Figure 10A and 10C, respectively). Cells transiently transfected to
contain α4-mCherryα6-GFPβ2 nAChRs (Figure 10A) were treated with control media or 0.5 µM
farnesene for 24 hrs. We selected 0.5 µM farnesene to match previous studies with the similarly
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Figure 9. Farnesene Alters the Stoichiometry of α4α6β2* nAChRs in VTA DA Neurons
(A1 and B1) Mean NFRET percentage, (A2 and B2) mean NFRET pixel count, and (A3 and B3)
mean pixels/neuron histograms for saline-treated and farnesene-treated (0.1 mg/kg) VTA
dopamine neurons in male (A) and female (B) mice. All data are mean ± SEM. *, p < 0.05;
unpaired t-test. Exact p values are given in the Results section. Dots within bars represent the
values from individual mice within the designated treatment group; n = > 40 neurons per mouse
per treatment group.
structured terpene, menthol (Henderson et al., 2016) and farnesol (Avelar et al., 2019). In
farnesene-treated cells we noted a significant decrease in the mean pixel count (p < 0.0001,
Figure 10B1) and the mean NFRET percentage (p < 0.0001, Figure 10B2) which indicates a
significant decrease in the number of α4-α6 nAChR subunit pairings. Thus, the data obtained
through in vitro methods matches those obtained using mouse brain slices. Cells transiently
transfected to contain α4-mCherryα4-GFPβ2 nAChRs (Figure 10C) were also treated with
control media or 0.5 µM farnesene and we also observed a significant decrease in mean pixel
count (p = 0.0149, Figure 10D1) and mean NFRET percentage (p < 0.0001, Figure 10D2).
Accordingly, this indicates a decrease in the number of low-sensitivity α4(3)β2(2) nAChRs. These
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results are further summarized in Figure 11. Here we show that long-term farnesene treatment
promotes the inclusion of high-sensitivity nAChRs by transitioning the number of low-sensitivity
α4(3)β2(2) (Figure 11A) and α4α6β2 (Figure 11B) nAChRs to a majority of high-sensitivity
α4(2)β2(3) nAChRs.

Figure 10. Farnesene Favors High-Sensitivity nAChRs in Neuro-2a Cells
Representative neuro-2a cells transfected with α4-mCherry, α4-GFP or α6-GFP, and β2wt
nAChR subunits to produce (A) α4-mCherryα6-GFPβ2 nAChRs or (C) α4-mCherryα4-GFPβ2
nAChRs. Scale bar, 10 µm. Mean NFRET pixel count (B1 and D1) and NFRET percentage (B2
and D2) treated as control or with 0.5 µM farnesene for (A) α4-mCherryα6-GFPβ2 nAChRs or
(C) α4-mCherryα4-GFPβ2 nAChRs. All data are mean ± SEM. *, p < 0.05; **, p < 0.01; ****, p
< 0.001; unpaired t-test. Exact p values are given in the Results section. Dots within bars
represent the values from individual cells within the designated treatment group; n > 30 cells per
condition.
Farnesene Alters VTA Dopamine Neuron Function
Although we found no significant changes in nAChR upregulation or downregulation on
VTA neurons, the changes in stoichiometry observed in VTA dopamine neurons and neuro-2a
cells suggest farnesene alters stoichiometry, potentially toward high-sensitivity α4β2 nAChRs.
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Figure 11. Farnesene Favors High-Sensitivity nAChRs in Neuro-2a Cells
(A) α4β2 nAChRs assemble in two stoichiometries and we observed that farnesene treatment
shifts a mixed population of HS and LS α4β2 nAChRs to a majority of HS α4β2 nAChRs. (B) In
examining α4α6β2 nAChRs, under control treatments ~65% of the population are α4α6β2
nAChRs while the remainder is likely α4β2 nAChRs. Following treatment with farnesene, <14%
of the nAChRs are α4α6β2 nAChRs.
To examine this in an in vivo model we used brain slice whole-cell electrophysiology. Given that
high- and low-sensitivity α4β2* nAChRs can be functionally distinguished through
concentration-response relationships (Nelson et al., 2003; Xiao et al., 2009), we utilized similar
methods to determine whether farnesene treatment altered nAChR stoichiometry on putative
VTA dopamine neurons. Mackey et al. (2012) have previously demonstrated α6 nAChRs exhibit
complete overlap with tyrosine hydroxylase in VTA dopamine neurons. Thus, several previous
investigations have used α6-GFP fluorescence, in addition to other electrophysiological markers,
as a method to identify dopamine neurons within the VTA and SNc (Mackey et al., 2012;
Henderson et al., 2016; 2017; Avelar et al., 2019). However, more recent investigations have
shown that α6-GFP nAChRs are present on glutamate neurons in the medial portions of the VTA
(Yan et al., 2018). To increase our chances of identifying putative dopamine neurons, we
targeted α6-GFP positive cells (Figure 12A1-2) in the lateral VTA that exhibited classical
electrophysiological markers of dopamine neurons (Margolis et al., 2006; 2008): hyperpolarizing
sag (Ih), firing frequency, and action potential widths >2 milliseconds. Together, these features
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have been proven to provide a robust method of identifying putative dopamine neurons (Mackey
et al., 2012; Henderson et al., 2017). We used coronal brain slices obtained from saline or 0.1
mg/kg farnesene treated mice using a dosing paradigm that matches

Figure 12. Farnesene Enhances the Affinity and Potency of Nicotine.
Representative images of VTA pDA neurons in a brain slice (bregma -3.1) were identified
through the presence of α6-GFP nAChRs in IR-DIC (A1) and GFP fluorescence (A2) imaging
modes. Scale bars, 20 μm. (B) Representative inward currents from VTA pDA neurons (α6GFP+) with 10 s applications of 500 nM (B1) or 10 µM (B2) nicotine in voltage-clamp mode.
Arrows indicate start of nicotine puff application and dotted red lines indicate baseline prior to
puff and the duration of nicotine application. (C) Average nicotine concentration response of
peak-current amplitude of VTA pDA neurons (n = 7 neurons/4 mice and 5 neurons/3 mice per
nicotine concentration for saline and farnesene-treated mice, respectively). (D) Representative
waveforms of sEPSCs from VTA pDA neurons recorded from saline-treated or farnesene-treated
mice in the presence of 30 µM picrotoxin. (E) Mean sEPSC frequency (E1) and amplitude (E2)
in saline-treated and farnesene-treated mouse brain slices (n = 9 neurons/4 mice and 9 neurons/3
mice for saline- and farnesene-treated mice, respectively). For all assays, drug treatments were
consistent with the CPP assay paradigm using 0.1 mg/kg farnesene. (C and E1-2) Data are mean
± SEM. ***, p < 0.005; ****, p < 0.0001; unpaired t-test. Exact p values are given in the Results
section. Dots within bars represent the values from individual neurons within the designated
treatment group.
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the above CPP protocol and targeted bregma -3.1 to match confocal microscopy assays. Putative
VTA dopamine neurons were voltage-clamped at -65 mV and 0.5, 5, 10, and 100 µM
concentrations of nicotine were applied using localized pressure injection with a micropipette (5
psi, 10 s applications) (Figure 12B1-2, 12C). In the farnesene-treated condition we noted a
leftward shift in the concentration-response of nicotine, indicative of a shift toward more highsensitivity nAChRs (Figure 12C). In addition to recording nicotine-stimulated inward currents,
we also recorded sEPSCs in pDA neurons (Figure 12D). Here, we observed that chronic
farnesene increased the baseline frequency (p = 0.0163) and amplitude (p < 0.0001) of sEPSCs
on putative VTA dopamine neurons compared to saline treatment (Figure 12E1-2).
Farnesene Acts as a Partial Agonist of nAChRs
The previous report on farnesol, another green apple flavorant, showed that farnesol did
not stimulate nAChR-mediated currents on its own but likely functions as a noncompetitive
antagonist (Avelar et al., 2019). To examine farnesene’s pharmacological actions, we first started
with acute applications on putative VTA dopamine neurons (Figure 13A-B). We observed that 5
and 500 µM farnesene stimulates inward currents in putative VTA dopamine neurons (mean
peak current amplitudes of 27.5 ± 3.3 and 58.5 ± 9.6 pA, respectively, Figure 13B). We note that
0.5 µM farnesene (consistent with in vitro NFRET assays) did not produce any notable inward
currents (data not shown). Using ACSF containing DhβE (0.3 µM), we observed that farneseneinduced (500 µM) inward currents are dependent on β2* nAChRs (Figure 13A). Finally, we
used 100 µM nicotine to obtain a comparative efficacy for farnesene and determined that
farnesene possessed ≤ 44.0 ± 7.3% efficacy compared to nicotine (at 100 µM) on putative VTA
dopamine neurons. Five and 500 µM farnesene had a significantly lower peak current amplitude
compared to 100 µM nicotine (p < 0.0001 and < 0.0031, respectively). In examining peak current
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Figure 13. Farnesene Acts as a Partial Agonist on nAChRs
(A and B) Voltage-clamp recordings from putative VTA dopamine neurons. (A) Five and 500
µM farnesene and 100 µM nicotine were applied to putative VTA dopamine neurons. The β2*
nAChR antagonist, DhβE (0.3 µM) blocked inward currents stimulated by 500µM farnesene. (B)
Mean peak current amplitude for farnesene and nicotine applications on pDA neurons in the
VTA. (C-E) Voltage-clamp recordings from neuro-2a cells transiently transfected to contain α4GFPβ2 and α6-GFPβ2β3 nAChRs. (C) Representative images of neuro-2a cells that contain α4GFPβ2 or α6-GFPβ2β3 nAChRs. (D) Representative inward currents stimulated by 300 ms
applications of 500 µM farnesene on neuro-2a cells containing α4-GFPβ2 or α6-GFPβ2β3
nAChRs. (E1-2) Mean peak current amplitude of 500 µM farnesene and nicotine applications (3
µM and 100 µM Nicotine for α6-GFPβ2β3 and α4-GFPβ2 nAChRs, respectively) on neuro-2a
cells containing nAChRs. Data are mean ± SEM. **, p < 0.01; ****, p <0.0001; one-way
ANOVA with post hoc Tukey (B) or unpaired t-test (E). Dots represent data from individual
neurons or cells. Exact p values are given in the Results section.
amplitudes of nAChRs on dopamine neurons, it is difficult to isolate exactly which subtypes are
activated. To address this, we used neuro-2a cells transiently transfected to contain either α4GFPβ2 or α6-GFPβ2β3 nAChRs (Figure 13C). These two nAChR subtypes exhibit distinct
sensitivities to nicotine and can be maximally stimulated by 3 µM nicotine (α6-GFPβ2β3
nAChRs) or 100 – 300 µM nicotine (α4-GFPβ2 nAChRs) (Henderson et al., 2014). For neuro-2a
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cells containing nAChRs, we applied 500 µM farnesene (300 ms applications) and observed
mean peak current amplitudes of 21.2 ± 3.0 and 23.8 ± 6.1 pA for α6-GFPβ2β3 and α4-GFPβ2
nAChRs, respectively (Figure 13E1-2). Using 3 µM and 100 µM nicotine, we observed mean
peak current amplitudes of 109.7 ± 14.3 (p < 0.0001) and 1190.4 ± 192.3 (p < 0.0001) pA for α6GFPβ2β3 and α4-GFPβ2 nAChRs, respectively (Figure 13E1-2). Thus, the comparative efficacy
of farnesene to nicotine is 19.3 ± 2.7 and 2.1 ± 0.6% for α6-GFPβ2β3 and α4-GFPβ2 nAChRs,
respectively.
Discussion
With the growing popularity of ENDS products among all ages and the large preference
for flavored e-liquids (Huang et al., 2018; Mead et al., 2018; Schneller et al., 2018), the goal of
our study was to determine how one green apple flavorant, farnesene, may affect vaping-related
behaviors using behavioral, neurobiological, and neurophysiological assays. Menthol has long
been the most studied flavorant for its large prevalence in combustible cigarettes and is known to
enhance nicotine reward (Henderson et al., 2016; Henderson et al., 2017) and nicotine
reinforcement (Wang et al., 2014; Biswas et al., 2016). Yet, with the increase in flavorant
production with more than 15,000 ENDS flavorant options available to the vaping community
(Hsu et al., 2018), there is an urgent need to understand how flavorants alter neurobiology and
neurophysiology. A recent investigation revealed farnesol (a green apple flavorant similar in
structure to farnesene) behaves similarly to menthol by enhancing nicotine reward; but differs in
the fact that it causes reward-related behavior on its own (Henderson et al., 2017; Avelar et al.,
2019). Here we noted similar findings: farnesene, a green apple flavorant, causes reward-related
behavior on its own. However, one key difference from the previous report is that farnesene
produces reward in male and female mice while farnesol only produced an effect with males
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(Avelar et al., 2019). Additionally, farnesol caused significant upregulation of α6-containing
nAChRs (Avelar et al., 2019), but farnesene did not upregulate nAChRs. Instead, farnesene was
observed to alter nAChR stoichiometry to promote the expression of more high-sensitivity
nAChRs as evidenced by electrophysiology and NFRET assays in mouse brain slices and
cultured cells.
This is a very significant finding considering that >90% of adolescents ENDS users and
>70% of adult ENDS users prefer flavored products (Mead et al., 2018; Schneller et al., 2018).
Given the absence of restrictions on most flavored ENDS, it is important we document the
effects that flavorants have on altering the addictive nature of nicotine and determining potential
addictive properties in flavorants alone. Although we observed reward-related behavior with
farnesene in both sexes, we did note sex differences in our CPP assays. First, females exhibited
reward-related behavior at all doses of farnesene examined (0.1, 1, and 10 mg/kg) while males
exhibited reward to only 0.1 mg/kg farnesene. This may be because of the fact that females
metabolize farnesene faster than males, similar to nicotine (Matta et al., 2007). Additionally,
females did not exhibit significant nicotine reward with 0.5 mg/kg nicotine. To date, nicotine
dose-response data has primarily been in male mice, and those in females are only given via
subcutaneous injection (Kota et al., 2008). Due to the lack of nicotine dose-response curve data
using intraperitoneal injections in females, this may explain the lack of significant nicotine
reward at the given dose. Although there is a significant change from baseline for nicotine +
farnesene in both males and females, the change from baseline is less than farnesene-alone in
both sexes. While others have reported significant CPP with 0.5 mg/kg nicotine in CPP assays
using both sexes, this could highlight the need to re-examine nicotine dose-responses with both
sexes in this assay. Additionally, we would like to note that acute farnesene did not significantly
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alter locomotor behavior compared to saline treatment in male or female mice. Although nicotine
and farnesol were observed to increase locomotor activity in mice, previous studies have
demonstrated these changes are likely mediated through α6β2* and α4α6β2* nAChRs (Drenan et
al., 2010; Cohen et al., 2012). Given that the farnesene-induced behavioral effects shown here
are likely mediated through high-sensitivity α4β2 nAChRs, this may be the reason we did not see
any significant changes in locomotor behavior between farnesene- or saline-treated mice.
Although farnesol and farnesene exhibit similar behavioral results, they differ in the
cellular aspects that drive reward-related behavior. Based on previously published findings that
chronic nicotine exposure promotes the upregulation of high-sensitivity nAChRs on VTA
dopamine, VTA/SNr GABA, and habenular neurons and the recent evidence that farnesol acted
in a similar manner, our initial investigations focused on the number of α4*, α6*, and α4α6*
nAChRs present on dopamine and GABA neurons as a consequence of farnesene exposure. We
noted no significant changes between farnesene and saline treatment groups. The reward-related
behaviors we noted may not be attributed to nAChR upregulation but, instead, by changes in
nAChR stoichiometry. While many are well-informed regarding the various subtypes of
nAChRs, there also exist distinct stoichiometries that confer different sensitivities to nicotine
(Nelson et al., 2003; Tapia et al., 2007). Both our microscopy measurements (NFRET) and brain
slice electrophysiology data support the fact that farnesene treatment, consistent with CPP
dosing, produces more high-sensitivity nAChRs on VTA dopamine neurons. This increase in
high-sensitivity (likely α4β2) nAChRs results in not only increased sensitivity to nicotine, but
also to the endogenous neurotransmitter acetylcholine (ACh).
In the case of changes in stoichiometry, we note there are limitations to our methods.
Currently, we possess only the capability to measure α4α6* nAChR stoichiometry in vivo. Thus,
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we required the use of heterologous cells and transfection methods in an in vitro system to
conduct fluorescence microscopy assays to study changes in α4β2 nAChR stoichiometry. We
acknowledge that this may not truly represent in vivo systems and we note a distinct difference
between the in vivo and in vitro findings with α4α6* nAChRs (compare Figures 9 and 10B1-2).
These two systems also differ in the time dependency of nAChR upregulation and stoichiometry
changes. Nicotine or flavorant induced nAChR upregulation and changes in stoichiometry occur
over the course of 10-12 days in vivo (Nashmi et al., 2007; Henderson et al., 2016; 2017),
whereas the in vitro system findings occur in 24 hr (Srinivasan et al., 2011). This difference in
time-dependency for in vitro preparations is accompanied by the lacking complexity of a cell’s
environment in vivo (Fu et al., 2019). Stoichiometry changes within in vivo systems are not only
brain region-specific (Fu et al., 2019), but they also rely on unique cellular machinery that is
absent in our in vitro model. Despite this, our transfection methods follow validated protocols
that have matched several in vivo mouse and human studies (Srinivasan et al., 2011; Henderson
et al., 2017), and we are able to detect a change in nAChR stoichiometry that is consistent with
our findings using brain slice electrophysiology as both suggest the presence of more highaffinity nAChRs.
Farnesene treatment significantly increased the frequency and amplitude of sEPSCs. The
excitatory inputs to the VTA dopamine neurons we studied are local and distal glutamate
neurons (medial VTA, prefrontal cortex) and distal cholinergic neurons (peduncular pontine
tegmentum and laterodorsal tegmentum). The inhibitory inputs are GABA neurons in the VTA,
rostromedial tegmentum, and interpeduncular nucleus. Thus, the changes in sEPSC frequency
and amplitude are likely due to changes in glutamatergic or GABAergic local inputs given that
we used a coronal brain slice preparation. While many of the cholinergic inputs are distal and are
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not present in a coronal slice preparation, some cholinergic signaling is maintained and this is
likely a source of elevated sEPSC frequency and amplitude. Regardless, the enhanced frequency
and amplitude of sEPSCs in VTA dopamine neurons suggests that farnesene triggers enhanced
activity that may drive dopamine release through the mesolimbic pathway and thus contribute to
reward-related behavior.
In addition to this, we observed that farnesene itself acts as a partial agonist, likely
through α6-containing nAChRs, as it exhibited very low efficacy on α4β2 nAChRs transiently
transfected into neuro-2a cells. Here, we must acknowledge that a dose of 500 µM is likely not
vaping-relevant but it was necessary to determine the comparable efficacy to nicotine. Despite
this, 5 µM farnesene still produced detectable inward currents in VTA dopamine neurons and
this suggests that farnesene may also weakly stimulate nAChRs in the VTA. Here, further
investigations would need to be conducted to determine the human vaping-relevant
concentrations of farnesene that would be present in the brain and how this specific
concentration alters neurophysiology. Even with these caveats, this finding is significant,
especially in the rising popularity of zero-nicotine e-liquids. Green apple flavors (depending on
the specific flavorants present) may directly stimulate nAChRs and this could be the rationale for
their popularity.
The data reported in this study suggest that (1) farnesene enhances nicotine reward and
displays reward-related behavior through the increase in high-sensitivity nAChRs on VTA
dopaminergic neurons; (2) that farnesene changes nAChR stoichiometry and results in an
enhanced affinity and potency of nicotine and ACh; and (3) that this ultimately leads to enhanced
excitatory postsynaptic currents on VTA dopamine neurons and thus greater likelihood of action
potential generation. Overall, this may explain why flavored ENDS are growing in popularity
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and may contribute to low cessation rates. The finding of enhanced nicotine reward when
flavorants are present and the fact that flavorants-alone may be rewarding, further indicates the
importance of studying flavorants for their potential to alter vaping-related behaviors. However,
there are components of this local VTA circuitry that still need to be elucidated: (1) how are
VTA glutamatergic inputs and their nAChRs altered by farnesene; (2) how are α4β2 nAChRs on
VTA GABA neurons altered functionally; and (3) what is the net effect of farnesene on
dopamine release. Additionally, there are several green apple flavorants that are still unknowns
in the scope of how they alter vaping-related behavior (methylbutyl acetate, hexyl acetate, and
ethyl acetate). Based on these findings, it is of importance we continue to investigate ENDS
flavors for their role in nicotine addiction. With the continuous rise in ENDS use, especially
among the adolescent population, it is critical we depict that ENDS flavors are not a simple
additive to the devices, instead they are an enhancer to the addictive properties of nicotine and a
potential threat to zero-nicotine flavored ENDS users as well.
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Abstract
While the use of combustible cigarettes has decreased in many urban regions of America,
the use of electronic nicotine delivery systems (ENDS) has dramatically increased. ENDS, or
electronic cigarettes (e-cigarettes), differ from combustible cigarettes given that there are no
restrictions on flavorant additives in e-liquids. With 95% of ENDS users vaping flavored eliquids, it is critical to understand how flavors alter vaping-related behaviors. We have
previously shown that menthol and green apple flavors enhance nicotine reward-related behavior
in a mouse model and in the present study have investigated how menthol and green apple
flavors alter e-Vape self-administration behavior in male mice. Adult C57/BL6J male mice were
used in vapor-inhalation self-administration assays. Mice were assigned vaping e-liquids (6
mg/mL nicotine with or without menthol or green apple flavor) to escalate on a fixed ratio 1
(FR1) schedule in daily 3 hr sessions to examine initiation-related behaviors. Following
escalation, mice were transitioned to a FR3 and PR schedules in 3 hr sessions to examine
reinforcement-related behaviors. Here we observed that male mice exhibited increased rates of
self-administration escalation on a FR1 schedule when assigned to flavored e-liquids. Upon
transition to FR3, mice continued to exhibit enhanced levels of reinforcement with flavored eliquids. We also observed that mice self-administer zero-nicotine green apple flavored e-liquids.
These data provide additional evidence that ENDS flavors enhance vaping-related initiation and
reinforcement-related behavior and promote the need to continue investigating the role ENDS
flavors play in vaping-related behaviors.
Implications
There has been much discussion recently regarding the impact of flavors on vapingrelated behavior. Our study here shows that flavors significantly enhance the acquisition and
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reinforcement of vaping-related behavior. This suggests that flavors in electronic nicotine
delivery systems significantly increase the risk of addiction-related behaviors among users of
vaping products.
Introduction
Since the inception of electronic nicotine delivery systems (ENDS) in 2003 (Bhatnagar et
al., 2019), ENDS have gained popularity among life-long cigarette smokers as a “safer”
alternative to smoking, as well as teens naïve to smoking. ENDS use continues to rise among the
adolescent population, with a 135% increase among high school students from 2017 to 2019
(Cullen et al., 2018), and a 114% increase among middle school students within the past year
alone (Cullen et al., 2018). Ongoing research has demonstrated the numerous harmful chemical
constituents found in ENDS, including heavy metals, cancer-causing chemicals, nicotine, and
flavoring agents (Walley and Jenssen, 2015; SGR, 2016a; Glasser et al., 2017; DeVito and
Krishnan-Sarin, 2018; St Helen et al., 2019). Most flavoring agents used are “generally
recognized as safe” (GRAS), although this provision applies only to food or drink. GRASlabeled flavorants have chiefly been studied in conditions subjected to first-pass elimination
mechanisms. Vaping, similar to smoking, presents a distinct pharmacokinetic profile due to the
rapid delivery of inhaled chemicals to the brain (Benowitz, 2009). Further, Flavor and Extracts
Manufacturers Association (FEMA), the organization responsible for verifying the flavoring
substances safe for the Food and Drug Administration (FDA), has stated that they do not
evaluate flavorants for contact through inhalation; they only evaluate for ingestion exposure
(Hallagan, 2018). With over 7,700 ENDS flavors to choose from and the increased use of zeronicotine flavored e-liquids, ENDS flavors have become a growing concern (Zhu et al., 2014;
Huang et al., 2018).
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A primary reason that flavors were banned in combustible cigarettes was the
understanding that flavors increase smoking initiation, especially in adolescents (Ahijevych and
Ford, 2010; Ahijevych and Garrett, 2010). We, and others, have previously shown that menthol
enhances nicotine reward-related and reinforcement-related behavior (Wang et al., 2014; Biswas
et al., 2016; Henderson et al., 2017). Additionally, we have shown that green apple flavor
enhances nicotine reward-related behavior and is rewarding by itself in male mice only (Avelar
et al., 2019). The mechanisms for these flavorant-induced effects on reward-related behavior is
not dependent on odorant and tastant effects as these previous reports have established that
flavorants in both cultured neuron (Henderson et al., 2017) and brain slice preparations (Avelar
et al., 2019) trigger changes in ventral tegmental area dopamine and GABA neuron function in a
manner that contributes to increases in dopamine neuron excitability. Thus, there is sufficient
evidence that ENDS flavors exert an effect that goes beyond both odorant and tastant effects to
alter neurons of the reward pathway directly and contribute to changes in behavior. For this
reason, we examined how mice escalate to nicotine vapor inhalation with or without menthol or
green apple, two very popular flavors among ENDS users. We also investigated the effect of
green apple flavor alone, as our recent investigations demonstrated this flavor alters rewardrelated behavior and midbrain neuron function in the absence of nicotine (Avelar et al., 2019).
To examine reinforcement-related behavior of various ENDS flavors, we have utilized a novel
vapor-inhalation (e-Vape) self-administration paradigm to accurately and efficiently model
human vaping in a non-invasive manner. Using e-Vape self-administration, we report that male
mice on a fixed-ratio 1 (FR1) schedule will escalate in their self-administration behavior with
menthol + nicotine, green apple + nicotine, and green apple-only e-liquids, and will maintain
reinforcement-related behavior on a FR3 schedule. These ENDS flavors were verified to act in a
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nAChR-mediated manner, demonstrated by pre-treatment injections of the nAChR antagonist,
DhβE, into mice prior to self-administration assays. The finding that flavored ENDS alter
vaping-related behaviors by increasing the rate of initiation through self-administration
escalation and eliciting greater reinforcement-related behavior demonstrates the need to examine
ENDS flavors for their role in enhancing vaping-related nicotine addiction.
Materials and Methods
Mice
All experiments were conducted in accordance with the guidelines for care and use of
animals provided by the National Institutes of Health. Protocols were approved by the
Institutional Animal Care and Use Committee at Marshall University. All mice used in these
assays were adult (3-6-months-old) male C57BL/6J mice obtained from the Jackson laboratory.
Mice were housed on a standard 12/12 hr light/dark cycle and allowed food and water ad libitum.
Mice were used in behavioral experiments during their light cycle between the hours of 9am12pm, 12-3pm, or 3-6pm for morning, afternoon, and evening sessions. We detected no
difference in responses during these three light-time periods. Mice were not food restricted to
attain operant behavior.
Drugs
All nicotine-containing e-liquids in this work used free-base nicotine. Free-base nicotine
(product number – N2472-100ML, lot number – 2AH0278) was obtained from Spectrum.
Dihydro-β-erythroidine (DhβE) hydrobromide, a β2* nAChR antagonist, (catalog number –
2349) was obtained from Tocris. 30% Propylene Glycol and 70% Vegetable Glycerin (30/70
PGVG) was obtained from La Jolla Alcohol Research, Inc. (La Jolla, CA). For these experiments
we used commercial e-liquids and e-liquids made to contain specific concentrations of nicotine
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and flavorants in PGVG. DhβE was dissolved in saline and injected into mice intraperitoneally,
at 2 mg/kg, prior to self-administration sessions. With the exception of the nicotine dose–
response, all nicotine-containing e-liquids used 6 mg/mL nicotine. For commercial e-liquids:
menthol + 6 mg/mL nicotine (brand name, King’s Menthol), zero-nicotine menthol (King’s),
green apple + 6 mg/mL nicotine (brand name, Fuji) and zero-nicotine green apple (brand name,
Ruby) e-liquids were purchased from a local smoke shop in 30/70 PGVG (Full Steam Vapor,
www.fullsteamvapor.com). The menthol e-liquids we used contain ~15 mg/mL menthol (Tierney
et al., 2016; Omaiye et al., 2019b). Green apple e-liquids contain 5 – 15 mg/mL of total green
apple flavorants (Tierney et al., 2016; Omaiye et al., 2019b). For nicotine dose-response in eVape self-administration assays, free-base nicotine was added directly into PGVG (30/70) to
reach concentrations of 3, 6, 12, or 18 mg/mL. While using store-bought e-liquids is directly
translational to human vaping, there are numerous reports that detail the varying concentrations
of nicotine and flavorants in refillable e-liquids (Krüsemann et al., 2018; Javadi-Paydar et al.,
2019; Omaiye et al., 2019b). Accordingly, we made e-liquids to contain specific concentrations
of nicotine (freebase), (-)-menthol (15 mg/mL), and green apple (15 mg/mL total of hexyl
acetate, ethyl acetate, and methylbutyl acetate at 2.5:1:1 ratio) in accordance with previously
published reports on e-liquid content (Krüsemann et al., 2018; Javadi-Paydar et al., 2019;
Omaiye et al., 2019b).
Self-Administration Assays
Operant vapor self-administration was conducted in four air-tight chambers with interior
dimensions of 21 cm L x 19 cm W x 12.5 cm H (La Jolla Alcohol Research Inc., La Jolla, CA,
USA, www.ljari.tech) (see Figure 14). The chambers were housed in a dark Plexiglas enclosure
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Figure 14. Setup and Timeline for Self-Administration Assays
(A1-2) Setup of e-Vape operant chambers. (A1) Mice are freely moving in an air-tight chamber
(dimensions given in Material and Methods) and air is circulated through a flowmeter that pulls
through a vape tank. Two nose-pokes are available on the left and right side of the chamber and
contingent delivery (duration, timeout, or FR schedule) is set by two control boxes. (A2) e-Vape
delivery (3 s) creates a distinct vapor cone for mouse inhalation. For additional details, see
www.ljari.tech. (B) Cohort 1 and 2 were used for commercial e-liquids displayed in Figures 2
and 3. (C) Cohort 3 was used only for nicotine dose-response in e-Vape self-administration
assays (Figure 4A only). (D) Cohort 4 was used to examine ‘neat’ e-liquids displayed in Figures
4B-4C and 5. Cohort 5 mice (not shown) were yoked to cohort 4 in order to assess plasma
cotinine levels.
that minimized extraneous light and noise. Two nose-poke holes were mounted above the floor
on the back-side walls of the chamber. Yellow cue lights were mounted in the nose-poke holes.
Airflow was vacuum controlled by an electric pump that allowed air flow at 1-2 L/min. The air
outlet was located at the top back corner of the right wall of the camber and connected through
tubing to a HEPA-Cap filter (product number – 26091, lot number - 3953048) from Midland
Scientific. The vapor port was located in the front of the chamber and the e-liquid solutions were
contained in a SMOK® baby beast TFV8 X-baby Q2 atomizer tank (0.40 ohms dual coil;
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Shenzhen IVPS Technology Co., Ltd., Shenzhen, China) that was activated by a custom ecigarette mod box and e-Vape controller (La Jolla Alcohol Research, Inc., La Jolla, CA, USA).
For the experiments described here, five cohorts of C57BL/6J mice were used: cohort 1
for examining commercial (store-bought) e-liquids (Figures 15 and 16A; n = 12-28); cohort 2
for examining DhβE effects on commercial e-liquids (Figure 16B-C; n = 5); cohort 3 for a
nicotine dose-response using ‘neat’ e-liquids (Figure 17A only; n = 8); cohort 4 for examining
nicotine with and without flavors in ‘neat’ e-liquids (Figures 17B-C and 18; n = 9); and cohort 5
for assessing plasma cotinine concentrations (n = 10).
In general, adult (3-months-old), male mice began vapor self-administration on a fixedratio (FR1) schedule on a Monday for 10 daily, 3-hr sessions, with a weekend abstinence
(Figure 14B-D). Mice were singly placed into air-tight operant chambers that contained two
nose-pokes (one active and one inactive) (Figure 14A). Nose-pokes in the active hole resulted in
a 3-s delivery of vaporized e-liquids through the vapor entrance port with a 60-s timeout. During
the timeout a yellow cue-light remained on. Inactive nose-pokes were recorded with no
consequences. Cohorts are described in further detail below.
Following FR1 escalation, mice were transitioned to a FR3 schedule where they were
maintained on an e-liquid for four consecutive days (starting on a Monday) to reach stable
responding and re-baselined to their original FR1 assigned e-liquid on day 5 (Friday). Mice were
used in a within-subjects, Latin square design to test multiple e-liquids. When DhβE (2 mg/kg)
was used, mice were given intraperitoneal injections immediately prior to 3 hr e-Vape selfadministration sessions (2 days with saline, 2 days with DhβE). For progressive ratio (PR)
assays, the following equation PR=2(2n/9) (n = number of e-Vape deliveries per session) was used
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to determine the number of active nose-pokes required for e-Vape delivery. Similar to FR1/FR3,
PR sessions lasted 3 hrs.
Cohort 1: E-Vape Self-Administration with Commercial E-Liquids
Cohort 1 (of 5) mice were used to examine FR1 and FR3 responding with commercial
(store-bought) e-liquids using a within-subjects design (Figures 14, 15 and 16A; n = 12-28).
Mice were assigned to the following e-liquids: PGVG, cue-light only (no e-liquid), 6 mg/mL
nicotine, green apple, green apple + nicotine, menthol (Figure 15C), or menthol + nicotine. For
these, each e-liquid was assigned to 4 mice (n = 28 total). As described in the main Methods text,
mice were escalated over 10-daily 3 hr FR1 sessions. In this cohort, mice assigned PGVG, cuelight only, or menthol-only did not acquire self-administration behavior. Thus, only mice
assigned to nicotine-only, green apple, green apple + nicotine, and menthol + nicotine were
transitioned to FR3 assays (n = 16). To be completely transparent, the mice assigned cue-light
only, menthol-only, and PGVG during FR1 were assessed initially on a FR3 schedule; but many
slept during the 3 hr sessions and were excluded from behavioral assays.
Upon transitioning to FR3, mice self-administered the same e-liquid assigned during FR1
for four days to obtain stable FR3 responding. Here, 4 of the 16 mice moved to FR3 failed to
reach stable responding (decreased responding to zero by day 4). Of these four, three were from
the group assigned nicotine-only and the fourth was from the group assigned green apple. Thus,
12 mice were moved to the next stage of FR3 responding. Following these exclusions, mice were
presented with menthol + nicotine, menthol-only, green apple + nicotine, green apple-only,
nicotine-only, or PGVG following a Latin square design. Each assigned e-liquid was maintained
on a FR3 schedule for 4 days and mice were re-baselined using their original e-liquid on the fifth
day. In between the 5-day protocol per e-liquid was a weekend abstinence (Figure 14). The
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mean of the final two sessions (days 3 and 4) per e-liquid was used to compare reinforcementrelated behavior between e-liquid assignment.
Cohort 2: DhβE Testing with Commercial E-Liquids
Following an identical FR1 and FR3 protocol as cohort 1, cohort 2 mice were used to
examine the dependence upon nAChR activation for the self-administration of commercial eliquids (Figures 14 and 16B-C; n = 20). Because 100% of the mice assigned menthol + nicotine
acquired self-administration on a FR3 schedule, mice were assigned this e-liquid for FR1 and
FR3. For the DhβE experiments, the 20 mice, each were randomly assigned PGVG, nicotineonly, green apple + nicotine, or menthol + nicotine so that each e-liquid was given to five mice
each. Starting on a Monday, following the weekend abstinence, mice were given intraperitoneal
injections of saline immediately prior to entering the self-administration chambers for a 3 hr FR3
session. This was repeated daily for two days (Monday/Tuesday). Following this, mice were
given intraperitoneal injections of DhβE (2 mg/kg) for two days immediately prior to FR3
sessions (Wednesday/Thursday). On the fifth day (Friday), mice were re-baselined to their
assigned e-liquid (PGVG, nicotine, green apple + nicotine, or menthol + nicotine without
injection of saline/DhβE). Finally, these mice were extinguished on PGVG on a FR1 schedule
over the course of 4 days.
Cohort 3: Nicotine Dose-Response
Cohort 3 mice were used exclusively for a within-subjects dose-response of nicotine in eVape self-administration assays (Figures 14 and 17A; n = 8). Here, mice were escalated on 6
mg/mL nicotine (no flavor) using a 10 session FR1 protocol identical to Cohort 1. After this,
they were continued on 6 mg/mL nicotine for four days to obtain stable FR3 responding.
Following this, mice were assigned 0 mg/mL (PGVG-only), 3 mg/mL, 12 mg/mL, or 18 mg/mL
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nicotine using a Latin square design. Mice self-administered their assigned nicotine dose for four
days (starting on a Monday) and then re-baselined to 6 mg/mL nicotine on the fifth day. Between
each nicotine dose assignment, mice had a two-day (weekend) abstinence similar to FR1
escalation. The mean of the final two days (days 3 and 4) was used to calculate the mean FR3 eVape deliveries. No exclusions were needed for this cohort.
Cohort 4: E-Vape Self-Administration Assays with ‘Neat’ E-Liquids
Cohort 4 (of 5) mice were assigned to ‘neat’ e-liquids (made in-house to contain exact
concentrations of nicotine and flavorant chemicals) (n = 9). These mice were escalated on a FR1
schedule identical to the one used for the other cohorts (Figures 14, 17 and 18). Also similar to
the other cohorts, these mice were transitioned to a FR3 schedule where they were presented
different e-liquids (menthol + nicotine, menthol-only, green apple + nicotine, green apple-only,
nicotine-only, or PGVG) using a within-subjects, Latin square design. These mice were
presented their assigned e-liquid for four days and then re-baselined to menthol + nicotine on the
fifth day. The following week they were moved to the next e-liquid within their presentation
sequence. Following the FR3 sessions and a weekend abstinence period, these mice were then
transitioned to a progressive ratio (PR) schedule where the number of active responses were
determined by the equation, PR = 2(2n/9), where n is the number of earned e-Vape deliveries
within a session. Similar to the FR3 sessions, mice were assigned e-liquids using within-subjects,
Latin square design. Mice were maintained on PR schedules for 4 days and then re-baselined for
2 days using 6 mg/mL nicotine + 15 mg/mL (-)-menthol. We chose menthol + nicotine as a
baseline since this reproductively provided the most robust response in mice. During PR
sessions, the active nose-poke was set to match FR1 and FR3 sessions; but on the final 2 days of
PR sessions, the active and inactive nose-pokes were reversed to examine presence of side bias.
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Finally, after assessing side bias, the mice were randomly assigned PGVG, 6 mg/mL nicotineonly, green apple-only, green apple + nicotine, menthol-only, or menthol + nicotine. Similar to
the DhβE experiments conducted on mice assigned commercial e-liquids, we pre-injected saline
immediately prior to 3 hr FR3 e-Vape self-administration assays to achieve a stable baseline of
responding (Monday/Tuesday). Following this, we pre-injected 2 mg/kg DhβE prior to selfadministration for two consecutive days (Wednesday/Thursday). On the fifth day (Friday), mice
were re-baselined to their assigned e-liquid (PGVG, nicotine-only, green apple-only, green apple
+ nicotine, menthol-only, or menthol + nicotine without injection of saline/DhβE). Mice were
transitioned to 6 e-liquids (PGVG, 6 mg/mL nicotine, green apple, green apple + nicotine,
menthol, and menthol + nicotine) so that the DhβE assays using neat liquids were done with 6
mice (green apple, green apple + nicotine, menthol, and menthol + nicotine) or 4 mice (PGVG
and nicotine) for each e-liquid assignment. Mice were removed from behavioral assays due to
age as at this point, they reached ~6 months of age.
Plasma Cotinine Assays
We used a plasma cotinine enzyme-linked immunosorbent assay (ELISA) kit (Origene,
EA100902) to examine concentrations after vapor inhalation sessions. For these assays, a fifth
cohort of mice naïve to e-Vape exposure were placed in e-Vape chambers and were given 25 eVape deliveries using a passive exposure paradigm that matched mice trained to self-administer
(identical session time to mice that received contingent e-Vape deliveries). 30 minutes after the
session, mice were anesthetized with CO2 and blood was drawn via cardiac puncture. Following
centrifugation (1500 rpm for 15 minutes at 4oC), plasma was extracted, and we followed the
established Origene cotinine ELISA kit protocol to assay plasma cotinine levels. Measurements
were taken using a Flexstation III (Molecular Devices).
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Statistical Analysis
All results are presented as mean ± SEM and all statistical analyses were performed using
GraphPad Prism. To examine the effect of nicotine and flavorants on escalation of e-Vape selfadministration behavior, we used a one-way repeated measures ANOVA (Figure 15). Nicotine
dose-response data was analyzed using a one-way repeated-measures ANOVA with nicotine
dose being the within-subjects factor (Figure 17). FR3 e-Vape responding between e-liquids was
analyzed with a one-way repeated measures ANOVA (Figures 16 and 17) or a two-way
ANOVA for comparisons among e-liquids and DhβE antagonism (Figure 16 and 18). All means
comparisons included the testing of each treatment group with all others within an experiment
using a post hoc Tukey or Bonferroni (selected post hoc tests are indicated in the figure legends).
Results
Effect of Flavors on Escalation and Reinforcement of Self-Administration Behavior
We first investigated self-administration behavior in adult male mice (cohort 1) that were
assigned commercial (store-bought) e-liquids. Mice were assigned PGVG (control), 6 mg/mL
nicotine, menthol + nicotine, green apple + nicotine, menthol (zero nicotine), green apple (zero
nicotine), and finally a cue-light only control (n = 4 each; Figure 15A). For ten 3-hr sessions,
mice were allowed to self-administer their assigned e-liquid on an FR1 schedule (Figure 15A).
Following the 10 sessions, menthol + nicotine and green apple alone produced the highest
number of FR1 deliveries (41.4 and 31.7 average FR1 deliveries, respectively), followed by
green apple + nicotine and nicotine-alone (23.6 and 6.93 average FR1 deliveries, respectively).
For both PGVG and cue-light only groups, mice gradually reduced the number of responses as
the sessions continued. A one-way ANOVA and post hoc Tukey means comparison revealed that
menthol + nicotine, green apple, and green apple + nicotine were significantly different from
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Figure 15. Acquisition of E-Vape Self-Administration Behavior
(A) Mice naive to vapor exposure were escalated on designated e-liquids in e-Vape selfadministration assays using 10 daily 3-h FR1 sessions (3-s puff with 60-s timeout) (n = 4
mice/group) with the indicated commercial e-liquids. Where not indicated, nicotine is 6 mg/mL.
Data are mean (± SEM) e-Vape deliveries for each session. (B) Mean inactive nose-pokes for
mice during sessions described in (A). (C) Adult male mice were assigned to 15 mg/mL (-)menthol for 10-daily FR1 sessions using a protocol identical to that used in A.
PGVG. We also observed that nose-pokes on the inactive side progressively decreased as FR1
sessions continued (Figure 15B). Additionally, we assigned mice to escalate on menthol alone
on a FR1 schedule; but mice exhibited behavior similar to extinction (Figure 15C).
Upon completing FR1 escalation, mice were then transitioned to a FR3 schedule and
continued on their assigned e-liquid for four consecutive days to reach stable responding. Next,
mice were used in a within-subjects design where they were presented e-liquids (PGVG, 6
mg/mL nicotine, green apple, green apple + nicotine, menthol, or menthol + nicotine) following
a Latin square design (n = 12; Figure 16A). Mice maintained their assigned e-liquid for 4 days
and were re-baselined on the fifth day using their original FR1 assigned e-liquid. Using a oneway repeated measures ANOVA, we observed a significant main effect of e-liquids on FR3
earned e-Vape deliveries (F(5, 45) = 37.7, p < 0.0001). Using a post hoc Tukey means comparison,
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Figure 16. Earned Reinforcements Mediated Through nAChR-Dependent Mechanisms
(A) Mice on a FR3 schedule were assigned commercial e-liquids during a 3-h e-Vape selfadministration session, n = 12 mice/group. (B) Mice were intraperitoneally injected with saline
or 2 mg/kg DhβE immediately prior to FR3 self-administration sessions. Two-way ANOVA with
post hoc Bonferroni; n = 5 mice. (C) All mice were assigned PGVG on a FR1 schedule to
examine extinction-related behavior. Data are mean (± SEM) e-Vape deliveries for each session.
Where not indicated, nicotine is 6 mg/mL. *, p < .05; **, p < .01; ***, p < .005; one-way
ANOVA with post hoc Tukey.
we determined that 6 mg/mL nicotine, green apple, green apple + nicotine, and menthol +
nicotine produced significantly more FR3 deliveries than PGVG (Figure 16A). Additionally,
mice assigned green apple + nicotine or menthol + nicotine earned significantly more FR3 eVape deliveries compared with 6 mg/mL nicotine (Figure 16A). Similar to previous
investigations (Wang et al., 2014; Biswas et al., 2016), menthol-alone did not result in any
apparent reinforcement-related behavior as mice earned few FR3 e-Vape deliveries (Figure
16A).
We have previously shown that both menthol and green apple flavorants alter behavior
through a nAChR-mediated mechanism (Henderson et al., 2017; Avelar et al., 2019). To confirm
that these flavor-induced changes in behavior were mediated through nAChRs, we used cohort 2

83

mice (following identical preceding FR1/FR3 self-administration assays) to determine whether
the β2-containing nAChR antagonist, DhβE, reduced self-administration behavior. To do this we
used a 4-day protocol where mice were divided into a between-subjects design and assigned
PGVG, 6 mg/mL nicotine, green apple + nicotine, and menthol + nicotine (n = 5 each). On days
1 and 2, mice were injected with saline immediately prior to entering the self-administration
chamber to establish a new baseline for FR3 responding. On days three and four, mice were
injected with DhβE (2 mg/kg; intraperitoneal injection) immediately prior to FR3 selfadministration sessions (Figure 16B). Using a two-way ANOVA, we observed a significant
effect with e-liquid assignment (interaction, F(3, 32) = 3.75, p = 0.021; e-liquid factor, F(3, 32) =
55.3, p < 0.0001; DhβE factor, F(1, 32) = 23.2, p < 0.0001). DhβE significantly reduced FR3
responding in mice assigned to nicotine, green apple + nicotine, and menthol + nicotine. These
data suggest that nAChR-mediated mechanisms are critical to e-Vape self-administration
behavior. We note that mice assigned PGVG in these assays exhibited higher FR3 e-Vape
deliveries compared to those in Figure 16A. This may be attributed to the fact that these mice
are different from those in Figure 16A, but their higher number of responses to PGVG may be
due to an extinction-related burst as they were previously assigned to menthol + nicotine for FR1
training. Following this final series of FR3 sessions, mice were re-baselined to their assigned eliquid during the DhβE trial to reach stable responding and then extinguished in four daily FR1
sessions with PGVG only (Figure 16C). Here we observed that mice extinguished e-Vape selfadministration behavior within 2-3 days.
Nicotine Dose-Response in E-Vape Self-Administration
There have been several reports that highlight the fact that ENDS e-liquids contain
concentrations of nicotine and flavorants that can be vastly different from their labeled amounts
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(Tierney et al., 2016; Omaiye et al., 2019b). Therefore, the translational value of achieving selfadministration with mice using commercial e-liquids popular in the vaping community is
tremendously reduced by concerns regarding consistency of the e-liquid constituents. For this
reason, we examined e-liquids made to contain specific concentrations of nicotine and flavorants
(‘neat’ e-liquids).
First, we decided to examine the dose-response of nicotine-only (zero flavorants) in mice
using 0 (PGVG), 3, 6, 12, and 18 mg/mL nicotine (n = 8; Figure 17A). Cohort 3 mice (see
Figure 14) were allowed to escalate e-Vape self-administration behavior using 6 mg/mL nicotine
during 10 daily, 3-hr FR1 sessions identical to those used for mice assigned commercial e-liquids
described above (cohort 1). Following 10 days of FR1 escalation, mice were transitioned to a

Figure 17. Dose-Response of Nicotine in E-Vape Self-Administration with Male Mice
(A) Dose–response of nicotine only (unflavored) at concentrations of 0 (PGVG only), 3, 6, 12,
and 18 mg/mL in e-Vape self-administration 3-h FR3 sessions (n = 8 mice). (B) Adult male mice
were escalated on “neat” (−)-menthol + nicotine on a FR1 schedule (10 daily 3-h sessions). Data
are mean (± SEM) FR1 e-Vape deliveries per session. (C) Mice were placed on a FR3 schedule
to examine earned e-Vape deliveries for “neat” nicotine with or without flavors. Where not
indicated, nicotine is 6 mg/mL. (A, C) Data are mean (± SEM) FR3 e-Vape deliveries for each
condition. *, p < .05; **, p < .01; ***, p < .005; ****, p < .001. #, p < .05 vs. 6 mg/mL nicotine.
One-way ANOVA with post hoc Tukey.
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FR3 schedule and maintained on 6 mg/mL nicotine for 4 days to reach stable responding.
Following this, mice were used in a within-subject design and presented the different nicotine
concentrations using a Latin square design (Figure 17A). A one-way repeated-measures
ANOVA, with nicotine dose set as within-subjects factor, resulted in a main effect on e-Vape
responding (F(4, 36) = 22.3, p < 0.0001). Using a post hoc Tukey means comparison, we compared
all five doses and observed that only 6 and 12 mg/mL nicotine were significantly different from
PGVG (p < 0.0001 and p = 0.0025, respectively). Six mg/mL nicotine resulted in the highest
number of FR3 e-Vape deliveries and was also significantly different from 3, 12, and 18 mg/mL
nicotine (p < 0.0001, 0.0007, < 0.0001, respectively; Figure 17A). 6 mg/mL nicotine is also
preferred by human ENDS users who are new to nicotine use (Omaiye et al., 2019b).
Using ‘Neat’ E-Liquids, Mice Exhibit Vapor Self-Administration Trends Similar To
Prior Reports
Based upon prior analytical chemistry reports on ENDS e-liquid compositions, menthol
and green apple flavors are present at concentrations of 15 mg/mL (Omaiye et al., 2019b).
Furthermore, green apple e-liquids were in many cases constituted of hexyl acetate, ethyl acetate,
and methylbutyl acetate (Tierney et al., 2016; Omaiye et al., 2019b). Accordingly, we made
menthol e-liquids using 15 mg/mL (-)-menthol and green apple e-liquids using 15 mg/mL green
apple (hexyl acetate, ethyl acetate, and methylbutyl acetate at a 3:1:1 ratio) in PGVG. In eliquids containing nicotine, we used 6 mg/mL based on the peak response we noted (Figure
17A). Similar to assays described with commercial e-liquids, mice escalated on a FR1 schedule
for 10 3-hr e-Vape self-administration sessions using a protocol identical to that used for
commercial e-liquids (n = 9; Figure 17B). Next, mice were transitioned to a FR3 schedule for 4
days on their assigned e-liquid to reach stable responding. Following this, mice were used in a

86

within-subjects design to examine PGVG, 6 mg/mL nicotine, green apple, green apple +
nicotine, menthol, and menthol + nicotine. Mice were assigned e-liquids using a Latin square
design, maintained their e-liquid for 4 days, and were re-baselined using menthol + nicotine on
the fifth day. The final 2 days of FR3 responding on each e-liquid were averaged to calculate the
number of FR3 e-Vape deliveries (Figure 17C). Using the ‘neat’ e-liquids, we observed a trend
in FR3 responding that was similar to the commercial e-liquids. Using a one-way repeated
measures ANOVA, we noted a significant effect of e-liquid treatment (F(5, 42) = 12.7, p <
0.0001). Using post hoc Tukey means comparison, we noted a significant difference between
mice assigned 6 mg/mL nicotine, green apple + nicotine, and menthol + nicotine when
compared to PGVG (p = 0.033, < 0.0001, and < 0.0001, respectively, Figure 17C). Additionally,
we noted a significant difference between menthol + nicotine versus nicotine-alone (p = 0.017).
Although green apple + nicotine produced a 68.8% increase in FR3 responding versus nicotine
(mean FR3 e-Vape deliveries of 20.7 and 12.3, respectively), these two conditions were not
statistically different from each other (p = 0.213). In order to determine whether our e-Vape
methods produce relevant plasma cotinine concentrations in mice, we utilized a plasma cotinine
ELISA assay and a yoked paradigm (see section below).
Following FR3 responding, mice were then moved to a PR schedule. Here, required nosepokes were determined by the equation, PR = 2(2n/9), where ‘n’ is the number of earned e-Vape
deliveries within the session. PR responses were maintained for 2 days on a mouse’s prior
assigned active nose-poke. On the next two days, the active and inactive nose-pokes were
switched to examine the presence of a side bias. Upon switching the active nose-poke
assignment, mice gradually switched responding from the inactive (previously active) to the
active (previously inactive) nose-poke during their 3-hr PR session (Figure 18A). This supports
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the fact that the mice have learned the self-administration behavior and do not have a side-bias
toward operant behavior. When all 4 days of PR were averaged, we noted a trend that was
similar to FR3 e-Vape deliveries (Figure 18B), and using a one-way repeated measures ANOVA
we noted a significant main effect (F(5, 40) = 10.9, p < 0.0001). Similar to FR3 sessions we noted a
significant difference between green apple, green apple + nicotine, and menthol + nicotine when
compared to PGVG (Figure 18B). Additionally, menthol + nicotine resulted in significantly
more earned PR deliveries when compared to nicotine alone. Finally, we used DhβE to examine
the role of β2* nAChRs in reinforcement-related behaviors of mice assigned to these ‘neat’ eliquids (Figure 18C). Using a two-way ANOVA, we detected a significant effect of e-liquid and
pre-treatment (interaction, F(5, 54) = 5.40, p = 0.0004; e-liquid factor, F(5, 54) = 7.50, p < 0.0001;
DhβE factor, F(1, 54) = 52.3, p < 0.0001). With nicotine, green apple, green apple + nicotine, and

Figure 18. Mice Exhibit Vapor Self-Administration with ‘Neat’ E-liquids
(A) Raster plots that show the number of nose-pokes on the active/inactive sides for one mouse
on the first day when the nose-poke assignments were reversed to examine side bias. (B) Mice
were place on a PR schedule and assigned nicotine with or without flavors (n = 9). (C) Mice
were pre-injected with saline or 2 mg/kg DhβE prior to a FR3 self-administration session (n = 4–
6/condition). (B and C) Data are mean (± SEM) e-Vape deliveries per mouse. In all cases,
nicotine is 6 mg/mL. *, p < .05; **, p < .01; ***, p < .005; ****, p < .001; one-way ANOVA
with post hoc Tukey.
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menthol + nicotine, we detected a significant difference between saline and DhβE pre-treated
mice (Figure 18C). We detected no difference with mice assigned to PGVG or menthol alone.
Plasma Cotinine Concentration in Mice Following E-Vape Self-Administration
Our vapor self-administration methods are translational to human vaping only if they
produce relevant plasma concentrations of nicotine and cotinine. To determine if our methods
produce relevant concentrations of cotinine in the plasma of mice, we utilized an ELISA assay
designed to measure plasma cotinine. We assigned a separate group of mice (cohort 5) to a
yoked vapor self-administration group of mice (cohort 4). This separate group was divided in
two where one was given 6 mg/mL nicotine (n = 4) and the other was given 15 mg/mL menthol
+ 6 mg/mL nicotine (n = 6). In a passive e-Vape chamber, mice were given 25 e-Vape deliveries
(3 s puff) to mimic the number of deliveries mice achieve at the end of escalation training (see
Figure 17B-C). While nicotine-only mice typically receive fewer e-Vape deliveries than mice
assigned nicotine + menthol, we delivered 25 e-Vape puffs to both groups to examine how the
presence of menthol may alter nicotine/cotinine pharmacokinetics. This is based on the rationale
that menthol may slow the metabolism of nicotine (Gilpin et al., 2014; Mead et al., 2018;
Montanari et al., 2020). Mice assigned nicotine-only had a mean plasma cotinine concentration
of 67.1 ± 8.5 ng/mL while mice assigned menthol + nicotine had a mean plasma cotinine
concentration of 78.0 ± 14.1 ng/mL. Here we demonstrate that plasma cotinine concentrations
obtained from e-Vape self-administration in mice is relevant to the plasma cotinine concentration
obtained from vaping in humans (16-140 ng/mL).
Discussion
The goal of this study was to establish our vapor self-administration assays and examine
the effects of ENDS flavors on vaping-related behaviors in a mouse model. With the growing
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popularity of flavored ENDS and the plethora of flavor options (Zhu et al., 2014; Krüsemann et
al., 2018), it is important to establish a model relevant to human vaping that can then be used in
conjunction with high-resolution neurobiology and neurophysiological assays. Given our
previous studies (Henderson et al., 2017; Avelar et al., 2019) and the current popularity among
ENDS users, we chose to begin our studies with menthol and green apple flavor, with and
without nicotine. Prior research regarding flavors in rodent self-administration behavioral assays
reported enhanced nicotine reward- and reinforcement-related behavior; however, this data was
compiled using intravenous self-administration (Wang et al., 2014; Biswas et al., 2016) or
conditioned place preference (Henderson et al., 2017; Avelar et al., 2019). E-Vape selfadministration provides a unique methodology to study vaping-related behaviors in mice,
without surgery and using identical vaping products used by humans. While the novelty and
translational value of using commercial e-liquids is an option, the unavoidable problem with this
is the discrepancies between labeled and actual concentrations of nicotine and flavorants. Thus,
we made ‘neat’ e-liquids to contain specific concentrations of nicotine and flavorants to ensure
consistency. These e-liquids and our operant exposure paradigm produced cotinine levels that are
consistent with previously reported studies using vapor inhalation (Gilpin et al., 2014; JavadiPaydar et al., 2019; Montanari et al., 2020).
In this study, we note that flavored ENDS (menthol + nicotine, green apple + nicotine,
and green apple alone) enhance the rate of acquisition of self-administration behavior through a
FR1 schedule compared to nicotine alone or PGVG (Figure 15). In humans, we may consider a
finding like this to convey flavors may enhance the initiation of ENDS use by masking the
harshness of nicotine and providing a more palatable taste (Mead et al., 2018; Wickham et al.,
2018). However, mice experience taste and odor in a distinctly different manner than humans.
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Thus, it would be more accurate to rely on our previous publications that used administration
routes that bypassed odorant and tastant responses (intraperitoneal injections) to document
flavorant-induced changes in ventral tegmental area dopamine and GABA neuron firing
(Henderson et al., 2017; Avelar et al., 2019). Thus, this enhancement in escalation, FR3
responding, and PR responding may be indicative of enhancements in the neuronal activity that
mediates the nicotine reward pathway. We also note that our results with menthol do mirror the
results obtained using intravenous self-administration paradigms that examined menthol +
nicotine (Wang et al., 2014; Biswas et al., 2016). We also note that our dose-response with
vaporized nicotine was observed to exhibit an inverted-U dose response curve that is similar to
previous nicotine intravenous self-administration paradigms (Rollema et al., 2007; Pons et al.,
2008). In using DhβE, we determined that the self-administration behavior we observed is
mediated through nAChR activation. We note the differences between the use of commercial eliquids (flavored e-liquids were not blocked 100%) and ‘neat’ e-liquids (responding was
eliminated largely). This may be due to the fact that responding with the commercial e-liquids
was ~2-fold higher than the ‘neat’ e-liquids. This is likely due to varying concentrations of
nicotine (despite labeling) or unlabeled constituents. Several analytical reports have noted that
menthol and green apple e-liquids may contain additional flavorants of the vanilla flavor
category (Tierney et al., 2016), and this may provide additional enhancements in reinforcementrelated behavior.
In summary, we have used a novel contingent vaping-related model to reproduce trends
involving flavor-induced enhancement of nicotine-related behaviors (Wang et al., 2014; Biswas
et al., 2016; Henderson et al., 2017; Avelar et al., 2019). Furthermore, this study provides further
evidence that flavors can enhance nicotine reinforcement-related behaviors through a nAChR
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mechanism. We acknowledge this study is composed of only adult male mice and it is necessary
to examine these effects in both sexes and also at an adolescent time point. Since prenatal and
early exposure to nicotine triggers unique changes in neurobiology (Omelchenko et al., 2016;
Polli and Kohlmeier, 2018; Buck et al., 2019), it will be important to understand if a vapingrelated model causes similar changes in early exposure models. Furthermore, in this study we
examine only two flavor categories. Given the large number of flavors available, it is critical to
understand which flavors alter nicotine-related behavior and to also follow-up these behavioral
studies by investigating changes in neurobiology and neurophysiology.
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Abstract
Electronic nicotine delivery systems (ENDS) differ from combustible cigarettes given
that nicotine-salt or nicotine-freebase may be used depending on the product. We have
investigated how nicotine-salt and freebase formulations alter e-Vape® self-administration
(EVSA) behavior and plasma cotinine levels in male and female mice. Adult C57/BL6J mice
were used in EVSA and assigned vaping e-liquids (50:50 PGVG, 6 mg/mL nicotine-freebase, or
6 mg/mL nicotine-salt). Mice were escalated on a fixed ratio 1 (FR1) schedule in daily 2 hr
sessions and then transitioned to a FR3 to examine reinforcement-related behaviors. Here we
observed that mice assigned nicotine-salt exhibited increased EVSA on a FR3 schedule
compared to nicotine-freebase. Additionally, mice assigned nicotine-salt exhibited higher plasma
cotinine concentrations following delivery-controlled passive-inhalation sessions. These data
provide evidence that nicotine-salt formulations may contribute to greater reinforcement-related
behavior and highlight the need for further investigations regarding nicotine formulation in
ENDS.
Introduction
Since the introduction of ENDS in 2003 (Bhatnagar et al., 2019), their use has grown
among life-long cigarette smokers as a safer alternative to smoking, as well as teens naïve to
smoking. Ongoing research has demonstrated that ENDS have fewer toxic chemicals than
combustible cigarettes (Papaefstathiou et al., 2019), but there are numerous novel chemicals and
constituents in ENDS that need to be evaluated. Thus far, some ENDS-specific chemical
constituents have been identified to include heavy metals, carcinogenic chemicals, chemical
flavorants, and chemical odorants that have been shown to cause various levels of toxicity in cell
lines (Hua et al., 2019; Koopsamy Naidoo et al., 2019; Osei et al., 2019; Talih et al., 2019;
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Zahedi et al., 2019). Despite this, it should be noted that many of these studies are ongoing and
there is a great need to evaluate these chemicals at levels relevant to human vaping. Vaping,
similar to smoking, presents a distinct pharmacokinetic profile due to the rapid delivery of
inhaled chemicals to the brain (Benowitz, 2009). ENDS products are different from combustible
cigarettes as some products utilize nicotine-salts instead of nicotine-freebase. The increasingly
popular JUUL devices are the most prominent ENDS product to use nicotine-salts and their
success could be due to the cigarette-like pulmonary delivery of nicotine due to the use of salt
formulations (O'Connell et al., 2019). There are few investigations into the impact that nicotine
formulations have on reinforcement-related behaviors (O'Connell et al., 2019; Shao and
Friedman, 2020). To fill this gap, we have utilized an e-Vape® self-administration (EVSA)
paradigm to model human-related vaping behaviors. Many products that utilize nicotine-salts
contain higher concentrations of nicotine (JUUL, ~60 mg/mL). To avoid nicotine concentration
as an additional variable, we selected a nicotine dose of 6 mg/mL as this is both amenable to
mouse EVSA assays (Cooper et al., 2021) but is also a dose that is popular among humans that
use tank-based ENDS (Omaiye et al., 2019b). Accordingly, we utilized e-liquids made in-lab to
contain 6 mg/mL nicotine using either freebase or salt formulations. We then evaluated male and
female adult mice for EVSA on a fixed-ratio 3 (FR3) schedule following a previously described
protocol (Cooper et al., 2021). Here we observed that in both males and females, mice that were
assigned nicotine-salt exhibited significantly more aerosol deliveries than mice assigned
nicotine-freebase. Additionally, plasma cotinine analysis revealed that mice assigned nicotinesalt exhibited a significantly higher plasma value for cotinine following passive E-Vape®
sessions. These data highlight that nicotine formulations may facilitate different levels of
reinforcement related behaviors and one reason may be due to distinct pharmacokinetics.
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Material and Methods
Mice
All experiments were conducted in accordance with the guidelines for care and use of
animals provided by the National Institutes of Health. Protocols were approved by the
Institutional Animal Care and Use Committee at Marshall University. Adult (3 months old) male
and female C57BL/6 J mice were obtained in-house from breeding colonies (wildtype littermates
of α6-GFP mice). Mice were group-housed on a standard 12/12 h light/dark cycle and allowed
food and water ad libitum. For self-administration assays, mice were singly housed, and all
experiments were conducted during the light cycle.
Drugs
(-)-nicotine (N2472− 100ML, lot#: 2AH0278) was obtained from Spectrum. Nicotine-salt
(ditartrate dihydrate) was obtained from Acros Organics (AC415660500). (-)-menthol was
obtained from Alfa Aesar (A10474). Both nicotine formulations were mixed with propylene
glycol and vegetable glycerin (PGVG) at a 50:50 ratio at a final concentration of 6 mg/mL. This
dose was selected based on our previous investigation (Cooper et al., 2021). For both
formulations, nicotine content was based upon molecular weight of freebase to ensure equal
amounts of nicotine were present.
Self-Administration
EVSA was conducted in four air-tight chambers with interior dimensions of 21 cm L x 19
cm W x 12.5 cm H (La Jolla Alcohol Research, Inc. (LJARI), La Jolla, CA, USA) (Cooper et al.,
2021). Two nosepoke holes with cue lights were mounted above the floor on the back-side walls
of the chamber. Airflow was vacuum controlled by an electric pump that allowed air flow at 1
L/min. SMOK® baby beast TFV8 X-baby Q2 atomizer tanks (0.40 ohms dual coil; Shenzhen
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IVPS Technology Co., Ltd., Shenzhen, China) were activated by a custom e-cigarette mod box
(LJARI, La Jolla, CA, USA). Vapor delivery settings were controlled by an e-Vape® custom
controller at 400 ◦F and 65 W (LJARI, La Jolla, CA, USA).
Adult (3 months old), male (n = 14) and female (n = 14) mice began EVSA on a fixedratio (FR1) schedule on a Monday for 10 daily, 2 h sessions, with a weekend break. Mice were
singly housed in operant chambers (Cooper et al., 2021). Nose-pokes in the active hole of the
operant chamber resulted in a 3 s delivery of vaporized e-liquids through the vapor entrance port.
Inactive nose-pokes were recorded with no consequences. Following a nose-poke and 3 s vapor
delivery, a 30 s timeout period was initiated and signaled by a cue light in the nose-poke hole.
Mice were trained on nicotine (6 mg/mL freebase) with 15 mg/mL menthol as this provides the
most robust and consistent acquisition of self-administration behaviors (Cooper et al., 2021).
Using menthol-nicotine e-liquids, 50–60 % of mice acquire self-administration behavior based
on the criteria of active:inactive responding ≥2 (average responses on last 2 days). This is an
improvement over training with nicotine-alone (6 mg/mL freebase) as this results in a ~28 %
success rate (unpublished data). For this cohort, 7 males and 8 females escalated on the FR1
schedule (the remainder were excluded from further behavioral assays). Following the 10-day
FR1 protocol, mice continued on the same e-liquid but moved to a FR3 schedule for five days.
After this training period, all vaping-related exposure for mice involved menthol-free e-liquids
with the exception of the day they were re-baselined (Figure 19). Mice were randomly assigned
to 6 mg/mL nicotine-freebase or 6 mg/mL nicotine-salt using a within-subjects design. Mice
were maintained on these e-liquids for 4 days to establish stable FR3 responding with their
respective assignments. On day 5, mice were re-baselined with their training e-liquid (nicotine +
menthol). After both nicotine formulations, mice were assigned PGVG. Thus, all mice were used
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in all conditions. The mean of the final two sessions were used to compare reinforcement-related
behavior between e-liquid assignments.

Figure 19. E-Vape Self-Administration with Nicotine-Freebase and Nicotine-Salt Among
Male and Female Mice
Daily FR1 and FR3 EVSA nosepokes for male (A) and female (C) mice. Symbol colors indicate
e-liquid assignment (green, nicotine + menthol; grey, nicotine-freebase (FB); bronze, nicotinesalt; white, PGVG (vehicle control); and black, inactive nosepokes). Green squares indicate
sessions where mice were re-baselined to nicotine + menthol. Mean FR3 EVSA deliveries for
male (B) and female (D) mice that were assigned PGVG (vehicle), nicotine- FB, or nicotine-salt.
*, p < 0.05; **, p < 0.01; and ***, p < 0.001. All data are mean ± SEM.
Plasma Cotinine Assays
Examining the plasma cotinine values in mice assigned to self-administration assays
would vary greatly depending on the number of earned deliveries per mouse, and would
complicate any observations into the impact that formulation exerts on plasma cotinine
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concentration. To overcome this issue, a separate group of mice (n = 13 males and 13 females)
naïve to e-Vape® assays were assigned to PGVG, 6 mg/mL nicotine-freebase, and 6 mg/mL
nicotine-salt treatment groups and exposed to 15 non-contingent e-Vape® deliveries (3 s vapor
delivery every 8 min for 2 h). We used a plasma cotinine enzyme-linked immunosorbent assay
(ELISA) kit (Origene, EA100902) to examine concentrations after vapor inhalation sessions.
Mice were then immediately removed from chambers and were anesthetized with CO2 and blood
was drawn via cardiac puncture and placed on ice. Immediately after, plasma was separated via
centrifugation (1500 rpm for 15 min at 4˚C). We followed the established Origene cotinine
ELISA kit protocol to assay plasma cotinine levels. Measurements were taken using a
Flexstation III (Molecular Devices).
Statistical Analysis
All results are presented as mean ± SEM and all statistical analyses were performed using
GraphPad Prism 9. Data were analyzed using a two-way repeated measures ANOVA and a post
hoc Tukey was used for multiple comparisons.
Results
Using previously established protocols (Cooper et al., 2021), we trained male and female
mice to acquire EVSA behaviors on a FR1 schedule (Figure 19). Mice were randomly assigned
to either 6 mg/mL nicotine-freebase or 6 mg/mL nicotine-salt using a within-subjects design.
After assignment to both formulations, mice were assigned to PGVG. Using a two-way ANOVA
we detected a significant main-effect on sex (F(1,39) = 10.9, p < 0.01), formulation (F(2,39) = 58.7,
p < 0.001), but not on interaction (F(2,39) = 2.2, p > 0.05). In male mice, both nicotine
formulations produced FR3 deliveries that were significantly different from PGVG (Figure 19B,
p < 0.01 and 0.001 for nicotine-freebase and nicotine-salt, respectively). In female mice, both
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formulations exhibited a significant difference compared to PGVG (Figure 19D, p < 0.05 and
0.001 for freebase and salt, respectively). In both male and female mice, mice assigned nicotinesalt earned significantly more FR3 deliveries compared to nicotine-freebase (p < 0.01 and 0.05,
respectively). Comparing the mean earned FR3 deliveries between males and females, we noted
a significant difference for mice assigned nicotine-salt (p < 0.05).
In both male and female mice we observed a significantly higher concentration of plasma
cotinine in mice assigned to nicotine-salt when compared to nicotine-freebase (Figure 20, p <
0.05 and p < 0.01, respectively). Using a two-way ANOVA we observed a significant maineffect on sex (F(1,22) = 18.3, p < 0.001), formulation (F(1,22) = 20.0, p < 0.001), but not on
interaction (F(1,22) = 0.22, p > 0.05). Additionally, we noted a significant difference between the
plasma cotinine values in male versus female mice assigned nicotine-freebase or nicotine-salt (p
< 0.01 and p < 0.05, respectively).

Figure 20. Plasma Cotinine Levels Following Nicotine-Freebase and Nicotine-Salt
Administration in Male and Female Mice
Plasma cotinine levels of male (A) and female (B) mice that were assigned nicotine-FB, or
nicotine-salt following a single passive e-Vape® session. Data are mean ± SEM. *, p < 0.05; **,
p < 0.01.
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Discussion
Our data suggest that nicotine-salt produces greater reinforcement-related behaviors in
male and female mice when compared to nicotine-freebase. Additionally, non-contingent
exposure to nicotine-salt produced higher plasma cotinine values compared to nicotine-freebase.
Previous human studies reported that nicotine-salts in ENDS enables cigarette-like pulmonary
delivery of nicotine that reduced the desire to smoke (O'Connell et al., 2019). O’Connell et al.,
observed that nicotine lactate at all doses was delivered more rapidly into the systemic
circulation when compared to nicotine-freebase (2019). While it is difficult to separate the
precise mechanisms of subjective measures like ‘desire to smoke’, the pharmacokinetics
presented by O’Connell et al. show salt-based formulations facilitate a more-rapid delivery of
nicotine with a higher peak and area-under-the-curve (2019). Therefore, our results in mice agree
with this prior human study regarding plasma nicotine/cotinine levels. We believe this difference
in nicotine/cotinine pharmacokinetics may partially explain the observed differences in
reinforcement-related behavior. However, we must also consider that nicotine is less rewarding
than other addictive drugs (i.e., cocaine) and many equate continual nicotine use to be
maintained by circumventing withdrawal-related symptoms (McLaughlin et al., 2015).
Additionally, there may be other subjective influences between nicotine freebase and salt such as
novelty or even pH chemistry (Shao and Friedman, 2020) that may contribute to the behavior we
observed. This highlights the need to continue this investigation into formulation-based effects
and determine if withdrawal-related behaviors may differ as well.
While we did not directly measure nicotine levels, cotinine has been a widely used
biomarker of nicotine exposure in both humans and animal models for decades (Petersen et al.,
1984; Omelchenko et al., 2016; Montanari et al., 2020). One reason for this is the longer half-life
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of cotinine (~1 h in mice) (Siu and Tyndale, 2007) compared to nicotine (~7 min in mice) (Matta
et al., 2007). An additional limitation of this study is the use of a single dose of nicotine (6
mg/mL). At this dose, plasma cotinine values ranged up to ~100 ng/mL (males, nicotine-salt).
While this matches the 0-300 ng/mL seen in humans (Marsot and Simon, 2016), this highlights
the need to examine lower nicotine doses to identify the threshold for smoking/vaping-relevant
cotinine values. Nicotine has produced inverted-U behavioral responses in both rats and mice in
several paradigms (Torres et al., 2008). Thus, higher doses need to be examined as well.
Examining a full range of nicotine doses in the absence or presence of salt formulations may
reveal a formulation-specific effect regarding the sensitivity to nicotine’s rewarding and
reinforcing properties. We postulate 0.1-60 mg/mL (60 mg/mL nicotine-benzoate is present in
JUULs) nicotine will need to be examined to observe the threshold for reward/reinforcement and
the presence of nicotine’s well-characterized aversive properties (Grieder et al., 2019). As a final
note, we also must highlight our cotinine measurements were observed after a single day of
nicotine exposure and cannot account for nicotine tolerance that may occur over long-term
exposure.
A final limitation to this study is the brief period used for training (10 days) and
reinforcement-related behavior (4 days for each e-liquid assignment). We have used this brief
period in the process of developing a behavioral paradigm that can be used with adolescent mice.
Adolescence in mice is an extremely short period of time (~2 weeks (Laviola et al., 2003)).
These assays were designed to be utilized to examine both adult and adolescent vaping-related
behavior. We also acknowledge that our protocol uses menthol + nicotine. We specifically chose
this combination because menthol enhances nicotine reward (Henderson et al., 2017) and EVSA
acquisition rates (Cooper et al., 2021) by triggering the same nAChR-related mechanisms as
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nicotine (Henderson et al., 2017). We view this as similar to prior intravenous self-administration
assays that utilize stronger reinforcers (food or cocaine) to acquire operant behavior prior to
transitioning to contingent nicotine delivery (Goenaga et al., 2020). We admit this does introduce
some confounds, as menthol does interact with other Cys-loop ion channels; but this is at
concentrations higher than what is vaping-relevant (Hall et al., 2004; Corvalan et al., 2009;
Ashoor et al., 2013a). Additionally, menthol attenuates nicotine airway irritation through TrpM8mediated mechanisms (Fan et al., 2016).
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Abstract
The popular tobacco and e-cigarette chemical flavorant (-)-menthol acts as a
nonselective, noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs), and
contributes to multiple physiological effects that exacerbates nicotine addiction-related behavior.
Menthol is classically known as a TRPM8 agonist; therefore, some have postulated that TRPM8
antagonists may be potential candidates for novel nicotine cessation pharmacotherapies. Here,
we examine a novel class of TRPM8 antagonists for their ability to alter nicotine reward-related
behavior in a mouse model of conditioned place preference. We found that these novel ligands
enhanced nicotine reward-related behavior in a mouse model of conditioned place preference. To
gain an understanding of the potential mechanism, we examined these ligands on mouse α4β2
nAChRs transiently transfected into neuroblastoma-2a cells. Using calcium flux assays, we
determined that these ligands act as positive modulators (PMs) on α4β2 nAChRs. Due to α4β2
nAChRs’ important role in nicotine dependence, as well as various neurological disorders
including Parkinson’s disease, the identification of these ligands as α4β2 nAChR PMs is an
important finding, and they may serve as novel molecular tools for future nAChR-related
investigations.
Introduction
The single nucleotide polymorphisms (SNPs) of α4 and β2 receptor subunit genes
(CHRNA4 and CHRNB2), which comprise a major nicotinic subtype in the brain (α4β2), are
associated with heightened dependence on nicotine and initial subjective responses in both
African American and youth populations (Li et al., 2005; Ehringer et al., 2007). To date,
approved nicotine cessation pharmacotherapies have principally targeted α4β2 nAChRs: partial
agonist, varenicline (Coe et al., 2005; Mihalak et al., 2006); antagonist, bupropion (Slemmer et
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al., 2000; Richmond and Zwar, 2003). Despite this, smoking cessation rates remain low (Benli et
al., 2017), prompting the need for investigation into pharmacotherapies with a novel mechanism
of action that may produce higher cessation rates. Transient receptor potential (TRP) channels
have been investigated for their potential involvement in the effects of nicotine (Feng et al.,
2006; Oliveira-Maia et al., 2009; Talavera et al., 2009). The reason for this comes from the
understanding that menthol, the natural ligand for TRP melastatin 8 (TRPM8) and the most
popular and widely used tobacco and e-cigarette flavor, causes several biological effects that
contribute to nicotine reward and reinforcement.
One contributing effect is mediated through menthol’s interaction with TRPM8, which
results in a cooling sensation that may reduce the harsh throat irritation of nicotine and tobacco
(Willis et al., 2011; Wang et al., 2014; Ha et al., 2015; Liu et al., 2015; Fan et al., 2016; Lin et
al., 2017). This may contribute to smokers and vapers inhaling more nicotine, and thus may
contribute to elevations in plasma nicotine concentrations (Benowitz et al., 2004). In addition to
its counter-irritant effects, menthol has been shown to directly facilitate nicotine selfadministration. Oral menthol, the TRPM8 partial agonist and cooling agent, WS-23, and cold
temperatures (~11˚C) significantly increase nicotine intravenous (i.v.) self-administration in
female adolescent rats, compared to nicotine alone or other tastant/odorant cues. Menthol also
induces a considerable nicotine extinction burst, re-instates extinguished nicotine-seeking
behavior, and acts as a conditioned cue for nicotine (Wang et al., 2014), suggesting that menthol
may have direct effects on nAChRs beyond the sensory effects discussed above. In addition,
constellation pharmacology efforts have identified TRPM8 and a7 nAChR co-expression in cold
thermosensors from mouse and rat dorsal root ganglia and trigeminal ganglia (Teichert et al.,
2014).
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In recent years, the direct effects of menthol on nAChRs have begun to be identified.
Menthol enhances the nicotine-induced upregulation of nAChRs (Brody et al., 2013; Henderson
et al., 2017) and enhances reward-related behavior in conditioned place preference assays
(Henderson et al., 2017), the vapor self-administration of nicotine (Cooper et al., 2021),
intravenous self-administration of nicotine (Wang et al., 2014; Biswas et al., 2016), and nucleus
accumbens dopamine release (Zhang et al., 2018). These findings support the previous findings
that menthol may be a cue-reinforcer for nicotine use (Ahijevych and Garrett, 2010).
Given that menthol is a well-characterized agonist of TRPM8, some have speculated that
TRPM8 antagonists may be potential candidates as novel pharmacotherapies for smoking
cessation, by directly affecting nicotinic pharmacology or by blocking menthol’s counter-irritant
effects in relation to smoke inhalation. A novel class of menthol-derived TRPM8 antagonists has
recently been discovered (Journigan et al., 2020). Based on menthol’s ability to enhance nicotine
reward-related behavior, we tested these novel TRPM8 antagonists for their ability to modulate
nicotine reward-related behavior using a mouse model of conditioned place preference. Here, we
report that one of the most potent TRPM8 antagonists in this class (VBJ104, TRPM8 IC50 of 6 ±
1 nM) enhanced nicotine reward-related behavior, and this was due to its ability to act as a
positive modulator (PM) of α4β2 nAChRs.
Materials and Methods
Mice
All experiments were conducted in accordance with the Guide for Care and Use of
Laboratory Animals provided by the National Institutes of Health. Protocols were approved by
the Institutional Animal Care and Use Committee at Marshall University. Adult male and female
wildtype C57BL/6J mice (3–5 months old) were obtained from the Jackson Laboratory
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(https://www.jax.org/strain/000664). Mice were kept on a standard 12/12 h light/dark cycle at
22˚C and given food and water ad libitum.
Reagents and Dose Selection
The calcium-sensitive fluorescent probe, Calcium 6, was obtained from Molecular
Devices (Sunnyvale, CA, USA). Minimum essential medium (MEM) was obtained from
Corning. Opti-MEM, penicillin and streptomycin were obtained from Invitrogen Corporation
(Grand Island, NY, USA). Nicotine ditartrate dihydrate (product # 415660500) was obtained
from Acros Organics (Fair Lawn, NJ, USA). We utilized a nicotine dose of 0.5 mg/kg (with
respect to free base) for its previously determined rewarding effect for mice in conditioned place
preference assays (Tapper et al., 2004; Henderson et al., 2017). VBJ series compounds (see
Table 3) were prepared as described previously (Journigan et al., 2020). All molecules were
>99.6% pure, as determined by elemental analysis. For pharmacological evaluation, all
compounds were initially dissolved in 100% DMSO (0.01 M stocks) due to solubility. Further
dilutions of compounds were made in double-distilled H2O or extracellular solution (ECS) (≤100
µM).
CPP Assays
CPP assays were completed in a three-chamber spatial place preference chamber
(Harvard Apparatus, PanLab, dimensions: 47.5 × 27.5 × 47.5 cm) using male and female
C57BL/6J mice. Time in chambers was recorded by motion tracking software (SMART 3.0). A
10-day, unbiased protocol identical to previous studies (Henderson et al., 2016; Henderson et al.,
2017) was used where drugs (saline, nicotine (0.5 mg/kg), nicotine plus 0.5 mg/kg VBJ104, and
nicotine plus 1.0 mg/kg VBJ104) were given immediately before confinement in the right
white/grey chamber on drug days, and saline was given immediately before confinement in the
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left white/black chamber on saline days (via intraperitoneal injections). On day 1, a pre-test was
completed wherein mice were placed in the central chamber and allowed free access to the
apparatus for 20 min. Mice that spent >65% of the test in one chamber were excluded and the
remaining mice were counterbalanced. For counterbalancing, mice were separated into groups of
approximately equal bias, similar to previously published CPP methods (Sanjakdar et al., 2015).
No exclusions were necessary for these studies. Following counterbalancing, no initial biases
were noted. The mice received their designated drug injections on days 2, 4, 6, and 8, and
received saline injections on days 3, 5, 7, and 9. Each conditioning period lasted 20 min. On day
10, a post-test was completed whereby the mice were again placed in the central chamber and
allowed free access for 20 min. In total, 5 male and 5 female C57BL/6J mice, 3–5 months old,
were used in the CPP assays for each treatment group. Time spent in in the saline-paired chamber
was subtracted from time spent in the drug-paired chamber to score the pre-test and post-test.
CPP score (or change from baseline) was determined by subtracting the pre-test score from the
post-test score. A significant positive CPP score is indicative of reward-related behavior, while a
significant reduction is indicative of aversion-related behavior.
No sex differences were observed and data for males and females were combined (see
Results for specifics). Data are expressed as a change in baseline preference, which was
analyzed using a one-way ANOVA with a post hoc Tukey.
Neuro-2a Cell Culture and Transient Transfections
Mouse neuroblastoma-2a (neuro-2a) cells were cultured using standard techniques. Cells
were maintained in minimum essential medium (MEM, product #10-010-CV obtained from
Corning) plus 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin at
37˚C and 5% CO2 in a humidified incubator. Cells were plated at a density of 1.5–2.0 × 105 cells
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per well in clear 96-well culture plates previously coated with poly-l-ornithine. At 24 h after
plating, neuro-2a cells were transfected with α4 and β2 nAChR subunits using Lipofectamine3000 (Invitrogen) following manufacturer recommendations in Opti-MEM. The plasmid
concentrations used for transfection were 5 µg of α4 and β2 (mouse) nAChR subunits for each
96-well plate. At 24 h after transfection, the 96-well plates were washed and replaced with
standard culture medium. At 24 h after replacing with standard culture medium, 96-well plates
were used in Flexstation assays.
Calcium Accumulation (Calcium 6) Assay
The Calcium 6 procedure was carried out via a previously published procedure with
minor modifications using calcium 5 (Henderson et al., 2012b; Henderson et al., 2012a; Yi et al.,
2013). For this calcium accumulation assay, neuro-2a cells transiently expressing mouse α4β2
nAChRs were used (see above for transfection methods). On the day of the experiment, cells
were incubated in the dark for 2 h at 24˚C with 50% Calcium 6 dye (Molecular Devices). The
plates were then placed into a fluid handling integrated fluorescence plate reader (Flexstation III,
Molecular Devices, Sunnyvale, CA, USA) and fluorescence was read at an excitation of 485 nm
and emission of 525 nm from the bottom of the plate with changes in fluorescence monitored at
~0.8 s intervals. Baseline fluorescence was monitored for 20 s and then two drug additions (first
at 20 s and the second at 60 s) were applied using a Flexstation application speed of 2. At the
beginning of the Flexstation assays, each well in the 96-well plate started with 100 µL of
solution. For nicotine concentration response, the first addition contained only assay buffer (50
µL), and the second addition contained nicotine (50 µL) at 4X the target concentration.
For assays examining the VBJ compounds, potential PM activity was assessed using the
following protocol. For the nicotine control group, assay buffer (50 µL) was added in the first
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addition, and nicotine (50 µL of a 400 µM solution) was added to achieve a final concentration
of 100 µM. Treatment groups received the VBJ compound (50 µL of a 3X solution) in the first
addition and then the same nicotine solution (400 µM) with the desired concentration of the VBJ
compound (1X) in the second addition. Sham-treated groups were only given assay buffer.
Calculations
Functional responses were quantified by first calculating the net fluorescence (the
difference between control sham-treated and control agonist-treated groups). Results were
expressed as a percentage of control (100 µM nicotine). For each PM, six concentrations were
used in a series of concentration–response studies. Following transformation to log values,
sigmoidal-varied slope curves were fit to data using Prism 9 with no constraints (Graphpad, San
Diego, CA, USA). From these curves, EC50 and maximal changes in efficacy were determined
for each PM. Functional data were calculated from the number of observations (n) performed in
triplicate. Due to the use of log values in calculating the EC50 values, geometric (as opposed to
arithmetic) means were calculated for PMs in this study. All EC50 values are expressed as
geometric means (95% confidence limits). Due to solubility problems, compound concentrations
greater than 100 µM were not used in our concentration–response studies with VBJ compounds.
The DMSO concentration at this compound concentration was ≤1%, and this had no effects on
basal- or agonist-induced increases in fluorescence intensity.
Statistical Analysis
All results are presented as mean ± SEM and all statistical analyses were performed using
GraphPad Prism 9. Data were analyzed using a one-way ANOVA. When effects were shown to
be significant, a post hoc Tukey test was performed to compare the individual drug treatment
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groups. For CPP assays, males and females were analyzed separately using a two-way ANOVA.
No sex differences were noted; therefore, sexes were combined.
Results
We have previously shown that the TRPM8 agonist menthol enhances nicotine rewardrelated behavior when combined with nicotine (Henderson et al., 2017), and this likely happens
by directly binding to nAChRs (Henderson et al., 2018). We then decided to examine the impact
of a potent TRPM8 antagonist, VBJ104 (Figure 21), on nicotine reward-related behavior in a
mouse model of conditioned place preference (CPP). We hypothesized that the potent ligands of
TRPM8 that displayed antagonist properties may exert the opposite effect to menthol on nicotine
reward-related behavior, and result in a reduction in reward, as opposed to enhancement. We
used an unbiased 10-day CPP protocol, which was identical to previously published methods
(Henderson et al., 2016; Henderson et al., 2017; Avelar et al., 2019) (Figure 22A). Mice were
assigned to cohorts injected with saline, 0.5 mg/kg nicotine, 0.5 mg/kg nicotine plus 0.5 mg/kg
VBJ104, or 0.5 mg/kg nicotine plus 1.0 mg/kg VBJ104. Using a one-way ANOVA, we detected
a significant overall effect of drug treatment (F(3, 36) = 10.1, p < 0.0001).

Figure 21. Structures of Novel VBJ-Series Compounds.
IC50 values on hTRPM8 are from a previously published report (Journigan et al., 2020).
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Figure 22. Nicotine Plus VBJ104 Elicited CPP
(A1-2) Representative time-traces for a mouse used in a pre- and post-test in a conditioned place
preference assay and assigned to the 0.5 mg/kg nicotine treatment group. (B) Male and female
mice were assigned saline, 0.5 mg/kg nicotine, 0.5 mg/kg VBJ104 plus 0.5 mg/kg nicotine, or
1.0 mg/kg VBJ104 plus 0.5 mg/kg nicotine and used in a CPP assay (via intraperitoneal
injections; n = 10 mice per condition, 5 males and 5 females). *, p < 0.05; ****, p <0.0001.
Using a post hoc Tukey means comparison, we detected the presence of significant place
preference with 0.5 mg/kg nicotine (Figure 22B). This is similar to previous reports examining
nicotine reward-related behavior in mice (Tapper et al., 2004; Henderson et al., 2017; Avelar et
al., 2019). VBJ104, a mixture of two diastereomers, is composed of >85% of the 2SR, 9RS and
10SR isomers (isolated, hTRPM8 IC50: 1.4 ± 1.0 nM). We chose a dose equivalent to that of
nicotine (0.5 mg/kg VBJ104) and previous menthol investigations (1.0 mg/kg VBJ104
(Henderson et al., 2017)). Here, we observed that nicotine plus 0.5 mg/kg VBJ104 produced a
significant increase in reward-related behavior when compared to nicotine (p < 0.05; Figure
22B). Nicotine plus 1.0 mg/kg VBJ104 produced a significant CPP compared to saline (p <
0.0001), but not compared to nicotine alone. We observed nearly identical place preference
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between male and female mice for nicotine (CPP scores of 131.2 and 127.5, respectively) and
nicotine plus 0.5 mg/kg VBJ104 (CPP score of 261.5 and 269.8, respectively). Given the lack of
sex differences, we combined data for both males and females into Figure 22B.
Our behavioral results contradicted our hypothesis, given that we observed an
enhancement in nicotine reward-related behavior. To examine how these compounds could
enhance nicotine reward-related behavior, we conducted follow-up assays to determine their
effects on nAChR pharmacology. To do so, we used a Ca2+ flux assay with neuroblastoma-2a
cells transiently transfected with α4β2 nAChRs. While this cell type has been used extensively to
study nAChRs in electrophysiology and microscopy assays (Richards et al., 2011; Srinivasan et
al., 2011; Henderson et al., 2014), it is underutilized in fluorescence plate-reading assays
compared to HEK cell lines. Therefore, we created a control nicotine concentration–response
curve, and verified that our assay reproduced a nicotine EC50 value (81.1 ± 18.5 µM) consistent
with previous literature reports, which utilized a Flexstation platform (Nelson et al., 2003;
Gonzalez-Cestari et al., 2009; Henderson et al., 2018) (Figure 23). This EC50 indicates that our
transient transfection of α4β2 nAChRs and our functional analysis via Ca2+ flux likely measure
mostly low-sensitivity α4β2 nAChRs.
Next, we examined VBJ104 and five analogs (VBJ032, VBJ051, VBJ094, VBJ098, and
VBJ109; see Figure 21) for their ability to alter nAChR and nicotine-induced nAChR function.
As these compounds are unknowns, we used a two-addition drug application protocol (see
Figure 23A), wherein the first addition included the VBJ compounds by themselves (at varying
concentrations) and the second addition included the VBJ compound and 100 µM nicotine
(~EC60). We observed no α4β2 nAChR agonist activity with any of the VBJ compounds at
concentrations up to 100 µM (data not shown).

114

Figure 23. VBJ Compounds Did Not Exhibit Agonist Activity for α4β2 nAChRs
(A) Representative Ca2+ Flux trace from a single 96-well plate seeded with cells transiently
transfected with mouse α4β2 nAChRs. A1 and A2 designate drug additions 1 (vehicle) and 2
(100 µM nicotine). (B) Concentration-response of nicotine on neuroblastoma 2a cells transiently
transfected with α4β2 nAChRs. Data are mean ± SEM and are normalized to 1 mM nicotine. For
B, n = 6 individual experiments.
However, in combination with nicotine, we observed that the compounds enhanced
nAChR function in a concentration-dependent manner (Table 3 and Figure 24). Accordingly,
we classified these compounds as putative α4β2-positive modulators (PMs). VBJ104, which was
most potent as an antagonist for TRPM8, showed the lowest potency as a PM for α4β2 nAChRs
(EC50 of 4.6 µM, Table 3), but it exhibited the highest increase in efficacy (361%, Table 3).
The remaining VBJ compounds exhibited much higher potencies, with a drastically reduced
impact on efficacy compared to VBJ104 (Table 3 and Figure 24). VBJ098 showed no activity
as an agonist, PM, or antagonist.
Discussion
Menthol acts as an agonist of TRPM8 and a NAM of α4β2 nAChRs (Hans et al., 2012).
This novel series of compounds were characterized as antagonists of TRPM8 (Journigan et al.,
2020), and we found they failed to stimulate α4β2 nAChR activation on their own. However,
they increased nAChR function in a concentration-dependent manner. Accordingly, we have
deemed these compounds as putative α4β2 PMs. We acknowledge that further investigation
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hTRPM8
α4β2 nAChR PAM
Max Efficacy (normalized to 100
IC50a
EC50b
µM nicotine)c
VBJ032
49 ± 1 µM
77.6 nM
158.5 ± 8.6% (50 µM)
VBJ051
52 ± 1 nM
8.2 (0.8 – 47.2) nM
143.6 ± 7.1% (50 µM)
VBJ094
16 ± 1 nM
23.6 (1.8 – 68.2) nM
130.7 ± 7.8% (30 µM)
VBJ098
NE
NE
NE
VBJ104
6 ± 1 nM
4.6 (2.6 – 8.4) µM
360.7 ± 37.7% (100 µM)
VBJ109
52 ± 1 nM
29.7 (4.3 – 69.0) nM
125.6 ± 5.1% (50 µM)
a
, hTRPM8 IC50 data are previously published values from (Journigan et al., 2020).
b
, data are expressed as means with 95% confidence limits.
c
, concentration at which max increase occurs is indicated in parenthesis.
NE, indicates no detectable effect.
n = 4 – 7 individual experiments for each compound.
Compound

Table 3. In Vitro Ca2+ Flux Data
needs to be conducted to determine if these ligands act orthosterically or allosterically.
Therefore, we chose not to label these ligands as putative positive allosteric modulators (PAMs),
and instead limited our designation at this time to putative PMs.
It is important to mention that there exist two types of nAChR PAMs: type-I PAMs
potentiate nAChR peak-currents but have little impact on desensitization or inactivation; type-II
PAMs potentiate nAChR peak-currents, and also prolong activation by enhancing slow-phase
desensitization at the cost of fast-phase desensitization (Jones et al., 2012). While we have
determined that compounds such as VBJ104 can enhance agonist-induced α4β2 nAChR
function, there is a need to examine the impact on desensitization and open–close channel time.
As to how VBJ104 may enhance nicotine reward-related behavior, first we can consider
what is known regarding the mechanism of another TRPM8 ligand, menthol. In the case of
menthol, its ability to enhance nicotine reward and reinforcement lies in its ability to alter
dopamine neuron excitability (Henderson et al., 2017), enhance dopamine release (Zhang et al.,
2018), enhance nicotine-induced upregulation of nAChRs (Brody et al., 2013; Henderson et al.,
2017), and act on TRPM8-related mechanisms (Fan et al., 2016). While we have no evidence
that these VBJ series compounds can alter any of these mechanisms, the ability to act as a PM on
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Figure 24. VBJ Compounds Plus Nicotine Act As Positive Allosteric Modulators
(A) Representative Ca2+ flux from a 100 µM application of nicotine (left) and a 100 µM
application of nicotine in the presence of 30 µM VBJ104 on cells transiently transfected with
mouse α4β2 nAChRs. Data are mean ± SEM (triplicate data points). (B1–B6) Concentration–
response curves for varying concentrations of VBJ ligands in the presence of 100 µM nicotine.
For B1–B6, n = 4–7 individual experiments.
α4β2 nAChRs alone can explain how they enhance nicotine reward-related behavior. α4β2
nAChRs have been well-characterized to be critical in nicotine-related reward mechanisms
(Tapper et al., 2004; Nashmi et al., 2007; Ngolab et al., 2015; Grieder et al., 2019). Thus,
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enhancing the activity of nicotine on this subtype could have an impact on not only nicotine
reward and reinforcement, but also on tolerance and sensitization.
While these ligands have no potential utility in nicotine cessation, α4β2 nAChR PMs (or
PAMs) may be useful for other diseases and disorders. PAMs of nAChRs have been implicated
for their potential use in treatment of schizophrenia (Antonio-Tolentino and Hopkins, 2020) and
cognitive disabilities (Timmermann et al., 2012). Given that menthol exerts an effect on all
subtypes of nAChRs and many members of the Cys-loop superfamily (Hall et al., 2004;
Corvalan et al., 2009; Hans et al., 2012; Ashoor et al., 2013b; Ashoor et al., 2013a; Ton et al.,
2015), follow-up studies for these VBJ compounds’ activity on other nAChR subtypes and
ligand-gated ion channels may be necessary.
While the results of this study did not follow our original hypothesis, we have discovered
a new series of α4β2 nAChR PMs that may be useful as novel probes. As discussed above,
examinations of activity on the major nAChR subtypes, and possibly other members of the Cysloop superfamily, must be carried out. Additionally, another potential follow-up for this work
would be to expand our concentration–response studies to determine if VBJ104 may have a
concentration-dependent dual effect (see Figure 24B1). Similarly, there needs to be an expanded
dose range for our CPP assays. Currently, the higher dose of VBJ104 (1.0 mg/kg) produces a
lesser response than the 0.5 mg/kg dose. Nicotine exhibits an inverted-U dose response in CPP
assays, exhibiting a peak of reward-related behavior followed by aversion-related behavior at
higher doses. Thus, higher doses of VBJ104 may potentiate nAChR actions to a degree that
produces a similar aversion-related response. Thus, while we have failed to identify a novel
chemical scaffold for nicotine cessation, we may have discovered compounds that are useful in
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other areas of interest. This will require careful examination via assays related to learning,
memory, and anxiety-related behaviors.
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Abstract
The use of electronic nicotine delivery systems (ENDS) is distinctly different from
combustible cigarettes due to the availability of flavor options. For years, subjective measures
have been employed to demonstrate that adults and adolescents ‘prefer’ flavors for various
reasons: 1) they are pleasing and 2) they mask the harshness of nicotine. Despite this, there have
been few investigations into the molecular interactions that connect chemical flavorants to
smoking or vaping-related behaviors. Here we investigated the effects of green apple (GA)
ENDS flavorants in a translationally-relevant vapor self-administration mouse model and
observed that adult male and female mice self-administered GA flavorants in the absence of
nicotine. Using α4-mCherryα6-GFP nicotinic acetylcholine receptor (nAChR) mice, we
observed that mice exposed to GA flavorants in our vaping paradigm exhibited a sex-specific
increase (upregulation) of nAChRs that was also brain region specific. Functional assays
demonstrated that mice exposed to GA flavorants exhibited enhanced firing of ventral tegmental
area dopamine neurons and this contributed to enhanced dopamine release in the nucleus
accumbens core. These findings demonstrate that ENDS flavors alone change neurobiology and
may promote vaping-dependent behaviors in the absence of nicotine.
Introduction
For decades, nicotine has been characterized to be the primary addictive component of all
tobacco products, including electronic nicotine delivery systems (ENDS) (Stolerman and Jarvis,
1995; Cullen et al., 2018; Cullen et al., 2019). Nicotine is similar to many addictive compounds
as it alters dopamine (DA) neurotransmission (Sulzer, 2011; Faure et al., 2014). While nicotine’s
impact on the mesocorticolimbic system has long been studied, recent studies show that nicotine
contributes to several changes outside of the DA system that specifically control behaviors
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related to withdrawal, anxiety, and aversion (Fowler et al., 2011; Zhao-Shea et al., 2013; Shih et
al., 2014; Harrington et al., 2016; Pang et al., 2016). In addition to nicotine’s
psychopharmacological effects, a key contributor to ENDS use is the availability of chemical
flavorants that are banned in combustible products (Schneller et al., 2019). We have shown in
previous investigations that menthol and green apple (GA) flavorants alter reward-related
behavior, nAChR upregulation, nAChR assembly, and midbrain DA neuron firing (Henderson et
al., 2016; Henderson et al., 2018; Avelar et al., 2019; Cooper et al., 2020). Additionally, we have
observed that GA flavorants, in the absence of nicotine, can cause reward- and reinforcementrelated behaviors and alter DA neuron function (Avelar et al., 2019; Cooper et al., 2020, 2021).
In these prior studies, we have shown that GA flavorants enhance VTA DA neuron firing
(Avelar et al., 2019) or increase VTA DA neurons’ sensitivity to nicotine (Cooper et al., 2020) to
alter reward-related behavior. While these studies have highlighted that chemical flavorants are
likely central nervous system-active and can modulate neurobiology, neurophysiology, and
behavior, their major weakness is the fact that they used an injection-based behavioral assay
(conditioned place preference) with a low translational value to vaping-related behaviors.
In the present investigation, we utilized a vaping-relevant vapor inhalation model to
examine the impact that GA flavorants exert on behaviors associated with ENDS use. Popular
GA e-liquids use a mixture of hexyl acetate, ethyl acetate, and methylbutyl acetate, commonly at
a ratio of 3:1:1, respectively (Tierney et al., 2016). We have observed this GA flavorant mixture
to cause reinforcement-related behavior (Cooper et al., 2020); but we lack an understanding of
the role the individual flavorants contribute to the observed impact on behavior. Here, we
investigated individual GA flavorants in their role to alter vaping-related behaviors in the
absence of nicotine. We have shown that GA flavorants alter midbrain dopamine neuron function
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through changes in nAChR density and stoichiometry. While we show the neurobiological
changes are sex-specific, we also show the net result on function is the same among sexes. In
both male and female mice, GA flavorants enhance VTA DA neuron firing and DA release in the
nucleus accumbens (NAc) core. Together these results show GA flavorants alter nAChRs in the
mesolimbic pathway and suggest that they reinforce continued vaping-related behavior.
Material and Methods
Mice
All experiments were conducted in accordance with the guidelines for care and use of
animals provided by the National Institutes of Health. Protocols were approved by the
Institutional Animal Care and Use Committee at Marshall University. Mice were group housed
on a standard 12/12-hour light/dark cycle at 22oC and given food and water ad libitum. For
microscopy and behavioral assays, we used α4-mCherryα6-GFP mice (see below), originated
from a C57BL/6J strain that are genetically modified to contain α4-mCherry and/or α6-GFP
nAChR subunits (Henderson et al., 2017; Avelar et al., 2019; Akers et al., 2020). Following
behavioral assays (see below), mouse brains that were homozygous for α4-mCherry and
transgenic for α6-GFP were used in confocal microscopy assays (37 mice). For
electrophysiology assays, we used α6-GFP mice (discussed below). All mice were adults (3–5
months old). Both male and female mice were used and numbers of each are detailed below in
the methods for specific experiments and given in detail in corresponding figures.
Our genetically modified α4-mCherryα6-GFP mice were the result of crossing α4mCherry homozygous knock-in mice (Srinivasan et al., 2016) with α6-GFP bacterial artificial
chromosome transgenic mice (Mackey et al., 2012). α4-mCherry knock-in mice are backcrossed
to C57BL/6J mice every 10 generations while α6-GFP mice are continuously backcrossed to
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C57BL/6J mice (from Jackson Laboratory; https://www.jax.org/strain/000664). These mice are
now available from the Mutant Mouse Resource & Research Centers (MMRRC:068051-MU).
Genotyping
On postnatal day 21, mice were weaned and housed with same-sex littermates.
Concomitantly, tail biopsies were taken for genotyping analysis by PCR (Transnetyx, Cordova,
TN). Only mice that were transgenic for α6-GFP and homozygous for α4-mCherry were used in
confocal assays (see below), with the exception of α6-GFP and α4-mCherry mice used for
NFRET controls.
Drugs
Hexyl acetate (A0032) and methylbutyl acetate (A1076) were obtained from TCI
Chemicals. Ethyl acetate was obtained from Chem-Impex International Inc (00757). Nicotine
salt (ditartrate dihydrate) was obtained from Acros Organics (AC415660500). (-)-menthol was
obtained from Alfa Aesar (A10474). Propylene glycol was obtained from Tedia (PR1494-065),
and vegetable glycerin was obtained from J.T. Baker (2143-01). All e-liquids were mixed with
propylene glycol and vegetable glycerin (PGVG) at a 50:50 ratio at a final concentration of 15
mg/mL for flavor. For green apple mix we used hexyl acetate, ethyl acetate, and methylbutyl
acetate (3:1:1, respectively) following analytical investigations into commercial e-liquids
(Tierney et al., 2016; Omaiye et al., 2019b).
E-Vape Self-Administration (EVSA) Assays
EVSA assays were conducted as previously described using a commercial vapor selfadministration setup (www.ljari.tech; Figure 25; see (Cooper et al., 2021; Henderson and
Cooper, 2021)). Airflow was vacuum controlled by an electric pump that allowed air flow at 1
L/min. UWELL® Crown IV atomizer tanks (0.20Ω dual coil; Shenzhen UWELL Technology
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Co., Ltd., Shenzhen, China) were activated by a custom e-cigarette mod box (LJARI, La Jolla,
CA, USA). Vapor delivery settings were controlled by an e-Vape® custom controller at 400°F
and 65 W (LJARI, La Jolla, CA, USA).
During their light cycle, adult male (n = 19) and female (n = 17) mice began vapor
exposure acclimation on a Monday for five days with 15 mg/mL menthol + 6 mg/mL nicotine
salt (3 s puff, 25 deliveries/2h). The 15 mg/mL menthol + 6 mg/mL nicotine salt e-liquid
composition provides the most robust and consistent self-administration responding in mice
following acclimation (Cooper et al., 2021). The 5-day acclimation protocol differs from our
previous 3-day protocol (Cooper et al., 2021) and results in a nearly 100% success rate for mouse
acquisition of self-administration behavior. Following acclimation, mice were transitioned to a
fixed-ratio 1 (FR1) self-administration schedule on a Monday for 10 daily 2-hr sessions, with a
weekend abstinence period. Mice were singly placed into air-tight operant chambers that
contained two nose-poke holes (one active and one inactive). Nose-pokes in the active hole of
the operant chambers resulted in a 3 s delivery of vaporized e-liquids through the vapor entrance
port with a 30-s timeout (see Figure 25). During the timeout, a yellow cue-light remained on in
the active nose-poke hole. Inactive nose-pokes were recorded with no consequences. Following
EVSA training, mice that acquired self-administration behaviors (2:1, active:inactive ratio) were
transitioned to a FR3 schedule where they were maintained on a given e-liquid for four
consecutive days (starting on a Monday) to reach stable responding and re-baselined to 15
mg/mL menthol + 6 mg/mL nicotine on day 5 (Friday) (1 mouse was excluded following FR1).
Mice were used in a within-subject, Latin square design to test the following e-liquids: 15
mg/mL green apple (GA) mix (HA, EA, MBA; 3:1:1 ratio), 15 mg/mL hexyl acetate (HA), ethyl
acetate (EA), or methylbutyl acetate (MBA), and 50/50 PGVG. Following FR3 with the
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respective assignments, mice were assigned to PGVG control to examine extinction-related
behaviors. The mean of the four sessions each week of FR3 were used to compare
reinforcement-related behavior between e-liquid assignments.
Neuroblastoma-2a Cell Culture and Transient Transfections
Mouse neuroblastoma-2a cells were cultured in MEM with 5% fetal bovine serum, 100
IU/mL penicillin, and 100 µg/mL streptomycin. Cells were plated by adding 80,000 cells to
35mm glass-bottom imaging dishes (MatTek Corporation) and cultured in a humidified
incubator (37°C, 95% air, 5% CO2). For NFRET assays, cells were transfected with 500 ng of
each nAChR subunit cDNA plasmid ([α4-mCherryα4-GFPβ2-WT] for α4β2, [α6-mCherryβ2WTβ3-YFP] for α6β2β3, [α4-mCherryα6-GFPβ2-WTβ3-WT] for α4α6β2β3, and ([α3mCherryα5-GFPβ4-WT] for α3α5β4 subtypes). Following plating procedures, plasmid DNA was
mixed with 50 µL of Opti-MEM and P3000 at 2 µL/µg. Lipofectamine-3000 was separately
added to another 50 µL of Opti-MEM. After 5 min at 24oC, the two solutions were combined and
incubated at 24°C for 25 min. Plated cells then received the mixed solution, with an additional 2
mL of Opti-MEM, and were incubated for 24h. The following day, 500 nM filter-sterilized HA,
EA, or MBA was added after replacing the Opti-MEM with standard culture medium. Each
experiment included a sham control (no treatment). 24 h after drug/sham addition, cells were
fixed with 4% PFA for 20 min, washed twice with 1X extracellular solution (ECS), mounted
with Vectashield (Vector labs, H-1000) and coverslipped, and imaged on a confocal microscope.
Confocal Imaging of Mouse Brain Slices
α4-mCherryα6-GFP mice were passively exposed to 15 mg/mL GA or PGVG for 10
daily, 2-hr sessions at a rate of 25 deliveries per session (3-s puff). Following the completion of
non-contingent vapor exposure, mice were euthanized with CO2 and subjected to a swift cardiac
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perfusion with 10 mL ice-cold saline to reduce autofluorescence in the mCherry emission range.
Brains were then swiftly removed, flash frozen with acetone and dry ice, and then stored at 80°C. Brains were coronally sectioned (20 µm) using a cryostat, mounted with Vectashield
(Vector labs, H-1000), and coverslipped. We targeted bregma -3.1 mm (anterior-posterior limits
of -2.9 to -3.3 mm) for consistent sections of the midbrain, as well as bregma -1.8 mm (anteriorposterior limits of -1.5 to -2.0 mm) for habenula and hippocampal regions.
A Leica SP5 TCSII confocal microscope was used to excite α6-GFP and α4-mCherry at
488 and 561 nm, respectively. 20X images with a 10X digital zoom (for the midbrain) and 20X
images with a 5X digital zoom (for habenula/dentate gyrus) were collected for the quantitative
measurements of α4-mCherry and α6-GFP neuron raw integrated density (RID). Normalized
Förster Resonance Energy Transfer (NFRET) was calculated using the PixFRET ImageJ plug-in
to identify α4α6* nAChRs in the VTA (Henderson et al., 2017; Avelar et al., 2019; Akers et al.,
2020).
All experimenters were blind to drug treatment until all data analysis was completed.
Approximately 30-60 VTA dopamine neurons, and the medial/lateral habenula and hippocampus
(bilaterally) were imaged. Data from these images were averaged to provide RID values for each
mouse. A total of 37 mice were used in confocal assays, aged 3–5 months (n provided in Figures
27, 28, 30, 31).
Patch-Clamp Electrophysiology
Using brain slices from 3–5-month-old male and female α6-GFP mice, we identified
putative dopamine (DA) neurons in the VTA due to the selective expression of α6* nAChRs in
DA neurons (Mackey et al., 2012; Akers et al., 2020). Following recent work detailing the
presence of α6* nAChRs on medial VTA glutamate neurons (Yan et al., 2018), we restricted our
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recordings to the lateral VTA to increase our chance of accurately identifying DA neurons.
Following passive vapor exposure to 15 mg/mL GA-mix or PGVG for 10 daily, 2-hr sessions (3
s puff; 25 deliveries/session), mice were anesthetized with CO2 and then cardiac perfusion was
performed using ice-cold NMDG-based artificial cerebral spinal fluid (NMDG-ACSF) saturated
with 95% O2, 5% CO2 (carbogen) containing (in mM): 93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 10
MgSO4, 0.4 CaCl2, 30 NaHCO3, 5 Na-ascorbate, 3 Na-pyruvate, 2 thiourea, and 25 glucose.
Brains were placed in agarose for slicing with a Compresstome® VF-300-OZ (Precisionary
Instruments). Coronal brain sections (250 µm) were cut into cold carbogenated NMDG-ACSF to
obtain slices containing the VTA (target bregma -3.1 mm; anterior-posterior limits of -2.9 to -3.3
mm) and were then allowed to recover at 32°C in carbogenated NMDG-ACSF for 12-15 min.
Following this, slices were transferred to standard ACSF containing (mM): 125 NaCl, 2.5 KCl,
1.2 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 26 NaHCO3, and 11 glucose for one hour at 32°C. One hour
later, slices were transferred to the recording chamber and continuously perfused with
carbogenated ACSF (1.5 - 2.0 mL/min) at 32°C.
Neurons were visualized with an Axio Examiner A1 (Zeiss) equipped with an Axiocam
702 mono. Patch-clamp techniques were used to record electrophysiological signals with an
Integrated Patch-Clamp Amplifier (Sutter) using previously described methods (Avelar et al.,
2019; Akers et al., 2020; Cooper et al., 2020). Patch electrodes had resistances of 4 – 10 MΩ
when filled with intrapipette solution (in mM): 135 K gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10
HEPES, 2 Mg-ATP, and 0.1 GTP. Recordings were sampled at ≥10 KHz. The junction potential
between patch pipette and bath solutions was nulled just before gigaseal formation. Series
resistance was monitored without compensation throughout experiments using SutterPatch
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software. The recording sessions for neurons were terminated if the series resistance changed by
>20%.
For the recordings of spontaneous excitatory post-synaptic currents (sEPSCs), bath
perfusion of ACSF was switched to an ACSF solution containing 100 µM picrotoxin (SigmaAldrich, catalog number 124-87-8) to block GABAA receptors. After 5 minutes, DA neurons in
the VTA were voltage clamped at -65 mV to record sEPSCs. To isolate nAChR currents in VTA
GABA neuron recordings, standard ASCF (listed above) was supplemented with 0.5 uM
atropine.
Fast-Scan Cyclic Voltammetry (FSCV)
While collecting VTA slices, NAc sections (target bregma +1.0 mm; anterior-posterior
limits of +1.4 to +0.7 mm) were collected for FSCV. After recovery, slices were transferred to
the recording chamber and a carbon-fiber microelectrode was lowered to the NAc core. A 2 kHz
triangular waveform (−0.4 V to +1.0 V and back to −0.4 V, at a rate of 400 V/s) was applied at
20 Hz (Sutter IPA). Dopamine release was stimulated with a bipolar electrode (Plastics One),
placed ~250 µm from the NAc core (350 µA, 1, 5, or 60 pulses at 100 Hz, Master-9). Pulses
were delivered at 2-minute intervals to avoid signal rundown. Electrodes were calibrated using 0,
0.01, 0.1, 1, and 10 µM dopamine standards.
Calcium 6 Assay (Flexstation)
The calcium 6 procedure was used with minor modifications of a previously published
procedure using Fluo-4 (Gonzalez-Cestari et al., 2009; Henderson et al., 2010). For this calcium
accumulation assay, HEK293t cells were transiently expressed with α4β2 nAChRs. Cells were
plated at a density of 1.5-2.0 x 105 cells per well in clear 96-well culture plates previously coated
with poly-l-ornithine. On the day of the experiment, cells were washed with 100 µL extracellular
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solution (Henderson et al., 2010) and incubated in the dark for 1 hr at 24˚C with 50% Calcium 6
NW dye (Molecular Devices). The plates were then placed into a fluid handling integrated
fluorescence plate reader (FlexStation III, Molecular Devices, Sunnyvale, CA) and fluorescence
was read at excitation of 485 nm and emission of 525 nm from the bottom of the plate with
changes in fluorescence monitored at ~1.5 second intervals. For assessment of agonist activity,
100 µM concentrations of GA flavorants (HA, EA, or MBA) were delivered to α4β2 nAChRs
and the fluorescent response was monitored for 60 seconds. As a control, 300 µM nicotine was
used to stimulate maximal α4β2 nAChR activity. For antagonist assessment, increasing
concentrations of GA flavorants (1, 10, 100, 300, 1000 µM) were added with 300 µM nicotine.
A previously determined GA flavorant that acts as an antagonist, farnesol (Avelar et al., 2019),
was used as a control for this experiment.
Statistical Analyses
All results are presented as mean ± SEM and all statistical analyses were performed using
GraphPad Prism 9. FR3 e-Vape responding, A:I ratio data, and NFRET assays between e-liquids
were analyzed with a one-way analysis of variance (ANOVA) (Figures 25 and 33). Sexspecific, e-liquid-specific, or time-specific differences were determined through a mixed-effects,
two-way ANOVA with sex, e-liquid, and/or time as factors (Figures 25, 27, 28B5, 29, 30, and
32). Significant effects following ANOVAs were followed with a post hoc Tukey test. Figures
27-32 were analyzed through a student’s unpaired t-test following two-way ANOVA analysis.
Grubb’s outlier test was used to identify outliers.
Results
Male and Female Mice Self-Administer Vaporized GA Flavorants
We utilized a previously described paradigm (Henderson and Cooper, 2021) to train adult male
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and female mice to acquire e-Vape® self-administration (EVSA) behavior (Figures 25A and
26). Following training, we assigned mice to e-liquids containing 15 mg/mL hexyl acetate

Figure 25. Green Apple Flavors are Reinforcing in Both Sexes
(A1) Mice, naïve to vapor exposure, acquired vapor self-administration during 10 daily 2-hr FR1
sessions followed by 5 daily 2-hr FR3 sessions following previously established methods
(Cooper et al., 2021; Henderson and Cooper, 2021). Following acquisition, mice were randomly
assigned GA e-liquids until each mouse was exposed to all conditions. (A2) Vapor selfadministration chamber setup: 1 – controller; 2 – vaporizer; 3 – flow meter; 4 – vape tank mod
box; 5 – active and inactive nosepoke ports; 6 – inflow vapor port; 7 – outflow vapor port to
compressor. For additional details, see www.ljari.tech. (B) Earned EVSA deliveries for male and
female mice during acquisition training (males, n = 19 and females, n = 17). Mean EVSA earned
deliveries for GA e-liquids for male (C1) and female (C2) mice. FR3 Active:Inactive ratios for
male (D1) and female (D2) mice. Dots indicate individual data per mouse. Data are mean (±
SEM). Data were analyzed by one-way ANOVA with a post hoc Tukey.
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Figure 26. EVSA Deliveries Among Male and Female Mice
(A1-2) EVSA earned deliveries for each mouse during the FR1 acquisition phase. (B1-2) EVSA
earned deliveries for each mouse during the FR3 training (session 10-15) and testing sessions
(sessions 16-40). (C1-2) Active:Inactive ratio of each mouse during the FR3 sessions, including
mice that were excluded.
(HA), 15 mg/mL ethyl acetate (EA), 15 mg/mL methylbutyl acetate (MBA), 15 mg/mL green
apple (GA)-mix (3:1:1 HA:EA:MBA), and PGVG (vehicle) using a within-subjects Latin square
design (Figure 25C1-2). Upon analysis by two-way ANOVA, we failed to detect a significant
sex-difference (F(1,18) = 2.16, p = 0.159), however we detected a significant difference with eliquid assignment (F(4,72) = 20.20, p < 0.0001). Both males and females exhibited significant FR3
responding to GA-mix and individual flavorants (Males: F(4,70) = 6.46, p = 0.0002, Females:
F(4,70) = 7.025, p < 0.0001; one-way ANOVA; Figure 25C1-2); (post hoc analyses: HA, p = 0.001
and 0.0009; EA, p = 0.008 and 0.002; MBA, p = 0.003 and 0.002; and GA-mix, p = 0.0005 and
0.0003, for males and females, respectively) compared to PGVG. We also examined changes in
the active:inactive nosepoke distinction and observed that male and female mice did not differ in
their distinction between the active or inactive lever when assigned to different GA flavorants.
However, all assignments exhibited a ~2-fold increase when compared to PGVG (not significant,
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Figure 25D1-2).
Vaporized Exposure to GA Flavorants Induces nAChR Upregulation in the VTA
While we have previously shown that mice will self-administer GA e-liquids (Cooper et
al., 2021), we had not yet examined if vaporized delivery of GA flavorants alters nAChR density
in the brain regions relevant to reward or reinforcement. Because our mice undergoing selfadministration were utilized in a within-subjects design, we used a separate cohort of mice
exposed to non-contingent inhalation of 15 mg/mL GA-mix or PGVG for 10 daily, 2-hr sessions
with 25 deliveries/session. Using previously validated methods, confocal microscopy was used
to examine changes in nAChR density using α4-mCherryα6-GFP mice (Henderson et al., 2017;
Avelar et al., 2019; Cooper et al., 2020). We examined α4β2, α6β2* (* = indicates other subunits
may be present), and α4α6β2* nAChR density on VTA DA (α6-GFP+) neurons, α4β2 nAChRs
on GABAergic neurons of the dentate gyrus, as well as α4β2 and α6β2* nAChR density in the
medial habenula. Upregulation of nAChRs was assessed by quantifying the change in raw
integrated density (RID) of α6-GFP or α4-mCherry fluorescence.
Due to previously identified sex-specific effects (Avelar et al., 2019), we examined sexes
separately. In both males and females, mice exposed to GA-mix exhibited no change in α4* or
α6* nAChR density on VTA DA neurons compared to PGVG mice (p > 0.05; Figure 27C-D). In
males only, we noted an increase in α4α6* nAChRs on VTA DA neurons following exposure to
GA-mix (p = 0.036, Figure 27C). We did not observe any change in α4α6* nAChR density in
female mice following exposure to GA-mix (p = 0.73, Figure 27D).
GA Flavorants Alter DA Neuron Function in the VTA
While our neurobiology assays facilitate the examination of changes in nAChR density,
our microscopy methods do not provide any details regarding function. Therefore, we used
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patch-clamp electrophysiology to examine changes in function following exposure to GA-mix.
Similar to our prior reports (Akers et al., 2020), we used α6-GFP fluorescence to identify
putative VTA DA neurons. We exposed mice to PGVG or GA-mix using an identical paradigm
as utilized in our microscopy assays. We noted a significant increase in VTA DA neuron firing
frequency in male and female mice (Figure 28B1-5, p < 0.0001). This change in firing frequency
was not accompanied by any change in action potential spike waveform (action potential
amplitude, width, or afterhyperpolarization, Figure 28B3-4). We also noted a significant increase
in the frequency of spontaneous excitatory post-synaptic currents (sEPSCs) in VTA DA neurons
(Figure 28C1-3, p = 0.0039). We detected no difference in sEPSC amplitude (data not shown).
In addition to examining changes in VTA DA neurons, we also examined VTA GABA
neurons. VTA GABA neurons were identified in the lateral VTA (to avoid potential glutamate

Figure 27. Green Apple Upregulates a4a6* nAChRs in Male Mice Only
(A1) Schematic of target mouse brain region (bregma -3.1 mm). (A2) Sample 10X image of a
mouse coronal brain section at target bregma. (B) Sample images of PGVG and green apple
(GA)-treated VTA dopamine neurons. Scale bar, 10 µm. RID of a4*, a6*, and a4a6* nAChRs on
VTA dopamine neurons in PGVG and GA-treated male (C) and female (D) mice. Dots indicate
the RID values from individual mice. Data are mean (± SEM). One-way ANOVA with post hoc
Tukey.
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Figure 28. Green Apple Enhances VTA DA Neuron Firing Frequency and sEPSCs
(A1-3) Representative images of VTA dopamine neurons identified by α6-GFP fluorescence. (B14) Representative waveforms of VTA DA neuron firing from mice exposed to PGVG or GA-mix.
(B5) Mean data of VTA DA neuron firing frequency for male (white dots) and female (black
dots) mice. Representative waveforms (C1-2) and mean data (C3) of VTA DA neuron sEPSCs
recorded from mice exposed to PGVG or GA-mix. Individual dots represent data from individual
VTA DA neurons. (D1) Representative placement of patch and puffer orientation to target VTA
GABA neurons and putative GABA neurons were GFP(-) and Ih(-) (D2). (D3-4) VTA GABA
neuron firing frequency in mice exposed to PGVG or GA-mix. Representative waveforms (E)
and mean data (F) of increasing concentrations of ACh applied to VTA GABA neurons from
mice exposed to PGVG and GA-mix. All data are mean ± SEM; unpaired t-test. In F, data are
mean of 3–6 VTA GABA neurons. Dots within bars represent the values from individual cells
within the designated treatment group. Scale bars, 20 µm.
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neurons in the medial VTA) (Yan et al., 2018) by absence of GFP fluorescence and absence of Ih
(Figure 28D1-4). GA-mix-exposed mice exhibited a decrease in VTA GABA firing frequency
compared to PGVG-exposed mice (Figure 28D4, p = 0.0081). We applied increasing
concentrations of the endogenous nAChR agonist, acetylcholine (ACh) (Figure 28E) to VTA
GABA neurons and noted a change in ACh potency with neurons from GA-mix-exposed mice
compared to PGVG-exposed mice (Figure 28F). VTA GABA neurons do not contain α6 nAChR
subunits and instead express α4β2 nAChRs which have been shown to exhibit low- and highsensitivity agonist states (Nelson et al., 2003; Moroni et al., 2006; Tapia et al., 2007; Srinivasan
et al., 2011). Accordingly, this change in ACh potency suggests a potential change in α4β2
nAChR stoichiometry.
Next, we examined how VTA dopamine neurons’ response to smoking/vaping-relevant
concentrations of nicotine changed due to exposure to GA-mix. Here, we recorded cell-attached
firing frequencies until a stable response was observed (2 min) and then bath applied 500 nM
nicotine (Figure 29B1-3). Similar to previous investigations (Nashmi et al., 2007; Avelar et al.,
2019), we noted a nicotine-induced increase in VTA DA neuron firing frequency during acute
exposure to nicotine with control (PGVG-treated) conditions (Figure 29C, p = 0.03). In brain
slices prepared from male mice exposed to GA-mix, we noted an elevated baseline firing (similar
to Figure 28); however, we did not observe a significant increase in firing frequency due to
acute nicotine exposure (Figure 29C, p = 0.195).
GA Flavorants Alter nAChR Upregulation in the Medial Habenula in a SexDependent Manner
The medial habenula (MHb) is a key mediator of mechanisms related to nicotine, including
aversion, anxiety, and withdrawal (Fowler et al., 2011; Shih et al., 2014; Harrington et al., 2016;
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Pang et al., 2016). Accordingly, we examined α6* and α4* nAChRs in the medial and lateral
MHb regions, respectively (Figure 30A). Upon analysis by two-way ANOVA, we detected a
significant sex difference among α4* nAChR density (F(1,42) = 4.25, p = 0.046) and α6 nAChR
density (F(1,11) = 5.93, p = 0.033). We also detected a significant difference with e-liquid
assignment (F(1,11) = 34.32, p = 0.0001) and sex x e-liquid interaction (F(1, 9) = 7.07, p = 0.026)
among α6* nAChR density only. Following exposure to GA-mix, we observed an increase in
α6* nAChR density in the medial MHb (mMHb) in only female mice (p < 0.0001, Figure 30C1).
We failed to detect a change in MHb nAChRs in male mice (Figure 30B1-2).

Figure 29. Nicotine-Induced Firing Frequency in PGVG and GA-Mix Treated Mice
(A1-2) Representative VTA DA neuron in DIC and GFP imaging modes. (B1) 4-minute trace of
cell-attached recording before (black) and during (red) bath application of 500 nM nicotine. (B23) Highlighted waveforms of cell-attached firing pre-nicotine and during nicotine. (C) Firing
frequency data of mice exposed to PGVG or GA-mix pre- and post-nicotine bath application.
Data are mean ± SEM; unpaired t-test. Dots within bars represent the values from individual
cells within the designated treatment group.
We examined changes in mMHb neuron function as identified by α6-GFP expression in
slices prepared from α4-mCherryα6-GFP mice (Figure 30D). Neurons that were α6-GFP(+) in
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Figure 30. Green Apple Alters MHb nAChR Expression and Neuronal Function in a SexDependent Manner
(A) Sample 10X image of a α4-mCherryα6-GFP mouse coronal brain section at target bregma (1.8 mm) from PGVG and GA-mix treated mice. RID of a4* (B2, C2) and a6* (B1, C1) nAChRs
on medial habenula neurons in PGVG and GA-treated female and male mice. (D) Representative
images of slices prepared from α4-mCherryα6-GFP mice for electrophysiology. (E1)
Representative cell-attached recordings of medial MHb neurons from slices prepared from
PGVG or GA-mix-treated mice. (E2) Mean (± SEM) data of cell-attached firing frequencies.
Data were analyzed by unpaired t-test or one-way ANOVA with post hoc Tukey. Dots within
bars indicate the values from individual mice (microscopy) or individual cells
(electrophysiology). Scale bars, 20 µm.
the mMHb were observed to exhibit a non-significant decrease in firing frequency in female
mice (Figure 30E2, p = 0.1271). Despite observing no change in MHb nAChR upregulation in
male mice, we noted a significant decrease in mMHb neuron firing frequency (p = 0.0001,
Figure 30E2). We also noted a sex-specific difference in baseline firing frequency of neurons
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recorded from male and female mice (11.2 and 4.8 Hz, respectively; two-way ANOVA, sex
factor: F(1,19) = 13.7, p = 0.0015). We detected no change in sEPSCs (data not shown). Given this
sex-specific difference in MHb baseline firing, we note that we did not see a difference in VTA
DA or GABA neuron firing between sexes (see Figure 28B5). We also investigated nAChR
upregulation in the dentate gyrus of the hippocampus but saw no effects (Figure 31).

Figure 31. Green Apple Has No Effect on Hippocampal Dentate Gyrus Neurons
(A) Sample 10X image of a mouse coronal brain section at target bregma (-1.8 mm). RID of a4*
nAChRs on dentate gyrus neurons in PGVG and GA-treated male (B1) and female (B2) mice. All
data are mean (± SEM). Unpaired t-test. Dots indicate the RID values from each hippocampal
region of individual mice.
GA Flavorants Enhance DA Release in the NAc Core
Finally, we examined changes in NAc core DA release using fast-scan cyclic
voltammetry (FSCV) (Figure 32). We utilized brain slice FSCV methods as this facilitated the
use of the same mice used in VTA brain slice electrophysiology. Therefore, in the same animal
we can determine changes in the VTA→NAc pathway. DA detection was identified based upon
oxidation peaks at 600 mV and reduction peaks at -200 mV (Figure 32A2). We stimulated DA
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Figure 32. GA-Mix Enhances DA Release in Both Sexes
(A1-3) Schematic of stimulating and recording electrode placement at the nucleus accumbens
(NAc) core (bregma +1.0 mm) with representative voltammogram (A2) and GA-treated DA
waveform (A3). (B) Representative waveforms of PGVG-treated and GA-treated mice following
1P, 5P, and 60P stimulus trains. (C1 and D1) Mean DA peak response in male and female mice
treated with PGVG or GA-mix. (C2 and D2) Phasic:tonic ratio of PGVG- and GA-mix-treated
mice. All data are mean (± SEM). Two-way ANOVA with post hoc Tukey (C1 and D1) or
unpaired t-test (C2 and D2).
release using 1, 5, and 60-pulse trains to simulate tonic and phasic firing. At all stimulation
phases we observed that PGVG-treated male and female mice resulted in DA peaks of ~0.5 nA
(Figure 32C1 and D1). Male mice exposed to GA-mix exhibited enhanced DA release at 1-pulse,
5-pulse, and 60-pulse trains when compared to PGVG-treated mice (p = 0.0003, 0.0028, and
0.041, respectively; Figure 32C1). In female mice, we only observed a significant increase in
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DA release following a 60-pulse, 100 Hz trigger (Figure 32D1, p = 0.0147). Previous
investigations have shown that nicotine alters the phasic:tonic ratio of DA release (Rice and
Cragg, 2004). Accordingly, we examined phasic:tonic ratios in mice exposed to GA-mix and
observed that male and female mice exhibited no change in phasic:tonic ratios (Figure 32C2 and
D2).
GA Flavorants Alter nAChR Stoichiometry
We next examined nAChR stoichiometry in transiently transfected neuroblastoma-2a
cells using previously validated NFRET methods (Henderson et al., 2016; Henderson et al.,
2017; Avelar et al., 2019; Cooper et al., 2020). Neuroblastoma-2a cells were transiently
transfected with α4-mCherryα4-GFPβ2-WT nAChRs (Figure 33A) and exposed to 500 nM of
individual GA flavorants (HA, EA, or MBA). This concentration was chosen based upon
perceived pharmacologically relevant concentrations of tobacco flavorants (Henderson et al.,
2016; Henderson et al., 2017; Henderson et al., 2018). Here, we observed that cells exposed to
HA only exhibited a significant increase in mean NFRET (p = 0.002), which indicates a change
in nAChR stoichiometry toward low-sensitivity α4(3)β2(2) nAChRs (Figure 35) in agreement
with our electrophysiological investigation focused on VTA GABA neurons.
Next, we completed investigations into other nAChR subtypes. Similar to the α4β2
nAChR assays, transfected cells were treated with control media or one of the individual
flavorants (500 nM). For α4α6β2β3 (α4-mCherryα6-GFPβ2-WTβ3-WT) nAChRs, we observed
that cells exposed to HA and EA exhibited higher NFRET energy and an increased number of
NFRET pixels (Figure 33B2-3). The first indicates that there is likely to be a shift toward a
(α4)2(α6)1(β2)2 stoichiometry as the inclusion of more acceptor fluorophores (α4-mCherry)
would exhibit higher energy. The latter indicates there is an increase in the number of assembled
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Figure 33. Green Apple Flavors Alter nAChR Stoichiometry
(A1, B1, C1, D1) Representative neuroblastoma-2a cells transfected with corresponding nAChR
subunits in CTRL-, HA-, EA-, and MBA-treated cells. (A2, B2, C2, D2) Mean NFRET pixel
count for transfected cells treated 24 hrs with CTRL, HA, EA, or MBA. (A3, B3, C3, D3) Mean
NFRET of transfected cells treated 24 hrs with CTRL, HA, EA, or MBA. All data are mean ±
SEM. One-way ANOVA with post-hoc Tukey test. Dots 408 within bars represent the values
from individual cells within the designated treatment group; n > 30 cells per 409 condition.
nAChR pentamers that include both α4 and α6 nAChR subunits. The significance of this
observation is difficult to interpret. While α4α6β2 nAChRs are highly implicated in nicotinerelated reward (Liu et al., 2012; Engle et al., 2013; Akers et al., 2020), the various
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stoichiometries that may constitute this particular subtype have not been fully characterized.
Next, we examined α6β2* (α6-mCherryβ2-WTβ3-YFP) nAChRs that have been shown
to have a significant difference in potency for nAChR ligands and surface expression depending
on the inclusion of β3 nAChR subunits (Tumkosit et al., 2006; Kuryatov and Lindstrom, 2011;
Xiao et al., 2011; Henderson et al., 2014). Here, we observed that cells treated with HA exhibited
a decrease in mean NFRET (p = 0.0002, Figure 33C3). This indicates that HA treatment
decreases the inclusion of β3 nAChR subunits to produce more low-sensitivity α6β2(non-β3)
nAChRs. Finally, we examined α3α5β4 (α3-mCherryα5-GFPβ4-WT) nAChRs as they have been
shown to be crucial in aversion-related behaviors (Fowler et al., 2011; Frahm et al., 2011). Here
we observed that cells treated with HA exhibited a significant decrease in NFRET pixel count (p
= 0.029) but a significant increase in mean NFRET (p = 0.041; Figure 33D1-3). Potential FRET
pairings containing α3-GFP and α5-mCherry suggest that most α3α5β4 FRET pairs involve nonpentameric assemblies (Figure 34) given that α5 nAChR subunits are only auxiliary subunits.
The highest energy FRET paring being the (α3)2(α5)1(β4)2 nAChR assembly suggests that while
there is a decrease in NFRET pixel count, the increase in mean NFRET denotes a HA-induced
increase in α3α5* nAChRs (Figures 33D1-3 and 34).
Discussion
There have been several indications that ENDS users prefer flavors (Schneller et al.,
2019; Lanza et al., 2020; Leventhal et al., 2020; Jackson et al., 2021); however, there have been
no investigations regarding how vaping-relevant exposures to chemical flavorants alter
neurobiology. Similar to our previous work (Cooper et al., 2021), we have shown here that mice
will self-administer GA-mix in the absence of nicotine. However, in the present report we extend
the findings to show that individual flavorants will be maintained on a FR3 schedule in mouse
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Figure 34. Green Apple Flavorant-Induced Changes in α3β4 and α3α5β4 nAChR
Stoichiometries
(A) Representative immature and mature assemblies of α3β4 and α3α5β4 nAChRs ranked by low
to high energy levels FRET pairings. Non-adj, non-adjacent fret pair; adj, adjacent fret pair. (B14) Individual histograms from individual cells from a representative NFRET assay (same data set
as in Figure 7D1-3) identifying the histograms with the 1st, 2nd, or 3rd component of potential
NFRET energy state. Arrows (B1-3) indicate an increase (blue) or decrease (red) in total pixel
counts for each NFRET component.
EVSA assays. We further showed that vapor inhalation of these flavorants upregulate nAChRs in
a sex-dependent manner and stabilize distinct stoichiometries of nAChRs that impact function
(Figure 35). Nicotine is well-documented to stabilize high-sensitivity nAChRs (Kuryatov et al.,
2005; Srinivasan et al., 2011; Govind et al., 2012) in a cell and region-specific manner (Nashmi
et al., 2007) which, in part, results in the fast-desensitization of nAChRs on VTA GABA neurons
during repeated acute exposures to nicotine (Mansvelder et al., 2002).
What we have observed here with GA-exposed mice is distinctly different when
compared to nicotine. GA exposure increased high-sensitivity α4α6* nAChRs on VTA DA
neurons (males only). Despite this, all evidence suggests that midbrain GABA neuronal
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populations of α4β2 nAChRs were altered to low-sensitivity (α4)3(β2)2 nAChRs following
exposure to GA. This interpretation is supported by electrophysiology (decreased VTA GABA
neuron firing and shifted concentration-response to ACh) and NFRET assays. We also observed
an increase in α6* nAChRs in the mMHb in females and our in vitro data suggest these are
lower-sensitivity α6β2(non-β3) nAChRs (Figure 35). Similar to the GABA neurons, this is
supported by electrophysiology and NFRET assays. Given the projection of MHb neurons
(MHb→IPN→VTA, Figure 35), a decrease in MHb tone via low-sensitivity nAChRs likely

Figure 35. Summary of Green Apple’s Effect on Addiction-Related Brain Circuitry
(A) GA-mix alters nAChRs in a region and sex-specific manner. (B) Grey box indicates longterm nicotine exposure and green box indicates long-term GA exposure. Green arrows - VTA
DA; red - VTA GABA; blue - afferent glutamatergic. (B1-2) Nicotine causes a subtype- and cellspecific effect on nAChR upregulation that results in a higher degree of high-sensitivity α4β2
nAChR upregulation on VTA dopamine neurons. Ultimately these nAChRs are easily
desensitized by nicotine and this results in enhanced burst firing of VTA DA neurons that is
dependent upon acute nicotine. (B3) Green apple flavorants cause a distinct change as there is a
change in α4β2 nAChR stoichiometry toward low-sensitivity α4β2 nAChRs and leads to
decreased inhibitory input onto VTA DA neurons and an enhancement in DA release.
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contributes to decreased GABAergic inhibitory tone onto VTA DA neurons. Regardless, the
change in α4β2 nAChR agonist sensitivity on VTA GABA neurons, following GA-treatment, is
sufficient to reduce activity of GABA neurons, as evidenced by our electrophysiology. This,
combined with the increased number of α4α6β2* nAChRs, results in a heightened excitability of
VTA DA neurons that is distinct from nicotine-induced changes. Nicotine-induced changes
depend on acute activation by nicotine to increase DA neurotransmission and this occurs only
during phasic states (Rice and Cragg, 2004). Here, the increased DA neurotransmission occurs at
both tonic and phasic states and our electrophysiology assays show acute administration of
nicotine does not provide an increase in dopamine neuron cell firing (see Figure 29).
While mice self-administered all GA flavorants, we noted that not all flavorants impacted
nAChR assembly. HA was the only GA flavorant to change stoichiometry of all nAChRs studied
by NFRET, while EA was detected only to alter α4α6* nAChRs. MBA was not observed to
change any nAChR stoichiometries. This indicates that while some chemical flavorants provide
sufficient stimuli to self-administer, not all that do so change neurobiology. However, there are
several follow-up investigations that need to be completed to fully investigate this. Additionally,
there are several effects that deserve more precise investigations. First, we did note a potential
change in α3α5* nAChRs with our in vitro assays. We currently lack the capability of
conducting assays similar to what was done with our α4-mCherryα6-GFP mice; but utilizing
fluorescent α3 nAChR mice is a viable option for future studies. Overall, of the effects we
observed, we do not suspect that GA flavorants act through acute actions on nAChRs, as we have
shown that the chemical flavorants investigated here do no act as agonists or antagonists of
nAChRs (Figure 36).
We acknowledge that while our behavioral assays used a contingent drug delivery, our
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Figure 36. Green Apple Flavorants Are Neither nAChR Agonists Nor Antagonists
(A1-3) Hexyl acetate (HA), ethyl acetate (EA), and methylbutyl acetate (MBA) were added to
HEK293T cells transiently transfected with α4β2 nAChRs at concentrations up to 100 µM in
comparison to 300 µM nicotine. HA, EA, and MBA failed to activate α4β2 nAChRs. (B)
Increasing concentrations of HA, EA, and MBA were co-applied with 300 µM nicotine to test
for potential antagonist activity. HA, EA, and MBA failed to inhibit nAChR activity at all
concentrations tested. Farnesol, which has previously been shown to act as a nAChR antagonist
has been shown as a comparison to HA, EA, and MBA. In B, data are mean ± SEM of 3
independent experiments.
neurobiological and neurophysiological assays did not. Given this is the first investigation into
neurobiological/neurophysiological changes following vaping-relevant exposures to chemical
flavorants, we decided there was a need to conduct the first investigation using a controlled,
consistent delivery of GA flavorants. We have shown that with nicotine, upregulation of
nAChRs correlates to changes in reward-related behavior (Akers et al., 2020). Accordingly, there
is a need to determine if these changes connect to EVSA behaviors.
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Altogether, our data shows that GA flavorant mixtures, consistent with current-market eliquids, can impact reinforcement-related behaviors, in the absence of nicotine, due to changes in
nAChRs. This may provide mechanistic details as to why ENDS users of all ages tend to prefer
flavored products.
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CHAPTER 7
DISCUSSION AND FUTURE DIRECTIONS
Discussion
Combustible cigarette smoking has decreased by nearly 11% in the United States over the
past two decades. However, the use of electronic nicotine delivery systems (ENDS) has
increased tremendously among high school and middle school students alone, with over three
million users between the ages of 12 and 18 (Cullen et al., 2018; Cullen et al., 2019). Since 2014,
ENDS have become the most widely used nicotine delivery product among adolescents
(Arrazola et al., 2015). ENDS products were initially intended to improve smoking cessation
rates; however, ENDS companies have begun to target a new market of nicotine users with over
15,000 unique flavoring options available. As of 2020, more than 80% of ENDS users reported
flavored e-cigarette use (Wang et al., 2020). ENDS flavors have become more of a concern due
to the wide range available and the growing use of zero-nicotine flavored e-liquids, yet little is
known regarding the effects of flavors on nicotine dependence and vaping-related behaviors.
Due to this uncertainty, the FDA has prohibited the sales of flavored ENDS in convenience
stores, limited online vape-related sales, and enacted a ban on production and sales of flavored
pod-based ENDS (e.g. JUUL) other than tobacco and menthol flavors. Nevertheless, adolescents
are still accessing these products, while the ban does not pertain to tank-based systems and
disposable ENDS (e.g. Puff Bar).
Although many nicotine users attempt to quit, only about 7% are successful (CDC, 2000),
with an average of ~10 cessation attempts needed for success (Health, 2001). The typical end
result is relapse following negative withdrawal effects. Since the 2009 FSPTCA, menthol has
been the most widely studied flavoring chemical for its popularity and sole acceptance as a
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flavorant in combustible cigarettes. Menthol is known to intensify various smoking-related
behaviors and facilitates first-time nicotine use by masking the aversive properties of nicotine
(Wickham, 2015), while enhancing nicotine reward and reinforcement (Wang et al., 2014;
Biswas et al., 2016; Henderson et al., 2017), resulting in lower cessation rates compared to nonmenthol smokers. These findings may explain the popularity of flavored ENDS and signifies the
concerns with adolescent usage. This has led to our interests in ENDS flavoring chemicals,
including menthol and green apple flavorants – both being compounds that enhance nicotine
reward (Henderson et al., 2017; Avelar et al., 2019; Cooper et al., 2020) and reinforcement
(Cooper et al., 2021). With the dramatic increase in ENDS users over the years and the
popularity among flavored e-liquids, there is a critical need for studying the role ENDS flavors
play in nicotine dependence. These investigations were addressed through the following aims: 1)
examine ENDS flavors for their ability to enhance nicotine reinforcement; 2) determine the
effect of ENDS flavors on midbrain neurobiology; and 3) determine if ENDS flavors affect the
mesolimbic (reward) and habenulo-IPN (aversive) pathways’ neurophysiology, resulting in
subsequent dopamine release in the ventral striatum.
Following up on previous findings that menthol is not rewarding on its own, but instead
enhances nicotine reward likely through upregulation of nAChRs on VTA DA neurons
(Henderson et al., 2016; Henderson et al., 2017), we expanded these investigations into popular
green apple flavorants: farnesol, farnesene, hexyl acetate, ethyl acetate, and methylbutyl acetate.
To our surprise, we found that green apple flavors not only enhance nicotine reward and
reinforcement (similar to menthol), but they elicit reward and reinforcement on their own as
well. For the first time, we investigated the role of vaping flavors, through a vapor selfadministration paradigm, on the neurological function of a rodent model. The behavioral
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outcomes we identified were likely contributed to flavorant-induced alterations in nAChR level
and stoichiometry and neuronal function. Although we investigated five green apple flavorants,
they all elicited effects in a slightly different manner. Farnesol upregulated nAChRs on VTA DA
neurons similar to menthol (not shown in this dissertation), whereas farnesene, hexyl acetate,
ethyl acetate, and methylbutyl acetate prompted minor to no changes in nAChR density, but
instead induced stoichiometric changes through various nAChR subtypes. Despite the flavorantspecific intracellular alterations, all green apple flavorants enhanced the firing patterns of VTA
DA neurons while reducing that of the VTA GABA neurons. These neurophysiological changes
contribute to enhanced dopamine release in the NAc, and thus drive drug reward. We validated
dopamine release hypotheses through electrochemistry methods with hexyl acetate, ethyl acetate,
and methylbutyl acetate exposure. The entirety of these findings contributes a rigorous repertoire
of flavorant-induced changes that likely contribute to the high percentage of adolescent and adult
ENDS users.
Limitations
Despite the novelty of this work and the importance of these findings to the nicotine
addiction field of research, we fail to critically evaluate and elucidate the mechanisms involved
during nicotine withdrawal. Nicotine addiction encompasses 1) first-time use, 2) escalation, or
drug-taking behaviors, 3) neuroadaptations that further drive drug-taking behaviors, and 4) drugseeking behavior, or withdrawal. There are various cell-, region-, and drug-specific aspects of
withdrawal, however two major brain circuits are worth noting: habenulo-IPN and LHb-RMTgVTA aversive pathways. As previously discussed in Chapter 1, the medial and lateral habenula
play a key role in mediating the firing patterns of VTA DA neurons. Despite our investigations
into nAChR levels and neuronal firing of medial habenula neurons following GA-mix exposure
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(Chapter 6), further investigations need to be done throughout the entirety of these pathways to
identify the full scope of the effects of ENDS flavors on the aversive pathway associated with
withdrawal.
Although our α4-mCherryα6-GFP mice allow the analysis of in vivo nAChR density and
stoichiometry changes through FRET methods, another major limitation to this work is the
inability to examine nAChR subunits other than α4 and α6. Although α4*, α6*, and α4α6*
nAChRs are most commonly affected during nicotine addiction, our mouse line does not allow
stoichiometric investigations into α4(non-α6), α6(non-α4), or α3/α5* nAChRs. To compensate
for this limitation, we utilized in vitro methods to measure stoichiometric changes in α4β2,
α6β2β3, α4α6β2β3, and α3α5β4 nAChRs (see Chapters 2 and 6). Although useful to understand
how flavorants may impact nAChRs stoichiometry, our in vitro experiments need to be
replicated in a more translational model.
Third, our studies utilized adult mice, as opposed to adolescents. In 2018, 3.2% of adults
in the United States were e-cigarette users, while half were considered ‘dual-users’ (combustible
and electronic cigarette user) (SGR, 2020). Although investigations into adult vaping are
important, the critical area of interest is among the adolescent group. Ongoing behavioral
investigations into adolescent mice have begun to mimic what has been shown with adults, but to
a greater extent. Further studies need to be done in order to truly identify the risk of ENDS
among the United States youth.
Future Directions
This dissertation highlights the major flavorant-induced changes in neurobiology and
neurophysiology that contribute to vaping-related behaviors and dependence. These findings
suggest that ENDS flavors are not simply inert, but instead exert complex neurological effects
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that drive drug reinforcement. Based on these data, it is important to continue investigations into
ENDS flavors, including other fruit-flavored products, as we show that multiple flavorants
(similar in flavor profile) can elicit behavioral effects through different intracellular mechanisms.
Further, a logical follow up to these tank-based studies, are to examine other ENDS
devices, such as JUUL (pod-based; prefilled) and Puff Bar (pod-based; disposable) to further
identify how these products differ and contribute to adolescent usage rates. Pod-based ENDS are
known to utilize extremely high amounts of nicotine (60 mg/mL; JUUL), while the vague and
misleading labeling of these products leaves young individuals believing only trace amounts of
nicotine are present. These devices not only differ in nicotine concentration, but also in nicotine
formulation. The use of nicotine salt in many pod-based systems contributes to reduced nicotine
metabolism and increased bioavailability compared to nicotine freebase. These differences can
impact vaping-related behaviors tremendously by increasing adolescent ENDS use and
dependence greater than we have shown here with the tank-based systems.
Lastly, future investigations into specific flavorant-nAChR binding locations may
demonstrate the severity of one flavor’s long-term effects over another. We know the interaction
that nicotine has with nAChRs, and the neurological changes nicotine induces, however, little is
known regarding the pharmacological relevance of flavors in this system and how they directly
or indirectly affect nicotine addiction. Overall, filling these gaps is critical for the addiction field
and will contribute greatly to the regulation of ENDS use.
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